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Assessing the impact and cost-effectiveness of needle and
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hepatitis C transmission among people who inject drugs in
the UK: an analysis of pooled data sets and economic
modelling
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*Corresponding author lucy.platt@lshtm.ac.uk
Background: There is limited evidence of the impact of needle and syringe programmes (NSPs) and opioid
substitution therapy (OST) on hepatitis C virus (HCV) incidence among people who inject drugs (PWID),
nor have there been any economic evaluations.
Objective(s): To measure (1) the impact of NSP and OST, (2) changes in the extent of provision of both
interventions, and (3) costs and cost-effectiveness of NSPs on HCV infection transmission.
Design: We conducted (1) a systematic review; (2) an analysis of existing data sets, including collating
costs of NSPs; and (3) a dynamic deterministic model to estimate the impact of differing OST/NSP
intervention coverage levels for reducing HCV infection prevalence, incidence and disease burden, and
incremental cost-effectiveness ratios to measure the cost-effectiveness of current NSP provision versus
no provision.
Setting: Cost-effectiveness analysis and impact modelling in three UK sites. The pooled analysis drew on
data from the UK and Australia. The review was international.
Participants: PWID.
Interventions: NSP coverage (proportion of injections covered by clean needles) and OST.
Outcome: New cases of HCV infection.
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Results: The review suggested that OST reduced the risk of HCV infection acquisition by 50% [rate ratio
(RR) 0.50, 95% confidence interval (CI) 0.40 to 0.63]. Weaker evidence was found in areas of high
(≥ 100%) NSP coverage (RR 0.77, 95% CI 0.38 to 1.54) internationally. There was moderate evidence for
combined high coverage of NSPs and OST (RR 0.29, 95% CI 0.13 to 0.65). The pooled analysis showed
that combined high coverage of NSPs and OST reduced the risk of HCV infection acquisition by 29–71%
compared with those on minimal harm reduction (no OST, ≤ 100% NSP coverage). NSPs are likely to be
cost-effective and are cost-saving in some settings. The impact modelling suggest that removing OST
(current coverage 81%) and NSPs (coverage 54%) in one site would increase HCV infection incidence by
329% [95% credible interval (CrI) 110% to 953%] in 2031 and at least double (132% increase; 95% CrI
51% to 306%) the number of new infections over 15 years. Increasing NSP coverage to 80% has the
largest impact in the site with the lowest current NSP coverage (35%), resulting in a 27% (95% CrI 7% to
43%) decrease in new infections and 41% (95% CrI 11% to 72%) decrease in incidence by 2031
compared with 2016. Addressing homelessness and reducing the harm associated with the injection of
crack cocaine could avert approximately 60% of HCV infections over the next 15 years.
Limitations: Findings are limited by the misclassification of NSP coverage and the simplified intervention
definition that fails to capture the integrated services that address other social and health needs as part
of this.
Conclusions: There is moderate evidence of the effectiveness of OST and NSPs, especially in combination,
on HCV infection acquisition risk. Policies to ensure that NSPs can be accessed alongside OST are needed.
NSPs are cost-saving in some sites and cost-effective in others. NSPs and OST are likely to prevent
considerable rates of HCV infection in the UK. Increasing NSP coverage will have most impact in settings
with low coverage. Scaling up other interventions such as HCV infection treatment are needed to decrease
epidemics to low levels in higher prevalence settings.
Future work: To understand the mechanisms through which NSPs and OST achieve their effect and the
optimum contexts to support implementation.
Funding: The National Institute for Health Research Public Health Research programme.
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Plain English summary
A lmost half of people who inject drugs (PWID) have the hepatitis C virus (HCV), so preventingtransmission is crucial to reduce inequalities in health. The provision of clean injecting equipment
through needle and syringe programmes (NSPs) and opioid substitution therapy (OST) are the primary
interventions by which to reduce HCV infection among PWID in the UK. We undertook a study to
assess how effective both interventions are in preventing new cases of HCV infection and to examine the
cost-effectiveness (i.e. value for money) of NSPs. To estimate effectiveness, we conducted a review of
international evidence and analysed existing data that measure service use and HCV infection. We collected
data on the costs of running NSPs. We applied findings to mathematical models to estimate the effect on
the spread of HCV infection if we withdrew or increased the interventions, and assessed how cost-effective
they are. Use of OST reduces the chances of being infected with HCV infection by 37–60%, having a clean
needle or syringe for each injection reduces the chance of infection by 20–76%, and OST and having a
clean needle or syringe in combination reduces the chance of infection by 35–87%. We found NSPs to be
cost-effective and money saving in many settings: maintaining services could save up to £5.4M in HCV
infection treatment costs, as well as improving quality of life. Findings from the mathematical modelling
predict that removing either or both NSPs and OST would result in an increase in HCV infections over the
next 15 years. Increasing participation in NSPs in line with OST could reduce new HCV infections by half.
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Scientific summary
Background
Although there is good evidence that needle and syringe programmes (NSPs) and opioid substitution therapy
(OST) in combination reduce injecting risk behaviours and some evidence to show the impact on the incidence
of human immunodeficiency virus (HIV), there is little evidence of their impact on hepatitis C virus (HCV)
incidence among people who inject drugs (PWID). There had been no economic evaluations of NSPs undertaken
in Western Europe, and few studies have considered the costs saved as a result of care and treatment being
averted. In addition, previous existing studies relied on weak measures of NSP effectiveness. The aim of this
project was to provide evidence on the probable impact of existing coverage levels of NSPs and changes in the
extent of provision in preventing HCV infection incidence, and to assess the costs and cost-effectiveness of
current NSPs provision and increasing coverage on HCV infection transmission among PWID.
Objectives
The project answered the following research questions (RQs):
1. What is the impact of different coverage levels of NSP provision on the incidence of HCV infection
among PWID?
2. What is the contribution of other risk factors to HCV infection incidence and the overall transmission of
HCV infection among PWID?
3. What is the international evidence on the impact of NSPs with and without OST on the incidence of
HCV infection among PWID?
4. What are the costs associated with existing NSP provision in three UK settings?
5. What is the impact and cost-effectiveness of existing provision of NSPs, compared with no provision,
on HCV infection and HIV transmission and disease burden among PWID in three UK settings?
6. What are the possible strategies by which to increase the coverage of NSP provision in three UK
settings, and the probable impact and cost-effectiveness of these strategies?
Methods
Three linked data collection activities and the following analyses were undertaken:
1. Systematic review (RQ3).
We conducted a Cochrane-registered systematic review of published studies and unpublished analyses
that report on the effect of NSP exposure and/or OST on HCV infection incidence (Platt L, Reed J,
Minozzi S, Vickerman P, Hagan H, French C, et al. Effectiveness of needle/syringe programmes and
opioid substitution therapy in preventing HCV infection transmission among people who inject drugs.
Cochrane Database Syst Rev 2016;1:CD012021). Risk of bias for published non-randomised studies was
assessed using the ACROBAT-NRSI tool (A Cochrane Risk Of Bias Assessment Tool: for Non-Randomized
Studies of Interventions), developed by the Methods Groups of Cochrane. Risk of bias was not assessed
for the unpublished studies included in the review. We conducted a meta-analysis to estimate the
unadjusted effects of NSP exposure and/or OST on HCV infection incidence. Meta-analysis was
conducted using random-effects models, pooling univariable and multivariable models separately. We
examined heterogeneity with the I2-statistic and explored reasons for heterogeneity using univariable
random-effects metaregression.
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2. Analysis of pooled data (RQ1 and RQ2).
We collated six data sets previously used in a pooled analysis, for which the methods have been
published previously. We added an additional three data sets, namely a community survey of PWID in
Bristol (n = 336), Public Health England’s Unlinked Anonymous Monitoring Programme (UAMP) survey
from England and Wales (n = 3408) and the Australian Needle Syringe Programme Survey (n = 2391),
and we replaced one of the studies with updated data from Public Health Scotland’s Needle Exchange
Surveillance Initiative (n = 6988), adding in an additional 6041 individuals. All sources contained
comparable indicators on intervention use and new cases of HCV infection, except for UAMP, from
which 1567 antibody-negative dried-blood spots were tested. A total of 14,734 observations were
included, of which 7173 were anti-HCV negative and 185 were recent infections. The pooled data sets
were analysed using logistic regression to model the odds of recent infection by NSP and OST exposure,
adjusting for key confounders (injecting duration, sex, crack cocaine use and experience of prison) and
assessing the joint effects of NSPs and OST. We combined the findings of the pooled analysis with the
results of the systematic review in a meta-analysis.
An internationally standardised measure of an individual’s NSP coverage was used, which was defined
as the percentage of injections for which a new needle had been obtained (calculated as the average
number of new needles obtained divided by the average number of injections). Binary measures of
NSPs and OST were combined to form a measure of harm reduction coverage with four categories:
(1) full harm reduction (on OST and ≥ 100% NSP coverage), (2) partial harm reduction (on OST and
≤ 100% NSP coverage), (3) partial harm reduction (no OST, ≥ 100% NSP coverage) and (4) minimal
harm reduction (no OST, < 100% NSP coverage).
3. Economic evaluation (costing analysis and cost-effectiveness analysis; RQ4 and RQ5).
We collected cost data from three cities in the UK for the financial year 2013–14. Sites were selected
through a combination of convenience sampling based on the availability of impact data for the
cost-effectiveness analysis, existing relationships with service managers and the feasibility of conducting
a costing study. We collected cost data for three fixed sites, six pharmacies and three ‘other’ modalities
(a mobile outreach service, a drop-in centre and an out-of-hours pharmacy). For pharmacies, only a
subsample was costed in detail owing to the existence of multiple pharmacy NSPs in each setting.
Data were collected through staff interviews, the review of service statistics and financial reports.
We estimated the total and unit economic costs for distributing clean needles to PWID. Our approach
to costing was incremental to existing services and was particularly focused on needle and syringe
exchange. We followed standard methods for costing in an economic evaluation of a health
intervention; we include all costs regardless of the payer and estimated a ‘shadow cost’, whereby the
price does not accurately represent the value of resources. We estimated the cost-effectiveness of
current NSP provision compared with no provision. Findings were fed back to collaborators and NSP
staff to discuss plausibility as well as strategies to increase intervention coverage. For all analyses, health
benefits [quality-adjusted life-years (QALYs)] and costs (health-care provider perspective) were attached
to each HCV disease stage and we used recently published utility weights for injectors. Economic
model results are presented as incremental cost-effectiveness ratios (ICERs) and probabilistic uncertainty
analyses were used to estimate the uncertainty around the ICER, as well as the probability that the
intervention is cost-effective at different willingness-to-pay (WTP) thresholds.
4. Modelling impact (RQ4–6).
An existing dynamic deterministic model of HCV infection transmission and OST/NSP intervention
coverage among PWID was adapted. Intervention efficacy estimates were taken from the pooled analysis.
The model fits were used to estimate the impact of historical and current NSP coverage levels for reducing
HCV infection prevalence and disease burden in that setting, as well as the future impact of increasing or
decreasing NSP coverage levels. The model estimated the contribution of different behavioural risk factors
(e.g. homelessness and crack cocaine use) for increasing HCV infection transmission in these settings.
All analyses focused on three settings (Bristol, Dundee and Walsall), which were selected based on varying
levels of HCV infection prevalence and the availability of detailed behavioural data.
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Patient and public involvement included an advisory group consisting of members of the National Needle
Exchange Forum (a virtual network), Addaction (London, UK) and the Hepatitis C Trust (London, UK),
who were consulted on all aspects of the study design and emerging findings. Preliminary findings of the
pooled analysis and the costing analysis were also presented at the annual meeting of the National Needle
Exchange Forum (a virtual network), attended by NSP employees and service users.
Results
Systematic review
In the systematic review we identified 28 studies (21 published, 7 unpublished) from 5670 records from
North America (n = 13), the UK (n = 5), Europe (n = 4), Australia (n = 5) and China (n = 1), comprising
1736 HCV incident infections and 6513.04 person-years of follow-up. Overall HCV incidence ranged
between 0.09 and 42 cases per 100 person-years across the studies. Only two studies were judged to be at
moderate overall risk of bias, 12 were judged as being at serious risk of bias and seven were judged as being
at critical risk of bias; seven unpublished data sets were not assessed. Findings suggest that current OST
(from 12 studies across all regions) reduces the risk of HCV infection acquisition by 50% [rate ratio (RR) 0.50,
95% confidence interval (CI) 0.40 to 0.63; I2 = 0%; p = 0.89]. This effect was maintained in sensitivity
analyses excluding unpublished data sets or papers judged to be at critical risk of bias. We found no evidence
of differential impact by the proportion of female participants in the sample, region of study, main drug
used, history of homelessness or experience of prison. Weaker evidence was found for high NSP coverage
derived from seven studies from North America and Europe only (RR 0.77, 95% CI 0.38 to 1.54) with high
heterogeneity (I2 = 78.8%; p < 0.001). This effect remained consistent in sensitivity analyses. After removing
studies from North America, high NSP coverage in Europe was associated with a 56% reduction in HCV
infection acquisition risk (RR 0.44, 95% CI 0.24 to 0.80) with less heterogeneity (I2 = 12.3%; p = 0.337).
There was moderate evidence for the impact of combined high coverage of NSPs and OST from four studies,
resulting in a 71% reduction in the risk of HCV infection acquisition (RR 0.29, 95% CI 0.13 to 0.65).
Pooled analysis
Findings from the pooled analysis suggested that in unadjusted analysis, PWID currently using OST had a
65% reduced odds of HCV infection [odds ratio (OR) 0.35, 95% CI 0.26 to 0.48]. High coverage with
needles/syringes (≥ 100%) was not significantly associated with reduced odds of HCV infection (OR 0.83,
95% CI 0.60 to 1.16). Adjusting for the confounding effects of sex, experience of prison or injecting crack
cocaine did not alter the intervention effects. When examining the effects of combined harm reduction
interventions, the risk of new HCV infection was more than halved (54%) among those on full harm
reduction, defined as receiving OST and ≥ 100% NSP coverage [adjusted odds ratio (AOR) 0.44, 95% CI
–0.27 to 0.71], compared with those on minimal harm reduction (no OST, ≤ 100% NSP coverage). There
were reduced odds of HCV infection acquisition among those on partial harm reduction [i.e. those
exposed to high NSP coverage but not on OST (AOR 0.59, 95% CI 0.36 to 0.96)] and a higher effect for
those on OST but with low NSP coverage (AOR 0.59, 95% CI 0.36 to 0.96). Full harm reduction compared
with minimal exposure reduced the risk of injecting with a used needle/syringe by 50% (AOR 0.48, 95%
CI 0.38 to 0.62), reduced reuse of the same needle/syringe for injecting by 40% (AOR 0.59, 95% CI 0.40
to 0.88) and reduced the frequency of injecting (AOR –41.2, 95% CI –45.5 to –38.0). There was weaker
evidence for an association with injecting site infections or shared used of filters and spoons for drug
preparation. Full harm reduction was associated with twice the odds of testing for both HCV infection and
HIV (AOR 1.9, 95% CI 1.56 to 2.23 and AOR 1.9, 95% CI 1.6 to 2.20, respectively). Combining estimates
of NSP effectiveness from the systematic review with two data sets not already represented in the review
indicated that high NSP coverage reduced the risk of HCV infection acquisition by 39% (RR 0.61, 95% CI
0.43 to 0.87) with moderate heterogeneity (I2 = 30%; p = 0.189).
Costing analysis and cost-effectiveness
We observed a degree of variation in costs across the three different commissioning areas evaluated, and
variation in costs and outputs was observed across fixed sites and pharmacies. The primary cost driver in
DOI: 10.3310/phr05050 PUBLIC HEALTH RESEARCH 2017 VOL. 5 NO. 5
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Platt et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
xxv
most settings was the cost of supplies; this accounted for an average of 60% of total costs across sites
(range 23–80%). This was followed in most cases by administrative and overhead costs, which accounted
for 6–45% of total costs. There was some considerable uncertainty in our estimates owing to the fact that
cost and output data on NSP distribution are not routinely collected within the UK. The unit cost per
opioid needle distributed varied from £0.21 to £1.65, and the unit cost per opioid client (annually) varied
from £19.01 to £124.13. Some fixed sites handled a larger number of image and performance enhancing
drug users, resulting in a greater cost per opioid client; however, there was no clear distinction in the unit
cost per opioid needle between modes of distribution.
Overall, we found that needle and syringe exchange services are highly likely to be cost-effective at almost
any WTP threshold and are, in fact, cost-saving in some settings, despite some uncertainty in total outputs.
In Dundee the large majority of iterations from the model were cost-saving, and in both Bristol and
Walsall, the large majority of iterations were considerably below a WTP threshold of £13,000 per QALY
gained. The difference in cost-effectiveness between cities is partly driven by the population size of PWID
and the HCV infection prevalence in each study setting. Walsall had the smallest city-wide population of
PWID, so a reduction in infections and deaths had less of an overall impact on cost-effectiveness. These
cost-effectiveness estimates do not reflect the substantial gains from averting other health problems
associated with injecting drug use, including HIV and other infections. Previous research has indicated that
NSPs are highly effective in averting HIV infection; incorporating these health gains would substantially
improve cost-effectiveness.
Impact modelling
Findings from the impact modelling suggest that removing OST (current coverage 81%) and NSPs
(coverage 56%) in Bristol would increase HCV infection incidence by 329% [95% credible interval (CrI)
110% to 953%] by 2031 and at least double (132% increase, 95% CrI 51% to 306%) the number of
new infections over the next 15 years. In Dundee, which has the second highest NSP coverage (49%) of
the three settings, removing NSP would result in a 61% increase (95% CrI 12% to 219%) in new
infections, whereas removing OST (coverage 70%) alone would result in a 129% (95% CrI 43% to 543%)
increase. Increasing NSP coverage to 80% has the largest impact in Walsall, which has the lowest current
NSP coverage (28%), resulting in a 27% decrease (95% CrI 7% to 43%) in new infections and a 41%
decrease (95% CrI 11% to 72%) in incidence by 2031 compared with 2016. Increasing NSP coverage
to 80% results in an approximately 4% absolute drop in prevalence over 15 years in all settings owing to
the slow turnover of the population of PWID. Findings show that experience of homelessness and crack
cocaine injection increase transmission risk and, if these factors are removed, this could avert
approximately 60% of HCV infections over the next 15 years.
Conclusions
There is evidence from both the systematic review and the pooled analysis that current use of OST
compared with no intervention reduces the risk of HCV infection acquisition. The intervention effect from
the systematic review is strong but the evidence is considered to be of low quality because it is derived
from observational studies with serious risk of bias. This is in part attributable to the ACROBAT-NRSI
risk-of-bias assessment tool that we used, which compares study designs to randomised controlled trials as
a gold standard rather than assessing studies on their own merit. Findings from the review show weak and
low-quality evidence that NSP exposure reduces the risk of HCV infection acquisition, but with regional
variation and with a strong effect observed in Europe, as well as less heterogeneity across the studies.
Findings from both the review and pooled analysis suggest that the impact of combined high coverage of
NSPs and OST was greater. Findings show difficulties in measuring NSP coverage, most probably as a result
of misclassification of intervention coverage. Policies to ensure that NSPs can be accessed widely alongside
the provision of OST are needed, and obstacles preventing the concurrent use of both NSPs and OST could
be removed to maximise the reduction in HCV infection transmission. NSPs are cost-saving interventions in
some sites and cost-effective in others. Despite variations in coverage, NSPs and OST are probably
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preventing considerable HCV infections in the UK. Increasing NSP coverage will have the most impact in
settings with low coverage. Scaling up other interventions, such as HCV infection treatment, are needed to
decrease epidemics to low levels in higher-prevalence settings. Further research is needed to improve our
understanding of the mechanisms through which NSPs and OST achieve their effect, and of the optimum
contexts to support their implementation.
Funding
Funding for this study was provided by the Public Health Research programme of the National Institute for
Health Research.
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Chapter 1 Introduction
Evidence shows that injecting with used needles or syringes and sharing injecting equipment is the mainrisk factor for infection with the hepatitis C virus (HCV) and human immunodeficiency virus (HIV) among
people who inject drugs (PWID).1,2 The current primary interventions for reducing HIV/HCV infection
transmission among PWID are opioid substitution therapy (OST) and needle and syringe programmes
(NSPs).3 In 2005, there were an estimated 1700 NSPs in England, 70% of which were provided by
community pharmacies, with the rest offered by specialist community-based services and outreach/mobile
services and in custody suites.4 NSPs in England are funded through Drug Action Teams and Local Strategic
Partnerships, which are multiagency bodies involving local government, the police and health services.
Needle and syringe programmes are often a first point of contact with health services for PWID.
They provide support to minimise drug and sexual risk-related harms, including the provision of clean
needles/syringes and condoms in order to prevent blood-borne virus transmission, bacterial infections and
other adverse health outcomes. By maximising the amount of clean injecting equipment in circulation, it is
possible to minimise the time that contaminated equipment remains in use and the proportion of unsafe
injections.5,6 NSPs operate through a range of modalities including via fixed sites, outreach, peer PWID
networks, vending machines and pharmacies. Engaging in behaviours that are socially stigmatised and
illegal, PWID often have high rates of unemployment, homelessness and incarceration. NSPs also provide
access to longer-term support by referring clients to medical, drug treatment or social support services.
Drug treatment for opioid addiction and dependence also encompasses a range of strategies to manage
injecting drug use and to reduce associated harms, including medication-assisted treatment such as OST,
medication-assisted treatment combined with psychosocial approaches and residential rehabilitation. The
most commonly prescribed forms of OST are opioid agonist treatments, namely methadone maintenance
therapy and partial agonist buprenorphine maintenance treatment, or the increasingly popular naloxone
and buprenorphine (Subuxone®, Indivior Inc., Richmond, VA, USA). OST is prescribed to dependant users to
diminish the use and effects of illicitly acquired opioids. It is usually taken orally and therefore reduces the
frequency of injection and unsafe injecting practices.7 As a treatment for opioid dependence, OST has been
shown to increase health and social functioning, decrease crime and reduce the frequency of injection
and unsafe injecting practices.8,9 Evidence suggests that OST is most effective when it is continuous and
provided at adequate doses.10,11 In the UK, OST is prescribed by medically qualified clinicians or nurses
and dispensed in both primary care or community settings (sometimes co-located at NSPs).
Both NSPs and OST are complex interventions that not only seek to reduce immediate harms caused by
unsafe injecting practices, such as reducing HIV, HCV or bacterial infections, but also aim to address more
complex social problems experienced by PWID by providing integrated care and referrals to other agencies
including housing, social welfare, legal advocacy and sexual and mental health services. This report takes
a more focused definition of how the interventions reduce the risk of infection with HCV infection and
does not take into account the indirect routes or causal pathways through which the interventions might
work by addressing the underlying social issues that might lead to injecting risk behaviours.
Although there is good evidence that NSPs and OST in combination reduce injecting risk behaviours and
some evidence to show the impact on HIV incidence, there is little evidence of their impact on HCV
infection incidence among PWID.3,12–15 In 2012 and 2014, two reviews were published that estimated a
moderate effect of NSPs on reducing HIV transmission by 48% [95% confidence interval (CI) 3% to 72%]
and strong evidence for OST reducing HIV transmission by 54% (95% CI 33% to 68%).16,17 Similar
evidence is lacking for the effect of NSPs or OST on HCV infection. Previous reviews7,15,18 have synthesised
evidence for use of NSPs but have focused primarily on HIV as the main outcome and, as a consequence,
have failed to include all the available evidence on HCV infection.3 More recently, evidence on a range of
risk-reduction interventions on HCV infection seroconversion, including behavioural interventions, NSP and
OST, were reviewed.19 This study measured the effect of NSP use, defined inconsistently as any attendance
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at a NSP or attendance at one point in time, and showed an increased risk of seroconversion. Limitations
of this review included substantial heterogeneity across studies, a lack of clarity on the measure of NSP use
and a focus on evidence from North America, which limits the generalisability of findings to other settings,
including the UK. Our review on the effect of OST use on HIV transmission detected many more studies
than earlier Cochrane reviews.17 We also expect that not all evidence on the effect of NSP on HCV
infection transmission has been identified, so extending previous reviews would strengthen the evidence
base as well as provide a more refined measure of coverage of NSP that accounts for frequency and the
degree to which NSPs meet individuals’ requirement for needles/syringes.
A recent analysis of pooled data presented a clearer definition of NSP use, defining coverage in terms of
the proportion of injections with a sterile syringe. This analysis suggested that high coverage of NSPs
(‘100% NSP’, i.e. obtaining ≥ 1 sterile syringes per injection) or OST can each reduce HCV infection risk by
50%; and NSPs and OST in combination can reduce HCV infection risk by 80%.20 However, owing to a
small number of incident HCV infection cases (n = 40), the efficacy estimate for 100% coverage of NSPs
was weak (95% CI 0.22 to 1.12) and there was insufficient power to evaluate whether or not a
dose–response relationship exists. This project will provide a more robust understanding of the likely
impact of existing coverage levels of NSPs and changes in the extent of provision.
There have been no attempts to estimate the cost-effectiveness of NSP provision in England, although
NSPs and OST are the current primary interventions for reducing HIV/HCV transmission among PWID in
the UK.3 In addition, although a recent National Institute for Health and Care Excellence (NICE) evaluation
considered the cost-effectiveness of NSPs, they were unable to estimate the incremental cost-effectiveness
of increasing coverage because of ‘a paucity of evidence underpinning effectiveness’.21 Internationally, of
the economic evaluations of NSPs, none has been undertaken in Western Europe, few have considered
the costs saved as a result of care and treatment averted, and all studies have relied on weak measures of
NSP effectiveness, such as using either changes in self-reported syringe sharing or ecological data relating
NSP exposure to HCV infection prevalence or incidence in the population, which are unreliable and subject
to substantial bias (Guinness L, Martin N, Harker M, Greco G, Vickerman P, 2012, unpublished). There
is an urgent need to fill this evidence gap by producing the first Western European evidence for the
cost-effectiveness of NSPs and an economic evaluation to use empirical data on NSP effectiveness in
reducing HCV infection transmission at the individual level.
Rationale for current study
Evidence for the effect of NSP use on HIV and HCV infection incidence is inconsistent.22,23 Studies have
lacked sufficient evidence on the frequency of use of the intervention, the quantity of needles/syringes
distributed24 or insufficient sample sizes to accurately measure the effect.3 Economic evaluations of NSPs
have not focused on Western European data, and existing studies have relied on weak measures of NSP
effectiveness. Further evidence is essential in order to accurately estimate what level and combination of
intervention is needed to substantially reduce HCV infection in PWID and the costs associated with
increasing coverage to the optimal level.
Research objectives
The aim of this project was to assess the impact and different coverage levels of needle and syringe
provision with and without OST on the incidence of HCV infection among PWID as well as the costs and
cost-effectiveness of NSPs.
INTRODUCTION
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There were six linked objectives.
l Objective 1: use pooled data sets and a deterministic model to measure the impact of different NSP
coverage levels in the presence and absence of OST on the incidence of HCV infection among PWID in
the UK.
l Objective 2: estimate the contribution of risk factors (e.g. homelessness and crack cocaine use) to HCV
infection incidence and the overall transmission of HCV infection among PWID.
l Objective 3: conduct a systematic review of international evidence on the impact of NSPs with and
without OST on the incidence of HCV infection among PWID.
l Objective 4: estimate the costs associated with existing NSP provision in three UK settings.
l Objective 5: estimate the impact and cost-effectiveness of existing provision of NSPs, compared with no
provision, on HCV and HIV transmission and disease burden among PWID in three UK settings.
l Objective 6: determine possible strategies to increase the coverage of NSP provision in three UK
settings, and the probable impact and cost-effectiveness of these strategies.
Research design
The aims and objectives listed above were achieved through the implementation of five linked data collection
activities and analyses. The findings from each study are summarised in the individual chapters below.
Chapter 2 details the systematic review, Chapter 3 provides an analysis of pooled data sets, Chapter 4
outlines the costing analysis, Chapter 5 details the impact modelling and Chapter 6 outlines the
cost-effectiveness analysis.
DOI: 10.3310/phr05050 PUBLIC HEALTH RESEARCH 2017 VOL. 5 NO. 5
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Platt et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
3

Chapter 2 Systematic review of the effectiveness
of needle and syringe programmes and opioid
substitution therapy in preventing hepatitis C
transmission among people who inject drugs
Objectives
Our primary objective was to assess the impact of NSPs and OST together and alone on the incidence of
HCV infection among PWID. Our secondary objective involved exploring the effect of sample characteristics
(e.g. experience of prison, homelessness, use of stimulant injection) on the transmission of HCV infection
among PWID.
Research questions
The specific research questions to be answered through the review were:
1. How effective is OST in reducing HCV infection incidence among PWID?
2. How effective are NSPs with and without the use of OST for reducing HCV infection incidence
among PWID?
3. How does the effect of NSP and OST vary according to the duration of treatment (i.e. weekly vs.
monthly attendance for NSPs)?
4. How does the effect of NSPs vary according to the type of service (fixed vs. mobile site; high vs.
low coverage)?
5. How does the effect of OST vary according to the dosage of OST, the type of substitution used and
adherence to treatment?
International evidence supports the use of combination interventions to prevent and treat HIV among
PWID with the provision of NSPs, OST and HIV antiretroviral treatment as the key interventions.25 There is
good evidence that NSPs and OST reduce injecting risk behaviours and increasing evidence to show an
impact on HIV incidence.16,17 However, evidence of their impact on HCV infection incidence among PWID,
in combination or alone, is limited.3,8,12–15,20
Methods
The full methods used in the review are published in Platt et al.26,27 This is an open access article under the
terms of the Creative Commons Attribution-Non-Commercial Licence, which permits use, distribution and
reproduction in any medium, provided the original work is properly cited and is not used for commercial
purposes. Here, we summarise the methods in brief as well as some of the key findings of the review. We
conducted two primary searches of the literature based on key search terms identified by the review of
reviews and the recent review of the effect of OST and NSPs on the risk of HIV and HCV infection among
PWID.3,17 The purpose of the two searches was to (1) identify studies that directly measured the impact of
NSPs/OST on HCV infection incidence and (2) identify longitudinal studies that measured HCV infection
incidence and report the impact of NSPs/OST as part of an adjusted analysis.
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We searched MEDLINE (1946 to November 2015), PsycINFO (1806 to November 2015), EMBASE (1980 to
November 2015), Global Health (1910 to November 2015), Cumulative Index to Nursing and Allied Health
Literature, Cochrane Central Register of Controlled Trials, Database of Abstracts of Reviews of Effects,
NHS Economic Evaluation Database, Health Technology Assessment database, The Cochrane Library, the
Cochrane Drug and Alcohol Register and Web of Science for observational and experimental studies
measuring exposure to NSPs and/or OST (compared with no intervention) among PWID and HCV infection
incidence. All searches were conducted in November 2015. When no measure was reported in observational
studies, authors of studies were contacted and asked to provide unpublished data. We also searched
publications of key international agencies as well as conference abstracts. Reference lists of all included
articles were reviewed for eligible papers. A copy of the search strategy is published in Platt et al.26
Selection criteria
We included all observational (prospective and retrospective cohorts, cross-sectional surveys and
case–control studies) and experimental studies [randomised controlled trials (RCTs)] that measured
exposure to either intervention versus no intervention or a reduced exposure, and that reported HCV
infection incidence as an outcome.
We included cross-sectional surveys if they included a serological measure of recent infection [e.g. through
positive ribonucleic acid (RNA) results on antibody-negative samples]. We excluded cross-sectional studies
(including serial cross-sectional studies) reporting HCV infection prevalence only. We excluded studies
relying on self-reported data for the outcome.
Participants
We focused on studies of PWID (opioids and/or stimulants). Studies that include participants undergoing
opportunistic HCV infection testing (outside the study setting) were excluded, as were those relating to
PWID in the prison setting, because addiction services and treatment provision in this setting differ
significantly from community and health-care settings.
Outcome
Our outcome of interest was incidence of HCV infection in PWID as measured via repeat testing such as the
detection of HCV RNA-positive status among HCV antibody-negative results or antibody avidity. Studies
were also included if they reported a minimum of two HCV seroconversions (HCV antibody negative to HCV
antibody positive) among the study participants from tests conducted at different time points.
Methods used in this systematic review in relation to the search strategies and approaches to data
synthesis follow methods applied in a similar review to assess the impact of OST on HIV incidence.17
Intervention
Exposure to NSPs was defined as the proportion of injections that are covered by a clean needle/syringe or
attendance at a NSP. When it was not possible to estimate the proportion of injections covered by a clean
needle/syringe, we defined exposure accounting for frequency of injection and the degree to which the
NSP meets the individual’s requirement for needles/syringes.
Exposure to OST was defined as current or recent continuous or interrupted treatment (past 6 months or for
the duration of HCV infection observation period), or any past treatment with methadone or buprenorphine.
Interventions were defined as current OST (within past 6 months) or lifetime use of OST, and high NSP
coverage (regular attendance at a NSP or all injections covered by a new needle or syringe) or low
NSP coverage (irregular attendance at a NSP or < 100% of injections covered by a new needle or syringe).
Control intervention
l No OST.
l Low coverage NSP or no NSP.
EFFECTIVENESS OF NEEDLE/SYRINGE PROGRAMMES AND OPIOID SUBSTITUTION THERAPY
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Types of comparisons
l OST versus no OST.
l High NSP coverage with no OST versus low coverage NSP.
l Low NSP coverage with no OST versus no NSP.
l Combined high/low NSP coverage with OST versus no OST and low/no coverage NSP.
Data collection and analysis
Two reviewers screened all title and abstracts, and disagreements were resolved following discussion.
Full texts were screened by two people to assess eligibility. Data were extracted independently by two
people and then checked for consistency. Full-text papers in languages other than English were translated
by individuals fluent in those languages.
Meta-analysis was conducted using random-effects models, pooling univariable and multivariable models
separately. We examined heterogeneity with the I2-statistic and explored reasons for heterogeneity using
univariable random-effects metaregression. We examined heterogeneity with the I2 and τ2 statistics, and
explored reasons for heterogeneity using univariable random-effects metaregression to evaluate the
impact of the following covariates on intervention effect: geographical region of study; recruitment
setting (community based or treatment); percentage of female participants; main drug injected; type of
NSP; frequency of injecting; dose, duration and adherence to NSP/OST (i.e. continuous or interrupted
treatment); and study design. There was insufficient information to assess the impact of adherence to
NSPs/OST (i.e. continuous or interrupted treatment). We used Stata® version 14.0 (StataCorp LP, College
Station, TX, USA) in all analyses and transferred the data into RevMan software version 5.3 (Cochrane,
The Nordic Cochrane Centre, Copenhagen, Denmark).
Grading of evidence
Risk of bias for all studies was assessed using the ACROBAT-NRSI tool (A Cochrane Risk Of Bias
Assessment Tool: for Non-Randomized Studies of Interventions), which is in development by the Methods
Groups of Cochrane.28 We assessed the overall quality of the evidence for the primary outcome using
the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) system. The GRADE
Working Group developed a system for grading the quality of evidence,29–32 which takes into account
issues related not only to internal validity but also to external validity, such as the directness of results.
In particular, they provide key information concerning the quality of evidence, the magnitude of effect of
the interventions examined and the sum of available data on the main outcomes.
The GRADE system uses the following criteria for assigning grades of evidence:
l High – we are very confident that the true effect lies close to that of the estimate of the effect.
l Moderate – we are moderately confident in the effect estimate. The true effect is likely to be close to
the estimate of the effect, but there is a possibility that it is substantially different.
l Low – our confidence in the effect estimate is limited. The true effect may be substantially different
from the estimate of the effect.
l Very low – we have very little confidence in the effect estimate. The true effect is likely to be
substantially different from the estimate of effect.
Grading is decreased for the following reasons:
l serious (–1) or very serious (–2) study limitation for risk of bias
l serious (–1) or very serious (–2) inconsistency between study results
l some (–1) or major (–2) uncertainty about directness (the correspondence between the population,
the intervention or the outcomes measured in the studies actually found and those under consideration
in our systematic review)
l serious (–1) or very serious (–2) imprecision of the pooled estimate (–1)
l publication bias strongly suspected (–1).
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Grading is increased for the following reasons:
l Strong evidence of association – significant relative risk of > 2 (< 0.5) based on consistent evidence
from two or more observational studies, with no plausible confounders (+1). Very strong evidence of
association – significant relative risk of > 5 (< 0.2) based on direct evidence with no major threats to
validity (+2).
l Evidence of a dose–response gradient (+1).
l All plausible confounders would have reduced the effect (+1).
Results
Text in this section is reproduced from Platt et al.26 and Platt et al.28 which are published open access
under the terms of the Creative Commons Attribution-Non-Commercial Licence, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited and is not used
for commercial purposes.
Study selection
Figure 1 shows the number of studies identified, reviewed and selected and the reasons for exclusion for
both searches.
We identified 21 papers that directly included measures of the impact of exposure to either OST or NSPs
on HCV infection transmission. In addition, we identified 11 eligible prospective studies that measured
HCV infection incidence and contacted authors of these articles. Of these, unpublished data were obtained
from seven cohort studies in Montreal, Canada;33 Baltimore, USA;34 San Francisco, USA;35 London, UK;36
and Sydney and Melbourne, Australia.37,38 The full text of 141 papers was reviewed. A total of 19 papers
were included, and 120 papers were excluded for the following reasons: no HCV infection incidence data
(n = 55); no measure of intervention exposure (n = 34); contain no primary data (n = 20); the sample was
not PWID (n = 1); all the sample were recruited from the intervention (n = 9); and the article could not be
obtained in its original language (Japanese) (n = 1).
In total, we included 21 published studies14,39–58 and seven unpublished studies33–37,59,60 comprising 1827
HCV incident infections and 8789.7 person-years of follow-up. Overall HCV infection incidence ranged
between 0.09 and 42 cases per 100 person-years across the studies.
Excluded studies
A total of 101 studies (104 articles) were excluded in which there was no outcome of interest assessed
(43 studies); no intervention of interest (32 studies); no comparison of interest (all participants on OST)
(nine studies); no outcome and no intervention of interest (11 studies); no outcome and no comparison
of interest (four studies); or when the study was an editorial or overview (two studies).
Description of studies
Participants and setting
We included studies undertaken in the USA (n = 8), the UK (n = 5), Canada (n = 5), the Netherlands (n = 1),
France (n = 1), Italy (n = 1), Spain (n = 1), Australia (n = 5) and China (n = 1). Twenty-five studies reported
the sex of participants, for which the mean proportion of female participants was 32% (range 2.8–55.9%).
Across 14 studies, on average, 40.7% (range 9.2–69.2%) of participants had experience of recent or
past homelessness and 35% (range 18.2–90%) had past or recent experience of prison (n = 12 studies).
The mean reported use of stimulants was 32.7% (range 0–75%, n = 19 studies) and a mean of 50.5%
(range 18.2–100%) of participants reported heroin use (n = 13). Across 14 studies, a mean of 50.6% of
participants reported injecting daily (range 18.2–84%).
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Type of interventions
Twenty-one of the included studies reported the impact of OST,14,20,39,40,45–47,49,51–53,55,57,58 including seven
unpublished estimates.33–37,59,60 Seventeen studies reported the impact of NSPs,14,20,41–44,47,48,50,54,56,58 including
five unpublished sources,33–35,59,60 and four reported combined measures of NSPs with OST,14,33,44,47
including one unpublished data source.33 One study looked at the impact of distributing injecting
paraphernalia (defined as spoons and filters) by itself, with needles/syringes and in combination with OST.47
Study design
There was much variation in the included studies in terms of sample size (range 46–2788), method of
recruitment involving street outreach (n = 12), respondent-driven sampling (RDS) alone (n = 2), street
outreach, snowball sampling or RDS combined (n = 4), and service attenders (n = 7). A range of study
Records identified through database
searching with IMPACT search
(n = 5798)
(MEDLINE, n = 799; PsycINFO, n = 373; 
Global Health, n = 490; EMBASE, n = 1838; 
CINAHL, n = 68; WOS, n = 1587; CENTRAL, 
n = 519; DARE, n = 13; NHS EED, n = 20; 
HTA, n = 3; CLib, n = 21; CDAG register, 
n = 67)
Records identified through database 
searching with LONGITUDINAL search 
(n = 5647)
(MEDLINE, n = 1793; PsycINFO, n = 206; 
Global Health, n = 163; EMBASE, n = 1819; 
CINAHL, n = 29; WOS, n = 1637)
Records after duplicates removed
(n = 5801)
Records screened
(n = 5801)
Full-text articles 
assessed for eligibility
(n = 141)
Records excluded
(n = 5660)
• Full-text articles excluded with 
   reasons, n = 104 
   (referring to 101 studies)
• Studies awaiting classification, n = 6
Studies included in
qualitative synthesis
(n = 28)
Studies included in
quantitative synthesis
(meta-analysis)
(n = 28)
FIGURE 1 Flow chart of included studies. CDAG, Cochrane Drug and Alcohol Register; CENTRAL, Cochrane Central
Register of Controlled Trials; CINAHL, Cumulative Index to Nursing and Allied Health Literature; CLib, Cochrane
Library; DARE, Database of Abstracts of Reviews of Effects; HTA, Health Technology Assessment; NHS EED, NHS
Economic Evaluation Database; WOS, Web of Science. Reproduced from Platt et al.,26,27 which are published open
access under the terms of the Creative Commons Attribution-Non-Commercial Licence, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited and is not used for
commercial purposes.
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designs were included, such as case–control studies (n = 2), cross-sectional studies (n = 3), prospective
cohort studies (n = 20), retrospective cohort studies (n = 2) and serial cross-sectional surveys (n = 1).
For cohort studies, the duration of follow-up time ranged between 1 and 22 years. Included studies
were published between 1995 and 2014. Key study characteristics are included in Table 1.
Methodological quality: risk-of-bias assessment
Twenty-one original non-randomised published studies were assessed. Two were judged as being at
moderate overall risk of bias, 17 were judged as being at serious risk of bias and seven were judged as
being at critical risk of bias. For two studies, we did not have sufficient information to make a judgement.
A summary of the risk-of-bias assessment is included in Table 2.
Effects of interventions
Current use of opioid substitution therapy versus no current opioid
substitution therapy
Of the 28 studies, we pooled data from a total of 17 studies to assess the impact of current OST use on
HCV infection incidence,14,39,40,45–47,49,52,53,55,56,58 including five unpublished estimates.33,36,37,59,60 Current use
of OST was defined as reporting use of OST within the past 6 months (yes or no)33,46,49,58,60 or as reporting
use of OST either within 6 months or > 6 months ago,36 use of methadone at the time of survey,39,47,52,59
continuous use of OST throughout the follow-up period,40,45,53 with one study defining continuous use
as daily use of methadone (any dosage) in the past 6 months14 or in the past month.37 One study used a
3-month time frame to measure the use of opioid agonist therapy maintenance treatment.55 One study
measured current use of buprenorphine.34
All comparison groups were made against no intervention. All the included studies were longitudinal
studies, with the exception of one case–control study49 and two cross-sectional surveys.47,59
The 17 studies included a minority of women (range 3–53%), a high proportion of the samples had
experience of prison (range 18–60%) and homelessness (9–70%), and use of stimulants ranged
between 1% and 51% across the studies. A total of 1073 HCV infection incident cases were included over
4990.29 person-years of follow-up.
Of these 17 studies, 12 presented adjusted estimates on which the primary analyses were focused.
Adjusted estimates controlled for potentially confounding effects of the following factors: duration of
injection; frequency of injection;33,36,60 area of residence, homelessness, sharing injecting equipment or
needles;2 sex, geographical region, use of condoms, injection of cocaine, duration of injection and sharing
injecting equipment;45 duration of injection, frequency of injection and age of whole cohort;34 unstable
housing, cocaine, heroin or methamphetamine injection, cohort of recruitment, year of recruitment and
follow-up time;46 survey year, homelessness, stimulant injection and duration of injection;47 sex, age,
duration of drug use and injection of cocaine;49 age, duration of injection, sex, ethnicity, homelessness or
prison in the past 3 months;55 sex, ethnicity, age, frequency of injecting, sharing needles/syringes, not
receiving OST while reporting opioid use,58 injected at follow-up, pooled money to buy drugs, injection
with used needles and backloading.53
Random-effects meta-analysis of multivariable estimates shows that OST was associated with a 50%
reduction in the risk of HCV infection [rate ratio (RR) 0.50, 95% CI 0.40 to 0.63] with little evidence of
heterogeneity between studies (I2 = 0; p = 0.889) (Figure 2).
Sensitivity analyses
This effect was increased when excluding estimates from four unpublished data sources33,34,36,53 (RR 0.42,
95% CI 0.31 to 0.58) and little evidence of heterogeneity between studies (I2 = 0%; p = 0.96). The effect
was maintained when limiting the analysis to exclude all unpublished data sets as well as one study that
was judged to be at critical risk of bias49 (RR 0.43, 95% CI 0.31 to 0.59; I2 = 0%; p = 0.93). The effect was
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TABLE 1 Characteristics of included studies
Author and
year Country Study design
Sex
(% female) Age (years) Sample
HCV per
100
person-years
New HCV
cases/
person-years Interventions Comparison
Aitken et al., 201737 Australia Cohort 31.7 29.4 (median) 98 8.6 17/196 OST current No OST in
past month
Use of OST in past month
Bruneau, 201533 Canada Cohort NA < 30 (37.4%) 285 17.3 102/589.35 OST; NSP (high); combined
NSP/OST
No OST in past
6 months; low
(< 100%)
NSP coverage(1) Use of OST in past 6 months;
(2) high NSP (> 100% coverage);
(3) OST in past 6 months and
high (> 100% coverage)
Craine et al., 200939 Wales Cohort 29.0 27.2 (mean) 286 5.9 17/287.33 OST current Not in OST
In OST at interview
Crofts et al., 199740 Australia Cohorta 41.9 29.2 (mean) 73 22.2 13/85.4 OST current Not on OST
Continuous OST during
follow-up
Hagan et al., 199541 USA Case–control 45.0 < 25 (24%) 46 20/NA NSP (low) Never used NSP
Ever used NSP
Hagan et al., 199942 USA Cohort 38.0 < 25 (19%) 187 20.8 26/209 NSP (high, low) Never used NSP
Current, regular or sporadic
NSP use
Holtzman et al., 200943 USA Cohort 38.0 < 21 (28%) 1288 139/NA NSP (low) No use of NSP in
past 6 months
NSP participation in the past
6 months
Hope et al., 201144 UK Cross-sectional 23.0 < 25 (17%) 119 40 14/35 OST current; NSP alone (low,
high); NSP/OST combined
No OST, low or
no NSP coverage
Use of OST in past 4 weeks;
high NSP (≥ 100% coverage) or
low NSP (< 100% coverage)
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TABLE 1 Characteristics of included studies (continued )
Author and
year Country Study design
Sex
(% female) Age (years) Sample
HCV per
100
person-years
New HCV
cases/
person-years Interventions Comparison
Hope, 201559 UK Cross-sectional 25.0 919 9.9 30.3 OST current; NSP Low NSP,
no OST
Use of OST in past 4 weeks;
high NSP coverage
(≥ 100% coverage)
Judd, 201536 UK Cohort 29.0 27.4 149 42 49/116.7 OST current
Use of methadone in past
6 months or longer
Lucidarme et al.,
200445
France Cohort 17.6 26.9 (mean) 165 11 16/178.4 OST current No OST
No definition
Maher, 201560 Australia Cohort 38.0 24 (median) 368 24.9 53/212.86 OST current No OST
OST in past 6 months
Mehta, 201534 USA Cohort 34
(median,
baseline)
324 17.8 27/166.5 OST current No OST
OST in past 6 months
Nolan et al., 201446 Canada Cohort 30.4 23–34 1004 6.32 184/2108.4 OST current No OST
Active participation in MMT in
past 6 months
Page, 201535 USA Cohort 21.7 33.7 (mean) 552 25.1 171/681.3 NSP (low) No NSP
NSP use in the past 3 months
Palmateer et al.,
201447
Scotland Cross-sectional 27.5 34 (mean) 2788 7.3 392/602.7 OST current; NSP (high)
OST/NSP combined; OST at time
of survey; high NSP (> 200%)
coverage and not on OST; low
NSP (< 200%)
No OST; low
NSP coverage
Patrick et al., 200148 Canada Cohort 30.3 34 (median) 155 29.1 62/207.95 NSP (high) No attendance
at NSP
Attendance at least once per
week at NSP in past 6 months
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Author and
year Country Study design
Sex
(% female) Age (years) Sample
HCV per
100
person-years
New HCV
cases/
person-years Interventions Comparison
Rezza et al., 199649 Italy Case–control 2.8 > 28 (21%) 106 28.6 21/73.4 OST current No OST
OST in past 6 months
Ruan et al., 200751 China Cohort < 28 (44%) 86 33.0 47/258 OST other Never used OST
Ever used OST
Use of NSP in past 6 monthsb
Roy et al., 200750 Canada Cross-sectional 27.0 31.8 (mean) 359 27.1 94/267 NSP (low) No NSP use in
past 6 months
Spittal et al., 201252 Canada Cohort 53.4 23 (median) 148 11.6 45/338.6 OST current Not in MMT
In OST at time of survey
Thiede et al., 200053 USA Cohort 48.9 < 25 (5.4%) 80 0.09 4/80 OST current and other Left treatment
and not enrolled
at follow-upContinuous treatment during
follow-up. Interrupted treatment;
left treatment at least once
during follow-up but had
re-entered by end of study
Thorpe et al., 200254 USA Cohort 39.7 18–22 (52%) 353 10 29/327.2 NSP (low) No use of NSP in
last 6 months
Use of NSP in past 6 months
Tsui et al., 201455 USA Cohort 31.9 15–18 (16%) 552 25.1 145/680 OST current and other No OST
Opioid agonist therapy
maintenance treatment in past
3 months; OST other opioid
agonist detoxification in past
3 months
Vallejo et al., 201556 Spain Cohort 27.3 ≥ 25 (40%) 137 39.8 42/105.4 OST other Never used OST
Lifetime use of OST
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TABLE 1 Characteristics of included studies (continued )
Author and
year Country Study design
Sex
(% female) Age (years) Sample
HCV per
100
person-years
New HCV
cases/
person-years Interventions Comparison
Van Den Berg et al.,
200714
The
Netherlands
Cohort 33.0 31.4 (median) 168 6.78 57/598.56 OST current; NSP alone;
combined OST/NSP
No OST or no
injecting; low
(1–99%) or no
NSP coverage
(0%)
OST ≥ 60mg of
methadone daily
High NSP (100% coverage);
low NSP (1–99% coverage)
van Beek et al., 199857 Australia Cohorta 55.9 < 20 (61.5%) 152 20.9 26/148.2 OST other Never used OST
Ever used OST
White et al., 201458 Australia Cohort 25.0 27 (median) 127 7.9 20/215.2 OST; NSP (low) No NSP. (1) No
OST, mainly
injected heroin,
(2) no OST,
mainly injected
another drug
Accessed NSP in past 6 months;
OST in past 6 months
MMT, methadone maintenance therapy; NA, not applicable.
a Denotes retrospective cohort design.
b This study was dropped because it did not report 95% CIs around the effect estimate or report new HCV cases in exposure and comparison groups to be able to estimate it.
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TABLE 2 Risk-of-bias assessment for included studies
Study Confounding Selection bias
Measurement
of interventions
Departures from
intended interventions Missing data
Measurement
of outcomes
Selection of
reported result
Overall risk
of bias
Aitken et al., 201737 Critical Critical Serious No information Critical Low No information Critical
van Beek et al., 199857 Critical Serious Serious No information Critical Low Low Critical
Bruneau, 201533 Moderate Serious Moderate No information No information Low Low Serious
Craine et al., 200939 Serious Serious Serious No information Serious Low Low Serious
Crofts et al., 199740 Critical Serious Low No information Serious Serious Low Critical
Hagan et al., 199541 Serious Serious Serious No information Low Low Low Serious
Hagan et al., 199942 Moderate Serious Low No information Low Low Low Serious
Holtzman et al., 200943 Serious Serious Moderate No information No information Low Low Serious
Hope et al., 201144 Moderate Moderate Serious No information Low Low Low Serious
Hope, 201559 Moderate Moderate Serious No information No information Low Low Serious
Judd, 201536 Moderate Critical Critical No information Critical Low Low Critical
Lucidarme et al., 200445 Moderate Serious Serious No information Serious Low Low Serious
Maher, 201560 Moderate Serious Serious No information No information Low Low Serious
Mehta, 201534 Moderate No information No information No information No information Low Low No information
Nolan et al., 201446 Serious Serious Moderate No information Low Low Low Serious
Page, 201535 Moderate No information No information No information No information Low Low No information
Palmateer et al., 201447 Serious Serious Moderate No information Serious Low Low Serious
Patrick et al., 200148 Serious Moderate Serious No information Serious Low Low Serious
Rezza et al., 199649 Serious Low Serious No information Critical Low Low Critical
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TABLE 2 Risk-of-bias assessment for included studies (continued )
Study Confounding Selection bias
Measurement
of interventions
Departures from
intended interventions Missing data
Measurement
of outcomes
Selection of
reported result
Overall risk
of bias
Roy et al., 200750 Serious Serious Serious No information Critical Low Low Critical
Ruan et al., 200751 Critical Critical Serious No information Serious Low Low Critical
Spittal et al., 201252 Serious Serious Moderate No information Low Low Low Serious
Thiede et al., 200053 Moderate Moderate Low No information Low Low Low Moderate
Thorpe et al., 200254 Serious Serious Serious No information Moderate Low Low Serious
Tsui et al., 201455 Moderate Moderate Low No information Moderate Low Low Moderate
Vallejo et al., 201556 Serious Serious Low No information Serious Low Low Serious
Van Den Berg et al.,
200714
Serious Serious Moderate No information Serious Low Low Serious
White et al., 201458 Moderate Serious Moderate No information No information Low Low Serious
Reproduced from Platt et al.28 This is an open access article under the terms of the Creative Commons Attribution-Non-Commercial Licence, which permits use, distribution and reproduction
in any medium, provided the original work is properly cited and is not used for commercial purposes.
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slightly reduced when limiting the analysis to exclude two studies47,49 that reported baseline measures of
effect only (RR 0.51, 95% CI 0.40 to 0.65; I2 = 0.0%; p = 0.807) and two studies that reported incident
RRs only34,39 (RR 0.51, 95% CI 0.40 to 0.64; I2 = 0%; p = 0.853). These data are not shown.
A random-effects meta-analysis of 16 studies that presented univariable estimates suggests that OST was
associated with a 40% reduction in the risk of HCV infection (RR 0.60, 95% CI 0.47 to 0.76), with only
moderate evidence of heterogeneity between studies (I2 = 31.7; p = 0.09) (Figure 3).
Metaregression
Based on univariable metaregression of unadjusted estimates, we found no evidence that effectiveness
varied by other covariates including geographical location. We did find evidence of differential impact in
the proportion of female participants in the sample. With each 10% increase of female participants in the
sample, the effect of intervention exposure was reduced (RR 1.59, 95% CI 1.13 to 2.29) (see Table 15).
History of opioid substitution therapy
Three studies published unadjusted estimates of history of OST use, comprising 115 HCV infection cases
over 511.6 person-years and from three prospective cohorts.51,56,57 One study did not define the time frame
and was coded as past experience of OST.56
Three studies published unadjusted estimates of interrupted OST use.40,46,53 Two of these studies were
prospective cohorts and one was retrospective, and a total of 200 HCV infection cases were included over
Note: weights are from random-effects analysis
Overall (I2 = 0.0%; p = 0.889)
Bruneau, 201533
Lucidarme, 200445
Current OST use (last 6 months)
Subtotal (I2 = 0.0%; p = 0.889)
Maher, 201560
Thiede, 200053
Mehta, 201534
White, 201458
Tsui, 201455
Craine, 200939
Reference
Nolan, 201446
Judd, 201536
Rezza, 199649
White, 201458
Palmateer, 201447
0.50 (0.40 to 0.63)
0.74 (0.47 to 1.16)
0.41 (0.12 to 1.40)
0.50 (0.40 to 0.63)
0.46 (0.25 to 0.84)
0.40 (0.01 to 4.20)
0.82 (0.19 to 3.54)
0.18 (0.04 to 1.00)
0.39 (0.18 to 0.87)
0.34 (0.12 to 0.99)
Risk ratio 
(95% CI)
0.47 (0.29 to 0.76)
0.49 (0.17 to 1.47)
0.34 (0.10 to 1.11)
0.56 (0.12 to 2.56)
0.52 (0.23 to 1.18)
100.00
25.04
3.39
100.00
13.91
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2.41
2.00
8.23
4.59
Weight (%)
22.02
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3.62
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FIGURE 2 Impact of current use of OST vs. non-OST use on HCV infection incidence from adjusted analyses.
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2273.8 person-years. Interrupted OST use was defined as use of OST at baseline but not at follow-up,46 or
leaving OST at least once during follow-up.40,53 One prospective cohort study comprising 149 HCV infection
cases over 680 person-years examined OST for detoxification,55 and two studies measured high dosage
(≥ 60 mg) or low dosage (1–59 mg) of methadone for daily use14 or use some time in the past 6 months.33
Both these studies were prospective cohorts and included 148 HCV infection cases over 598.6 person-years.
A random-effects meta-analysis showed no impact among studies measuring historical use of OST (RR 0.81
95% CI 0.52 to 1.27) or among those measuring interrupted use (RR 0.80 95% CI 0.57 to 1.10).51,56,57
The one study measuring the impact of OST used for detoxification was not associated with reduced HCV
infection risk acquisition (RR 1.45, 95% CI 0.79 to 2.66).55 High dosage with OST was associated with a
reduction of HCV infection acquisition (RR 0.52, 95% CI 0.29 to 0.94) but low dosage was not (RR 0.85,
95% CI 0.44 to 1.65) (Figure 4).14,33
Note: weights are from random-effects analysis
Current OST use (last 6 months)
Aitken, 201737
Bruneau, 201533
Craine, 200939
Crofts, 199740
Hope, 201559
Hope, 201559
Hope, 201559
Judd, 201536
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Tsui, 201455
Van Den Berg, 200714
White, 201458
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Subtotal (I2 = 31.7%; p = 0.092)
Reference
0.80 (0.31 to 2.07)
0.74 (0.47 to 1.16)
0.27 (0.09 to 0.77)
1.80 (0.50 to 6.46)
1.06 (0.35 to 3.23)
1.31 (0.08 to 21.48)
1.55 (0.14 to 17.27)
0.47 (0.16 to 1.36)
0.34 (0.11 to 1.02)
0.43 (0.24 to 0.76)
0.60 (0.14 to 2.54)
0.67 (0.45 to 0.99)
0.51 (0.29 to 0.90)
2.11 (0.83 to 5.37)
0.30 (0.02 to 5.69)
0.31 (0.14 to 0.67)
0.67 (0.39 to 1.14)
0.14 (0.04 to 0.51)
0.65 (0.15 to 2.93)
0.60 (0.47 to 0.76)
Risk ratio 
(95% CI)
Australia (Melbourne)
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FIGURE 3 Impact of current use of OST vs. no OST on HCV infection incidence findings from unadjusted analyses.
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Needle and syringe programmes versus lower or no needle and syringe
programmes coverage
A total of 15 studies reported measures of NSP exposure and HCV infection incidence,14,20,41–44,47,48,50,54,58
including five unpublished estimates.33–35,59,60 Only five studies published adjusted estimates,33,42,44,47,48
restricting the sensitivity analysis that could be conducted. We therefore focused our primary analyses on
pooling unadjusted estimates.
Comparison groups consisted of non-attendance in the NSP14,34,35,41–43,48,50,54,60 or lower coverage of
injections covered by a clean needle or syringe,14,44,47,59 or a needle or syringe obtained from a safe source.33
High coverage versus non-attendance or lower coverage
We pooled data from seven studies that reported unadjusted measures of high NSP exposure and HCV
infection incidence,14,42,44,47,48 including two unpublished data sets.33,59 High NSP coverage was defined
as obtaining 100% of needles and syringes from a safe source33 or reporting ≥ 100% of injections covered
by a clean needle or syringe,14,44,59 or ≥ 200% of injections covered by a clean needle/syringe.47 Other
measures of high coverage were defined as regular attendance at least once per week at a NSP48 or
obtaining most of all needles/syringes from a NSP in the past 6 months.42 The seven included studies
consisted of four prospective cohorts14,33,42,48 and three cross-sectional surveys,44,47,59 comprising 641 HCV
infection cases over 1015.51 person-years.
Note: weights are from random-effects analysis
Ever used OST
Vallejo, 201556
Ruan, 200751
van Beek, 199857
Subtotal (I2 = 0.0%; p = 0.491)
Interrupted OST use
Crofts, 199740
Nolan, 201446
Thiede, 200053
Subtotal (I2 = 86.1%; p = 0.001)
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Tsui, 201455
Subtotal (I2 = .%; p = .)
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Bruneau, 201533
Van Den Berg, 200714
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Reference
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0.50 (0.20 to 1.30)
1.08 (0.37 to 3.17)
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0.66 (0.55 to 0.79)
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0.80 (0.57 to 1.10)
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Risk ratio 
(95% CI)
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55.77
100.00
55.69
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The primary analysis focused on seven studies that measured high-level uptake of NSP coverage. This
primary analysis compared the effect of high-level NSP coverage versus no intervention33,42,48 or lower levels
of coverage.14,44,47,59 These seven studies included a median of 27% of women (range 23–38%), a high
proportion of the samples had experience of prison (range 26–60%) and homelessness (range 2–58%),
and use of stimulants ranged between 17% and 63% across the studies.
A random-effects meta-analysis suggested no evidence of high coverage of NSPs associated with a
reduction in the risk of HCV infection (RR 0.77, 95% CI 0.38 to 1.54) with evidence of high heterogeneity
between studies. (I2 = 78.8; p < 0.001) (Figure 5).
Sensitivity analyses
This effect remained the same when excluding the unpublished data sets (RR 0.71, 95% CI 0.23 to 2.19;
p < 0.001).33,59 The effect was also maintained when limiting the analysis to a subset of four studies that
excluded three studies assessed to be at critical risk of bias or that were unpublished data sets (RR 0.71,
95% CI 0.17 to 2.98), with evidence of within-study heterogeneity (I2 = 89.6%, p < 0.001).14,33,59 The
effect was increased when we excluded studies that reported only incident rate ratios (RR 0.78, 95% CI
0.35 to 1.74; I2 = 80.3%; p < 0.001).14 The effect was further decreased when we excluded studies that
reported baseline measures only (RR 1.26, 95% CI 0.55 to 2.93; I2 = 87.0%; p < 0.001).44,47,59 Limiting the
analysis to a further subset of four studies that adjusted for confounders, the effect remained the same
(RR 0.79, 95% CI 0.39 to 1.61; I2 = 77%, p = 0.022; τ2 = 0.4482) (data not shown).
Metaregression
Based on univariable metaregression analyses, we found some evidence that the effectiveness of high NSP
coverage varied according to geographical region. After removing studies from North America, high NSP
coverage in Europe was associated with a 54% reduction in HCV infection acquisition risk (RR 0.44,
95% CI 0.24 to 0.80) with less heterogeneity (I2 = 12.3%; p = 0.337), whereas in North America it
remained insignificant (RR 1.58, 95% CI 0.57 to 4.42, I2 = 89.9%; p < 0.001).
Note: weights are from random-effects analysis
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FIGURE 5 Impact of high NSP coverage vs. low or no NSP coverage on HCV infection risk acquisition from
unadjusted analysis. Reproduced from Platt et al.,26,27 which are published open access under the terms of the
Creative Commons Attribution-Non-Commercial Licence, which permits use, distribution and reproduction in any
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Based on univariable metaregression analyses, the differential impact of NSPs according to geographical region
remained, with studies from North America having less impact (ratio of RRs 3.73, 95% CI 0.95 to 14.7;
p= 0.06). There was no differential impact by recruitment site (p= 0.89), by proportion of participants reporting
stimulant use, homelessness, injection of stimulants or sex. (These data are presented in Appendix 1, Table 16.)
Low-level coverage of needle and syringe programmes versus no needle and
syringe programme coverage
Ten studies reported unadjusted measures of low-level NSP coverage and HCV infection incidence. Eight
were prospective cohorts14,34,35,42,43,54,58,60 and one was a case–control study.41 A total of 531 cases were
included in the analyses over 1617 person-years. One prospective cohort was dropped because it did not
report 95% CIs around the effect estimate or the number of new HCV infection cases in international and
comparison groups required to estimate it.50
A random-effects meta-analysis showed no evidence of an intervention effect of low NSP coverage on
HCV infection risk acquisition with moderate levels of heterogeneity (RR 1.41, 95% CI 0.95 to 2.09;
I2 = 62.3%; p = 0.007; τ2 = 0.19) derived from nine studies with a total of 3414 participants (Figure 6).
Combined needle and syringe programmes with opioid substitution therapy
versus low or no needle and syringe programme coverage and no opioid
substitution therapy
A total of four studies reported combined exposure to both NSPs and OST,14,44,47 including one
unpublished data set.33 These categories were defined as high coverage (≥ 100% or ≥ 200%) of injections
using clean needles or syringes14,44,47 or obtaining 100% of needles and syringes from a safe source33 plus
current use of OST at the point of survey44,47 or within the past 6 month,33 or daily use of methadone
during the past 6 months.14 OST use and low coverage (< 100% of injections covered by a clean needle
or syringe) was reported by three studies.14,44,47 A total of 518 HCV infection incident cases were included
in the analysis examining high NSP coverage and 449 for low NSP coverage. Only one study reported the
number of person-years.14 A random-effects meta-analysis showed that combined use of OST and high
Note: weights are from random-effects analysis
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coverage of NSP was associated with a 71% risk reduction in HCV infection acquisition (RR 0.29, 95% CI
0.13 to 0.65). The effect of exposure to OST and low coverage of NSP was less and non-significant
(RR 0.76, 95% CI 0.44 to 1.33) (Figure 7).
Publication bias
A funnel plot of 13 estimates (12 studies) suggested no evidence of publication bias in studies of current
OST exposure (Figure 8). A funnel plot of nine estimates (eight studies) suggested no evidence of
publication bias in studies of high NSP coverage (Figure 9).
Discussion
Text in this section is reproduced from Platt et al.26,27 which are published open access under the terms
of the Creative Commons Attribution-Non-Commercial Licence, which permits use, distribution and
reproduction in any medium, provided the original work is properly cited and is not used for
commercial purposes.
A primary meta-analysis of 12 observational studies, adjusting for key confounders and enrolling 5910
anti-HCV negative participants, showed that current use of OST compared with no intervention reduced
the risk of HCV infection acquisition by 50% (RR 0.50, 95% CI 0.40 to 0.63). The intervention effect is
strong, but the evidence is considered to be of low quality because it was derived from observational
studies with serious risk of bias. Nonetheless, the findings were robust to sensitivity analyses, excluding
studies judged to be at critical risk of bias, studies drawing on unpublished data, case–control and
cross-sectional studies reporting only baseline data and studies reporting only unadjusted estimates.
Note: weights are from random-effects analysis
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There also was no evidence of publication bias. All of these sensitivity analyses showed a statistically
significant benefit of OST. A funnel plot (see Figure 8) showed no evidence of publication bias.
A few studies reported other types of exposure to OST. Three studies reported past exposure to OST,51,56,57
three reported interrupted OST use,40,46,53 one measured OST use for detoxification,55 and two measured
high dosage (≥ 60 mg) or low dosage (1–59 mg) of methadone for daily use.14,33 Among these exposures,
only high dosage of OST was associated with a reduction in risk of HCV infection acquisition.
A primary meta-analysis of seven observational studies pooling unadjusted estimates and enrolling 5669
anti-HCV-negative participants show weak and low-quality evidence that NSP exposure did not reduce risk
of HCV infection acquisition. This effect remained consistent in sensitivity analyses. After removing studies
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FIGURE 8 Funnel plot with pseudo-95% confidence limits assessing publication bias in 12 studies of current OST
exposure. a, Unpublished data sets. IRR, incident rate ratio. Reproduced from Platt et al.,26,27 which are published
open access under the terms of the Creative Commons Attribution-Non-Commercial Licence, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited and is not used for
commercial purposes.
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FIGURE 9 Funnel plot with pseudo-95% confidence limits assessing publication bias in 15 studies of high NSP
exposure. The central line is plotted at the fixed-effect summary effect (RR 0.98, 95% CI 0.0.75 to 1.28).
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from North America, high NSP coverage in Europe was associated with a 61% reduction in HCV infection
acquisition risk (RR 0.39, 95% CI 0.24 to 0.64) with less heterogeneity (I2 = 0%; p = 0.428).
There was low-quality evidence for the impact of combined high coverage of NSP and OST from studies
comprising 3356 anti-HCV-negative participants, which suggested a 71% reduction in risk of HCV
infection acquisition (risk ratio 0.29, 95% CI 0.13 to 0.65). There were insufficient data to conduct a
sensitivity analysis with this intervention group. A summary of key findings and quality of evidence is
presented in Table 3.
Overall completeness and applicability of evidence
There is a substantial body of observational evidence that reviews the effectiveness of NSPs and OST in
reducing HCV infection acquisition among PWID. The majority of evidence was identified in North America
and Western Europe. Only one study was identified from China51 and no studies were identified from
Eastern Europe or South-East Asia, where the largest populations of PWID are located and where there is a
high prevalence of HIV, HCV and HIV/HCV co-infection among PWID.61–63
Quality of the evidence
Many studies included in the review were assessed as being at severe risk of bias. Of the studies that were
assessed, only two were judged as being at moderate overall risk of bias, 17 were judged as being at
serious risk and seven were judged as being at critical risk. There is a need to improve transparency and
consistency in the reporting of observational studies to facilitate systematic reviews of observational
studies. Only a few studies report the effect of exposure to NSPs adjusted for confounders (5/7), which
limited the sensitivity analyses that we could conduct. Therefore, efficacy estimates relating to NSP
exposure are limited to unadjusted estimates.
Potential biases in the review process
A potential bias in the review was the heterogeneity across the studies in the use of multiple effect
measures. Effect measures were converted into risk ratios in the meta-analysis, but this may have
introduced bias into our findings because we had to assume that risk ratios approximated odds ratios
(ORs), which may be inappropriate for some sites given the high incidence of HCV seroconversion. We
removed cross-sectional study designs that identified serological markers of incidence infection as part of
our sensitivity analysis. Effect estimates remained the same for current use of OST versus no intervention,
but not for high coverage of NSPs. The majority of studies recruited PWID currently or have done so
recently, which may not be representative of all PWID exposed to OST and may lead to an underestimate
of the effect of OST on HCV infection transmission. For example, in the Amsterdam cohort, people who
reported being on OST and having ceased injecting had a lower risk of HCV infection transmission.14
TABLE 3 Summary of findings for primary analyses
Outcomes Comparison
Relative effect
(95% CI)
Number of
participants
(studies)
Quality of the
evidence
(GRADE)
HCV infection incidence adjusted analyses:
number of HCV seroconversion follow-up –
mean 440.5 patient-years
Current OST vs. no
OST for PWID
Risk ratio 0.50
(0.40 to 0.63)
5910
(12 studies)
Low
HCV infection incidence unadjusted
analyses: number of HCV seroconversion
follow-up – mean 269 patient-years
High NSP coverage
vs. no/low NSP
coverage for PWID
Risk ratio 0.70
(0.38 to 1.54)
5669
(7 studies)
Very low
HCV infection incidence unadjusted
analyses: number of HCV seroconversions
follow-up – mean 356 patient-years
Combined OST and
high NSP vs. no OST
and low/no NSP
Risk ratio 0.29
(0.13 to 0.65)
3356
(4 studies)
Low
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Agreements and disagreements with other studies or reviews
Our review corroborates and underpins an earlier review that showed consistent and large effects of NSP
and OST on injecting risk behaviours associated with blood-borne virus transmission.8 Two recent reviews
focused on the effectiveness of OST and NSPs in reducing HCV infection incidence.3,19 Our findings
corroborate the most recent pooled analysis, which suggested that receiving OST and high coverage of
NSPs can reduce HCV infection risk alone, but that the effect of OST and NSPs is greater in combination.20
The estimate for association between exposure to NSPs and HCV infection incidence was weak in the
pooled analysis and focused on studies from the UK only. Findings from our subgroup analysis suggested a
stronger effect of high NSP coverage in Europe. This finding builds directly on the Turner et al.20 analysis
through the addition of one earlier paper14 and more recent studies and data sets59 to the meta-analysis,
and strengthens the effectiveness estimate for Europe suggesting reduced risk of HCV infection acquisition
(risk ratio 0.44, 95% CI 0.24 to 0.80). We found no effect of high NSP coverage when pooling estimates
from North America as well as greater heterogeneity across the studies. This corroborates findings from
another review that found an increased risk of seroconversion associated with NSP attendance and that
relied on evidence predominantly from North America.19
The lack of evidence for NSPs from studies in North America can be attributed to a mixture of confounding,
differences in injecting patterns, potential selection bias and misclassification of exposure. It has been shown
that people who attend NSPs regularly also report greater injecting risk behaviour and that, after adjustment
for injecting risk, any positive association between HCV infection transmission and NSP attendance is removed.
The effect of this residual confounding has been demonstrated in further analyses of a cohort of PWID in
Vancouver, which demonstrated that higher HIV seroconversion rates observed among daily NSP attenders was
associated with high-risk behaviours of attenders (including regular cocaine injection, sex work involvement
and homelessness), rather than use of the NSP.64 A study based in Seattle showed that people who were
homeless or who injected with used needles or syringes were more likely to become new NSP users.65
The higher proportion of stimulant injecting users in North America also means that the additional protective
effect of OST is absent, which may contribute to the impact of NSPs on HCV infection risk in European studies.
Potential selection bias may occur because samples of cohort studies are to some degree self-selected,
particularly when participants are lost to follow-up over time; they may be inherently different in terms of the
demographic characteristics and risk behaviours that can influence the outcome. Misclassification of exposure
may also occur because it is difficult to make a clear distinction between exposed and unexposed groups:
unexposed populations may have access to clean needles/syringes through other sources than NSPs. Consistent
measures of NSP exposure through coverage of injections by clean needles/syringes were used across the
European studies, whereas the North American studies drew on varied definitions of NSP use, which focused
on the frequency of attendance at NSPs. Comparability in the measurement of intervention exposure is
reflected in the higher heterogeneity observed among studies measuring exposure to NSPs (I2 = 80.9%;
p< 0.001) compared with OST exposure (I2= 0%; p = 0.959). This is particularly relevant in relation to
measures of intervention exposure that focus on the frequency of attendance at an NSP rather than a measure
of injections covered by clean needles and syringes, and further explains the lack of effect between high NSP
coverage and HCV infection incidence observed in North America.
Findings also corroborate two recent systematic reviews that measured the impact of NSPs and OST on
HIV transmission. These previous analyses of 12 observational studies estimated a moderate effect of NSPs
on reducing HIV transmission by 48% (95% CI 3% to 72%) and strong evidence for OST reducing HIV
transmission by 54% (95% CI 33% to 68%).16,17
A previous review of reviews from 2010 concluded that there was insufficient evidence to assess the
effectiveness of NSPs in reducing HCV infection incidence. This ‘meta’ review synthesised findings from
four primary reviews, three of which focused primarily on HIV as an outcome missing much of the relevant
data and the fourth of which predominantly relied on weaker study designs.3
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Implications for practice
Opioid substitution treatment reduces the risk of HCV infection acquisition among PWID. The evidence for
the effectiveness of high coverage NSP was more mixed, with good evidence from studies in Europe that
NSPs reduce HCV infection transmission. The intervention effect is strengthened by the combination of
OST and high-coverage NSP. OST and NSPs are recommended as key interventions for preventing
drug-related harm, including HCV infection transmission, by the World Health Organization (WHO), the
Joint United Nations Programme on HIV/AIDS, the United Nations Office on Drugs and Crime, the
European Centre for Disease Prevention and Control and the European Monitoring Centre for Drugs and
Drug Addiction. However, OST is not widely implemented in many countries, is prohibited in the Russian
Federation and is often restricted by age or duration of dependence prior to treatment entry.23
Our findings show the need to remove restrictions on the concurrent use of both NSPs and OST to maximise
reduction in HCV infection transmission. Distribution of needles/syringes through NSPs needs to be maintained
alongside the provision of OST. NSP and OST services need to recognise the role of sex and to develop
appropriate policies and practices to encourage women to use services addressing the specific injecting-related
risk behaviours that they face and addressing other health and social welfare needs. We identified only
three studies that examined effectiveness of interrupted use of OST, but effectiveness was reduced. Similarly,
available evidence to examine differences in effect by dosage was limited.
Implications for research
There is good evidence demonstrating the effectiveness of OST in reducing risk behaviour and the
transmission of HCV and HIV. However, there is a need to understand the role of the duration of OST use
in reducing the risk of both HIV and HCV. For NSPs, evidence needs to be strengthened, including more
consistent measurement in the coverage of NSPs across epidemiological studies to obtain better effect
estimates as well as to gain an understanding of how the injection of stimulants or prescription opioids
changes their effectiveness. Given the body of observational evidence on the effect of OST and NSPs on
reducing HIV and HCV infection incidence and other injecting-related harms, it is no longer ethical to
individually randomise exposure to OST or NSPs, so future trial evidence can be derived only from stepped
wedge clustered RCTs or using wait-list controls, if at all. Current guidance means that the quality of the
evidence typically will be assessed as low.
However, priorities for research needs to turn to implementation, the delivery of services and their
cost-effectiveness to ensure that existing services are maintained and to promote the introduction and
scale-up of services in countries and settings with emerging or growing epidemics of injecting and opioid
drug use. We need to understand the pathways between contextual factors and mechanisms of service
delivery, and the extent to which these influence effectiveness across different outcomes and settings. For
example, HIV and HCV infection epidemics continue unchecked in Eastern Europe, despite the implementation
of OST and NSP in some countries.66 Epidemics of HCV and HIV among PWID are growing in Sub-Saharan
African countries, including Tanzania and Kenya, where OST is currently being implemented, but little formal
evaluation is being undertaken. Research is needed here that does not employ experimental designs but rather
designs that take into account the specific economic, social and political context and different epidemiology
of HIV and HCV infection transmission in those contexts. We identified only one study conducted in a
middle-income country (China) and no studies in low-income countries.
There was insufficient evidence to examine differences in effectiveness by NSP modality or setting of OST.
This reflects a lack of evaluation of provision of OST or NSP in other settings. Further research is needed
to examine how the effect of NSPs differs by service modality including pharmacies, mobile clinics or
outreach services. Similarly, research into the effectiveness of OST delivered in specialist services,
community settings and prisons is needed.
Although evidence for the combined effect of OST and high NSP coverage seemed to be of higher quality,
we identified only four studies. Further evidence is needed to understand how effectiveness may differ by
modality and duration of OST, as well as by its impact on other health outcomes associated with injecting
drug use, such as bacterial infections and mental health.
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Finally, given the low quality of evidence, there is a need to improve transparency and consistency in the
reporting of observational studies to facilitate systematic reviews of observational studies.
Changes from original protocol
We have changed the title of the review to refer to opioids instead of opiates. Opioid encompasses
synthetic opiates as well as those derived from opium, whereas opiates includes only drugs derived from
opium. The original protocol specified that one sensitivity analysis would be to remove studies that
reported only incident rate ratios as effect estimates. We did not do this because only three studies used
incident rate ratios. Instead, we removed estimates derived from unpublished data sets as part of our
sensitivity analyses because seven estimates were derived in this way, making them a more substantive
part of the analysis.
There was insufficient evidence to answer some of the research questions that sought to examine
differences in effectiveness in terms of the following factors: duration of treatment, dosage of OST, type of
substitution used, NSP modality (fixed vs. mobile site) or setting of OST. This reflects a lack of evaluation of
the provision of OST or NSPs in other settings.
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Chapter 3 The impact of needle and syringe
provision on hepatitis C transmission among people
who inject drugs in the UK and Australia: an analysis
of pooled data sets
The aim of the study was to update a previous analysis of pooled data sets to provide a more robustunderstanding of the extent to which OST and NSP, alone or in combination, can reduce the risk of
HCV infection acquisition.
Methods
We collated six data sets previously used in a pooled analysis, methods for which have been published
previously.20 We added an additional three data sets, including a community survey of PWID in Bristol
(n = 336), Public Health England’s Unlinked Anonymous Monitoring Programme (UAMP) survey of PWID
from England and Wales (n = 3408), the Australian Needle Syringe Programme Survey (ANSPS) (n = 2391)
and replaced one of the studies with updated data from Public Health Scotland’s Needle Exchange
Surveillance Initiative (NESI) (n = 6988), adding in an additional 6041 individuals. These data are presented
in Table 4. We excluded one cohort data set used in the original analysis of recent initiates into injecting
because the data set did not contain information on use of NSPs and the population focused on young
and recent initiates into injecting, and were less comparable with the other samples.67
Two studies recruited PWID through NSPs (NESI, ANSPS) and one through both NSPs and drug treatment
clinics (UAMP).68–70 The remaining studies recruited via community settings (Wales) and through RDS
(Bristol, Leeds, Birmingham).20,39,44 Five of the studies included people who had injected in the past
4 weeks, whereas the UAMP, NESI and ANSPS included people who had ever injected drugs.
All studies, except for one, contained data on recent HCV infection, defined for cross-sectional surveys as
individuals who tested HCV RNA-positive among those who tested HCV antibody-negative from dried
blood spot (DBS) samples. The one cohort study defined incident infection as those who were HCV
antibody negative at baseline and were retested as antibody positive at 12-month follow-up.39 All samples
from the UAMP survey were tested for the purpose of the analysis. Anti-HCV testing was performed
using a previously published method, the accuracy of which is close to that achieved on venous blood
specimens.71 The residual DBS had been stored in the refrigerator with desiccant since anti-HCV antibody
testing, which has been shown to stabilise both anti-HCV and nucleic acids in DBS. Nucleic acid was
extracted from an area of approximately 28 mm2 punched from each DBS, using an automated platform
[Qiagen MDx (Qiagen, Hilden, Germany)]. Samples were tested for HCV RNA using nested polymerase
chain reaction amplification of the NS5B (non-structural protein 5B) region, which provides a product
suitable for differentiating different lineages of HCV infection.72
Outcomes
The primary outcome was new HCV infection (yes/no) based on the definitions described above. Secondary
outcomes were based on self-reported injecting risk behaviours (frequency of injecting, injecting with a
used needle or syringe, use of shared spoons or filters for drug preparation, injecting site infection) and
HIV/HCV infection testing.
Interventions
We used previously published outcome measures of OST use and NSP coverage.20 OST was defined as
current use of OST for all cross-sectional surveys, whereas in the cohort study it was defined as > 6 months
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TABLE 4 Summary of demographic, injecting risk behaviour, intervention coverage and outcome measures by study site
Characteristic Bristol 144 Leeds59 Birmingham59 aBristol 259 Wales39
aEngland and
Wales, UAMP70
aScotland,
NESI68
aAustralia,
ANSP69
Year 2006 2008 2009 2009 2004–6 2011–12 2008–12 2012
Study design Cross sectional:
RDS
Cohort: NSP
and community
Cross-sectional:
NSP, treatment
Cross-sectional: NSP
Inclusion criteria Injected in past 4 weeks
Injected in past
12 months Ever injected Ever injected
Total participants 299 302 310 336 406 (700) 3408 6988 2391
HCV infection prevalence, % (n/N) 59 (177/299) 60 (182/302) 42 (130/310) 60 (201/336) 26 (184/700) 46 (1567/3408) 54 (3709/6909)b 53 (1184/2243)
Female (%) 23 24 12 22 26 24 28 32
Age, years (median) 32 (26–37) 32 (27–37) 32 (28–38) 34 (29–39) 29 (24–34) 34 (29–40) 34 (29–39) 38 (31–45)
Duration injecting, median (IQR) 10 (6–16) 11 (7–16) 9 (4–13) 13 (7–18) 6 (3–12) 12 (6–18) 10.4 (6–16) 17 (11–25)
Ever homeless, % (n/N) 90 (270/299) 86 (260/301) 93 (287/310) 88 (295/336) 39 (158/405) 80 (2664/3331) 68 (4748/6985) NA
Homeless in past 12 months, % (n/N) 58 (174/299) 52 (156/301) 63 (194/310) 60 (175/295 39 (158/405) 36 (1209/3331) 24 (1654/6980) NA
Ever exchanged sex, % (n/N) 11 (34/299) 5 (16/302) 2 (5/310) 7 (24/336) 3 (18/599) 14 (343/2370) 5 (119/2314)
Ever been in prison, % (n/N) 81 (242/299) 81 (245/301) 85 (263/310) 77 (260/336) 71 (494/693) 72 (2401/3329) 60 (4188/6973) 51 (1192/2354)
Prison in the past 12 months, % (n/N) 42 (101/240) 36 (89/245) 43 (114/263) 32 (82/260) 46 (225/489) NA 15 (1070/6988) 23 (2206/9621)
New HCV infectionc 14/115 2/120 2/180 3/135 17/285 34/1809 51/3104 62/477
HCV infection incidence (per 100
person-years)
40 7.6 5.2 9.9 5.6 8.5 7.5 42.0
Abscess or sore at injection site, % (n/N) 59 (176/299) 45 (135/302) 49 (153/310) 46 (155/336) 72 (505/700) 28 (866/3092
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Characteristic Bristol 144 Leeds59 Birmingham59 aBristol 259 Wales39
aEngland and
Wales, UAMP70
aScotland,
NESI68
aAustralia,
ANSP69
Injection risk (past 4 weeks)
Injection in past 4 weeks, % (n/N) 100 100 100 100 100 75 (2500/3346) 79 (5512/6987) 91 (2166/2379)
Number of injections, median (IQR) 39 (14–84) 33 (12–60) 28 (8–83) 42 (18–84) 35 (8–84) 27 (8–63) 20 (4–76) 22 (9–50)
Injection with used needle/syringe,
% (n/N)
28 (83/299) 7 (20/302) 3 (10/310) 8 (28/335) 35 (35/407) 11 (231/2187) 69 (209/304) 16 (342/2073)
Shared filters, % (n/N) 47 (141/298) 28 (83/301) 33 (103/307) 49 (165/334) 40 (279/690) 23 (570/2454) 15 (199/1338)d 11 (228/1987)
Shared spoon/container, % (n/N) 94 (279/297) 96 (289/301) 41 (125/308) 86 (285/333) 50 (343/688) 27 (672/2465) 18 (299/1639) 23 (454/1987)
Injected while in prison, % (n/N) 21 (52/242) 17 (41/245) 12 (31/263) 24 (62/260) 7 (32/486) 16 (394/2451) 12 (509/4187) 34 (90/261)e
Injected crack cocaine, % (n/N) 62 (178/299) 61 (185/302) 56 (174/310) 75 (251/336) 12 (86/700) 55 (1840/3372) 6.5 (458/5581) 27 (642/2391)
Access to services
Tested for HIV, % (n/N) 77 (230/299) 73 (220/301) 71 (219/309) 83 (274/329) 79 (2563/3251) 73 (4911/6650) 87 (1997/2296)
Tested for HCV, % (n/N) 81 (235/291) 83 (250/301) 76 (231/303) 91 (303/332) 47 (317/669) 84 (2654/3169) 80 (5364/6694) 92 (2086/2267)
Never used a NSP, % (n/N) 8 (41/299) 5 (26/275) 5.7 (29/310) 5 (25/336) 18 (92/696) 32 (165/3378) 0 0
Low NSP coverage: (< 100%),
% (n or n/N)f
46 (137) 36 (108) 36 (111) 51 (172) 39 (126/325) 49 (1214) 22 (1180) 25 (500)
High NSP coverage: (> 100%), % (n) 54 (160) 64 (190) 64 (198) 49 (163) 54 (177) 51 (1222) 78 (4307) 74 (1466)
Currently on OST, % (n) 57 (172) 60 (180) 65 (203) 81 (241) 52 (149) 69 (2535) 82 (5106) 43 (1029)
IQR, interquartile range; NA, not applicable.
a Denotes additional data sets introduced to the analysis from previous pooled analysis by Turner et al.20
b NESI HCV-antibody positives: 161 tested weakly positive, coded here as HCV antibody positive.
c New HCV infection for all cross-sectional studies defined as HCV RNA positive in those antibody negative at baseline, for cohorts (Wales) defined as anti-HCV positive at follow-up.
HCV incidence for cross-sectional surveys calculated as I= [(365/T)n]/[(N – n) + (365/T)n] where I = incidence, T = estimated mean duration of the HCV antibody-negative/RNA-positive
‘window period’ = 75 days, n= number of HCV incident infections (HCV antibody negative and HCV RNA positive) and N = number susceptible (HCV antibody negative).
d 76% missing data.
e This is for in prison in the past 12 months.
f NSP coverage is coded so that those with missing data for number of needles obtained in the past 4 weeks but reporting injecting in past 4 weeks are coded as low coverage.
D
O
I:10.3310/phr05050
PU
BLIC
H
EA
LTH
RESEA
RCH
2017
VO
L.5
N
O
.5
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2017.
This
w
ork
w
as
produced
by
Platt
et
al.
under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth.
This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,
the
fullreport)
m
ay
be
included
in
professionaljournals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.
A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:
N
IH
R
Journals
Library,
N
ationalInstitute
for
H
ealth
Research,
Evaluation,
Trials
and
Studies
C
oordinating
C
entre,
A
lpha
H
ouse,
U
niversity
of
Southam
pton
Science
Park,
Southam
pton
SO
16
7N
S,
U
K
.
31
of OST in the past year (yes/no). An internationally used standardised measure of an individual’s NSP
coverage was defined as the percentage of injections for which a new needle had been obtained
(calculated as the average number of new needles obtained divided by the average number of injections
in past four weeks, with the exception of the NESI survey, which measures coverage over 6 months, and
the Birmingham study, which uses a 2-week time frame).5,73,74 The total number of needles or syringes
obtained from any source was taken, not limiting data to those needles/syringes obtained from a NSP.
We examined the effect of both interventions in two ways. First, we measured the impact of binary
measures of NSP and OST to assess their individual effect without considering the influence of the other
intervention. Second, we combined these binary measures to form a measure of harm reduction coverage
with four categories as used in the original analysis and comparable studies with high coverage defined as
≥ 100% of injections covered by a clean syringe for all sites (Table 5).14,20,68
Statistical analyses
Of the total 14,734 included participants across the eight studies, a total of 7173 were considered in
the primary analysis with an initial HCV antibody-negative result. The analysis involved (1) a meta-analysis
of the (unadjusted) effect of OST on new HCV infection incidence limited to 5543 participants; (2) a
meta-analysis of the (unadjusted) effect of high NSP coverage limited to 4947 participants; (3) a pooled
analysis of the (unadjusted and adjusted) effects of NSP and OST on new HCV incident infections confined
to 5280 estimates; and (4) a meta-analysis of the pooled effect estimates alongside estimates from a
recent systematic review.26 A flow chart summarising the numbers of HCV infection cases included in
analyses (1) to (3) is summarised in Figure 10. We also conducted a pooled analysis focusing on the effects
of NSP and OST on secondary outcomes (see below).
Meta-analysis
We conducted a meta-analysis to test for study heterogeneity in the effects of OST and high NSP coverage
on new HCV infection. Separate logistic regression models using fixed-effect meta-analyses were used to
estimate the study-specific associations of the (unadjusted) effects of OST and NSP on new HCV infection
and to examine levels of heterogeneity between study sites. As published elsewhere, counts of new HCV
infection cases were small, resulting in no cases in one intervention group in Birmingham20 and in the
2009 Bristol survey. We added one case and three controls to the intervention group with zero cases.75,76
We used the I2-statistic to assess between-study heterogeneity in the effects of the interventions on new
HCV infection.77
Pooled analysis of the effects of opioid substitution therapy and needle and
syringe programmes on new hepatitis C infection
There was no evidence of heterogeneity between the studies for OST (I2 = 13.6%; p = 0.324) or NSP
(I2 = 0%; p = 0.659) so the data were pooled in subsequent analyses and the augmented data points were
removed. We used logistic regression to model the odds of recent infection by NSP and joint effects of
OST exposure adjusting for key confounders of HCV infection risk including sex,41,45,51,67 injecting
duration,41,44,45,67 injecting crack cocaine45,67 and experience of prison.55
TABLE 5 Definition of combined harm reduction intervention
Intervention
NSP coverage ≥ 100%
Yes No
OST Yes Full harm reduction Partial harm reduction
No Partial harm reduction Minimal harm reduction
Full harm reduction includes individuals currently receiving OST but not injecting.
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Secondary outcomes
We also examined the risk of self-reported injecting risk behaviour and access to services according to
exposure to different levels of harm reduction (OST and NSP) as defined above. Measures of risk included:
(1) the proportion of needle/syringe sharing (n = 6217); (2) the frequency of injecting (n = 11,786);
(3) reuse of the same needle/syringe more than once for injecting (n = 1242); (4) used of shared filters
or spoons for the preparation of drugs (n = 7223); (5) self-reported symptoms of bacterial infections
(n = 5039); (6) receiving testing for HIV (n = 13,435); and (7) receiving testing for HCV infection (n = 14,026).
We used logistic regression for binary outcomes (measures 1, 2, 4–7) and linear regression for continuous
variables (measure 3). All models were adjusted for key confounders listed in the previous analysis
(sex,41,45,51,67 injecting duration,41,44,45,67 injecting crack cocaine45,67 and experience of prison55).
Baseline questionnaires
(n = 14,734)
Anti-HCV negative
(n = 7173)
Cross-sectional
(n = 6888)
Anti-HCV positive
(n = 7334)
No anti-HCV test
(n = 227)
Follow-up
(n = 516)
HCV RNA available
(n = 5940)
(168 HCV RNA +)
HCV new cases
Complete case data
(n = 5280)
• Positive, n = 158
• Negative, n = 5122
No HCV RNA tests
(n = 948)
HCV antibody available
(n = 285)
(17 HCV antibody +)
New cases
antibody +
(n = 17)
Negative
(n = 268)
antibody +
(n = 17)
Negative
(n = 252)
HCV RNA +
(n = 158)
Negative
(n = 5210)
HCV RNA +
(n = 140)
Meta-analysis 1
OST data
(n = 5653)
Meta-analysis 2
NSP data
(n = 4947)
Pooled analysis 1
NSP/OST
(n = 5280)
Negative
(n = 4538)
No OST data
(n = 572)
(10 HCV RNA +)
No NSP data
(n = 1278)
(28 HCV RNA +)
No NSP/OST data
(n = 945)
(27 HCV RNA +)
FIGURE 10 Flow chart summarising the combined HCV antibody and RNA test results among PWID in the UK and
Australia. +, positive.
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Pooled effects and systematic review findings
We conducted a meta-analysis using fixed-effects models to assess the pooled effects of study-level
associations between intervention exposure and new HCV infection incidence cases with findings from the
Cochrane systematic review reported in Chapter 1. Estimates from the review of European studies that
employed the same definition of high NSP coverage were extracted and combined with our additional
estimates from the UAMP and ANSP surveys. We used the I2-statistic to assess between-study
heterogeneity in the effects of the interventions on new HCV infection.
Findings
The eight studies in Table 4 summarise the characteristics of participants in each study. Approximately
26% of the participants were female, the median age ranged between 29 and 38 years, and the median
duration of injecting ranged between 6 and 17 years. The majority of participants had experience of
homelessness, ranging from 39% in Wales to 90% in the Bristol 2006 data set. Similar proportions had
experience of prison, ranging between 51% in the Australian data set and 90% in the Bristol 2006 data
set. Between 2% and 14% had ever engaged in sex work. The background prevalence of HCV infection
was highest in the 2009 survey in Bristol and Leeds (60%) and lowest in Wales (26%). Incidence of HCV
infection was highest in the Australian data set (42 per 100 person-years) and in the Bristol 2006 data set
(40 per 100 person-years) and between 5 and 10 per 100 person-years in all the other sites. Approximately
66% of participants currently injecting reported obtaining at least as many clean needles/syringes as
injections and 70% were currently receiving OST.
Meta-analysis to test for study heterogeneity in the effect of opioid
substitution therapy and needle and syringe programmes on the risk of
hepatitis C acquisition
The meta-analysis shows that high NSP coverage was associated with a slight reduction in the risk of HCV
infection but this was not significant (OR 0.76, 95% CI 0.54 to 1.06). Exposure to OST was associated
with a 45% reduction in the risk of HCV infection (OR 0.55, 95% CI 0.40 to 0.77). There was no evidence
of heterogeneity between the studies for the effect of either intervention (NSP: I2 = 0.0%; p = 0.659;
OST: I2 = 13.6%; p = 0.324). (These findings are summarised in Figures 11 and 12.)
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FIGURE 11 Meta-analysis summarising study-level estimates of the effect of high NSP coverage (> 100%) on HCV
infection incidence.
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Pooled analysis of the effect of opioid substitution therapy and needle and
syringe programmes on new hepatitis C infection
The impact of OST and NSP coverage on new HCV infections is summarised in Table 6 for the complete
case data (n = 5280). In the unadjusted analysis, PWID currently using OST had only a 65% reduced odds
of HCV infection (OR 0.35, 95% CI 0.26 to 0.48). High coverage with needle/syringes (≥ 100%) alone was
not significantly associated with reduced odds of HCV infection (OR 0.83, 95% CI 0.60 to 1.16). Following
adjustment for sex, experience of prison or injecting crack cocaine, the intervention effects of OST alone
was reduced [adjusted odds ratio (AOR) 0.61, 95% CI 0.43 to 0.87], but the effect of NSP alone was
not altered.
When examining the effects of combined harm reduction interventions, the risk of new HCV infection was
halved among those on full harm reduction (defined as receiving OST and ≥ 100% NSP coverage) (AOR
0.44, 95% CI 0.27 to 0.71) compared with those on minimal harm reduction (≤ 100% NSP coverage).
There were reduced odds of HCV infection acquisition among those on partial harm reduction exposed to
high NSP coverage but not among those on OST (AOR 0.59, 95% CI 0.36 to 0.96) and a higher effect for
those on OST but with low NSP coverage (AOR 0.41, 95% CI 0.22 to 0.75).
Pooled analysis of the effect of opioid substitution therapy and needles/syringe
programmes on injecting risk behaviours
A total of 15% of the sample reported injecting with a used needle/syringe in the past 4 weeks (958/6217),
20% had shared spoons or filters during the preparation of drugs (3018/14,734) and 30% had injected
with the same needle/syringe more than once (377/1242). The mean number of injections in the past
month was 44. Across five studies, 39.5% of participants had an abscess or sore at the injection site
(1990/5039). The majority (77.5%) reported ever having an HIV test (10,414/13,435) and a test for HCV
infection (81%, 11,440/14,026).
Injecting with a used needle or syringe
Participants in full harm reduction (≥ 100% NSP, OST) or partial harm reduction (≥ 100% NSP, no OST)
had a 50% lower risk of injecting with a used needle/syringe (AOR 0.5, 95% CI 0.38 to 0.62) than those
in minimal harm reduction (< 100%, no OST; AOR 0.5, 95% CI 0.41 to 0.65). Participants on OST but
with lower NSP coverage had a 30% reduced risk of injecting with a used needle/syringe (AOR 0.7,
Overall (I2 = 0.0%; p = 0.659)
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FIGURE 12 Meta-analysis summarising study-level estimates of the effect of current OST use on HCV infection incidence.
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95% CI 0.57 to 0.94) compared with those without OST. Current use of OST without taking into account
NSP coverage was not associated with reduced odds of injecting with a used needle/syringe (AOR 0.9,
95% CI 0.76 to 1.07). High compared with low needle/syringe programme coverage was associated with
a reduced odds of sharing a used needle/syringe (AOR 0.6, 95% CI 0.50 to 0.69). (These findings are
presented in Appendix 2, Table 18.)
Reuse of the same needles or syringes for injection
Across the five community cross-sectional surveys (n = 1195), full harm reduction compared with minimal
harm reduction was associated with a 40% reduction in the odds of reusing the same needle/syringe for
injection more than once (AOR 0.59, 95% CI 0.40 to 0.88). Partial measures of harm reduction were
not significantly associated with reuse of the same needle/syringe. Current use of OST alone was not
significantly associated with a reduction in reuse of the same needle/syringe (AOR 0.93, 95% CI 0.70 to
1.22). However, high coverage (≥ 100%) with needle/syringes was associated with a 40% reduction in
reuse of the same needle/syringe more than once (AOR 0.59, 95% CI 0.46 to 0.76). (These findings are
presented in Appendix 2, Table 19.)
TABLE 6 Association between intervention coverage defined as (a) combination harm reduction interventions and
(b) NSP coverage and OST alone and new HCV infection cases
Explanatory factors n Total % OR 95% CI p-value AOR 95% CI p-value
< 100 NSP, no OST 36 577 6 1.0 1.0
> 100 NSP, no OST 47 905 5 0.8 0.53 to 1.29 0.39 0.6 0.36 to 0.96 0.03
< 100 NSP, OST 19 896 2 0.3 0.18 to 0.57 < 0.001 0.4 0.22 to 0.75 < 0.001
> 100 NSP, OST 56 2902 2 0.3 0.19 to 0.45 < 0.001 0.4 0.27 to 0.71 < 0.001
Female 1.3 0.92 to 1.74 0.14 1.1 0.73 to 1.56 0.73
History of prison 0.9 0.69 to 1.24 0.59 1.4 0.98 to 2.05 0.06
Injection of crack cocaine 1.8 1.35 to 2.49 0.00 1.6 1.09 to 2.40 0.02
Duration of injection (years)
0–3 1.0 1.0
3.1–5 0.9 0.55 to 1.36 0.54 1.0 0.67 to 1.47 0.953
6–10 0.5 0.30 to 0.75 0.00 1.1 0.78 to 1.45 0.6853
11+ 0.8 0.53 to 1.10 0.15 1.1 0.86 to 1.49 0.361
Study
Bristol 1 1.0 1.0
Leeds 0.1 0.03 to 0.55 0.01 0.1 0.03 to 0.54 0.01
Birmingham 0.1 0.02 to 0.36 < 0.001 0.1 0.02 to 0.35 < 0.001
Wales 0.5 0.22 to 0.96 0.04 0.6 0.26 to 1.21 0.14
Bristol 2 0.2 0.05 to 0.59 0.01 0.2 0.06 to 0.75 0.02
NESI 0.1 0.06 to 0.22 < 0.001 0.2 0.10 to 0.38 < 0.001
UAMP 0.1 0.07 to 0.27 < 0.001 0.2 0.08 to 0.31 < 0.001
ANSP 1.1 0.58 to 2.00 0.81 1.3 0.64 to 2.54 0.49
On OST 0.4 0.26 to 0.48 < 0.001 0.6 0.43 to 0.87 0.007
High NSP coverage 0.8 0.60 to 1.16 0.27 0.8 0.55 to 1.12 0.182
AOR, adjusted odds ratio.
IMPACT OF NEEDLE/SYRINGE PROVISION ON HCV TRANSMISSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
36
Frequency of injecting
Among 10,514 participants reporting frequency of injection, we found that participation in full harm
reduction was associated with a mean reduction in injecting frequency compared with those in minimal
harm reduction (AOR –41.2, 95% CI –45.5 to –38.0). Participation in partial harm reduction with ≥ 100%
NSP coverage but no OST was associated with a reduction in injecting frequency compared with lower NSP
coverage and no OST (i.e. minimal harm reduction AOR –21.6, 95% CI 26.2 to –17.0). (These findings are
presented in Appendix 2, Table 20.)
Shared used of spoons and filters
Participants on full harm reduction had a 28% lower odds of sharing filters or spoons to prepare drugs
(AOR 0.78, 95% CI 0.66 to 0.98). The effect of partial harm reduction with or without OST or higher
coverage of needles/syringes results in the same proportional decrease in the risk of sharing filters or
spoons. Current use of OST without taking into account NSP coverage was not associated with a reduction
in the risk of sharing spoons and filters (AOR 0.94, 95% CI 0.83 to 1.06). High compared with low NSP
coverage was associated with a 12% reduction in the use of shared spoons and filters (AOR 0.88, 95% CI
0.78 to 0.98). (These findings are presented in Appendix 2, Table 21.)
Injecting site infections
There was a weaker association between the harm reduction intervention variable and injecting site
infections across the four community surveys, the Welsh cohort and the UAMP data set (n = 4259).
There was some evidence that current use of OST was associated with increased odds of an injecting site
infection (AOR 1.3, 95% CI 1.11 to 1.50). There was no association with the NSP coverage variable.
(These findings are presented in Appendix 2, Table 21.)
Hepatitis C and human immunodeficiency virus testing
Full harm reduction was associated with increased odds of testing for HCV infection. Odds of HCV
infection testing increased with greater harm reduction coverage, with participants on full harm reduction
having almost twice the odds of reported testing for HCV infection compared with those on minimal harm
reduction (AOR 1.9, 95% CI 1.56 to 2.23). Participants on OST had 1.5 times higher odds of being tested
for HCV infection (95% CI 1.36 to 1.71) and those with ≥ 100% NSP coverage had a 20% higher chance
of being tested for HCV infection (AOR 1.2, 95% CI 1.04 to 1.31). Similar associations were observed
with HIV testing. Participants on full harm reduction had twice the odds of reporting undergoing testing
for HIV (AOR 1.9, 95% CI 1.6 to 2.20) and odds of testing for HIV were 50% higher among those on OST
(AOR 1.5, 95% CI 1.36 to 3.04) and 20% higher among those with high NSP coverage (AOR 1.2, 95% CI
1.05 to 1.30). (These findings are presented in Appendix 2, Tables 22 and 23.)
Pooling estimates with systematic review findings
Combining estimates of NSP coverage from the systematic review with two data sets69,70 not already
represented in the review strengthened the evidence for the effect of high needle syringe programme
coverage on reducing the risk of HCV infection acquisition to 39% (RR 0.61, 95% CI 0.43 to 0.87) with
moderate heterogeneity (I2 = 30%; p = 0.189). The systematic review data comprised a total of 438 new
HCV infection cases from a sample of 3990. Similarly, the addition of 12 estimates from a systematic review
that examined the effectiveness of current use of OST comprising 998 new HCV infection cases from a
sample of 5910 supported the evidence for the effect of OST in reducing HCV infection risk acquisition
(RR 0.56, 95% CI 0.45 to 0.69; I2 = 0%; p = 0.620). These findings are summarised in Figures 13 and 14.
Conclusion
The analyses of pooled data sets from the UK and Australia showed strong evidence for the impact of full
harm reduction (OST with ≥ 100% NSP coverage) in reducing the risk of HCV infection acquisition,
injecting with used needles/syringes, frequency of injecting and increasing access to HIV/HCV infection
testing among PWID in the UK and Australia. The impact of high (≥ 100%) NSP coverage without OST
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reduced the risk of HCV infection acquisition by 40% compared with no OST and low (< 100%) NSP
coverage. Our meta-analysis showed a weaker effect of the effect of NSP coverage on HCV infection
incidence at the study level (OR 0.76, 95% CI 0.54 to 1.06). However, when this was combined with the
systematic review, the effect was stronger (OR 0.61, 95% CI 0.42 to 0.87).
Limitations
Our findings suggest a weaker effect of full harm reduction than reported previously, despite having a
sample size five times larger and greater study power. One reason for this may be that the majority of new
observations were derived from routine surveillance sets (UAMP, ANSP, NESI) that recruit from NSPs and
drug treatment centres. First, these data sets cover wide geographic areas for which the effectiveness of
Overall (I2 = 30.0%; p = 0.189)
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FIGURE 13 Meta-analysis combining pooled analyses with systematic review findings to measure the impact of
high NSP coverage (> 100%) on HCV infection incidence.
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FIGURE 14 Meta-analysis combining pooled analyses with systematic review findings to measure impact of current
OST exposure on HCV infection incidence.
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interventions is likely to differ, and this variation is not accounted for in the analysis. Second, the reported
numbers of needles/syringes obtained from the UAMP were 3–4 times lower than those reported by
community surveys, reflecting different inclusion criteria and settings. The community surveys were
undertaken in larger urban areas, whereas the UAMP include smaller towns and rural areas. Third, findings
clearly point to difficulties in accurately measuring the use of NSP coverage, which relies on correct recall
of the frequency of injecting and the numbers of needles/syringes obtained in a time period and does not
take into account secondary distribution (people taking additional needle/syringes to give to their peers).
Concluding remarks
This is the largest national UK-wide analysis of the effectiveness of OST and NSP among PWID on HCV
infection incidence. Findings clearly underline the importance of OST in combination with NSP as cornerstone
interventions to reduce HCV transmission among PWID and the need to prioritise these interventions to
prevent HCV. Findings also provide important new evidence of the role of high NSP coverage in reducing not
only HCV incidence but also injecting with used needles/syringes and show that increasing the circulation of
clean needles/syringes does not increase injecting frequency among PWID. The inclusion of the Australian
data set shows that findings are generalisable to other contexts.
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Chapter 4 Costing of needle and syringe
programmes
Introduction
Needle and syringe programmes have been shown to be cost-effective for the reduction of HIV
transmission in a wide range of settings.13,78,79 Recent studies indicate that NSPs could also substantially
reduce HCV infection rates.20,80 To date, there have been no economic evaluations of NSPs for HCV
infection reduction in Western Europe. This chapter aims to fill this gap by providing robust estimates of
the cost of NSP programmes in order to facilitate a cost-effectiveness analysis (see Chapter 5).
Methods
Needle and syringe programme costing
Description of the intervention
The intervention evaluated is NSPs. NSPs in England are funded through Drug Action Teams and Local
Strategic Partnerships, which are multiagency bodies involving local government, the police and health
services, and that can be provided through pharmacies, mobile vans or specialist fixed sites. In Scotland,
regional commissioning bodies are responsible for commissioning co-ordinated services for the region.
Needle and syringe distribution takes place through a range of modalities in the UK. There are three levels
of needle distribution detailed in NICE guidance.81 Level 1 includes the distribution of either loose or
packaged injecting equipment. Level 2 includes the distribution of injecting equipment in a bespoke ‘pick
and mix’ style and the dissemination of health promotion advice. Finally, Level 3 includes the distribution
of ‘pick and mix’ injecting equipment and health promotion advice, as well as the provision of ‘specialist
services’ (e.g. vaccinations, drug treatment and secondary care, including treatment for HCV and HIV).
The two most common modalities include pharmacy distribution and fixed-site distribution. Fixed-site NSP
programmes are contracted by commissioning bodies to provide needle and syringe exchange at Level 3
as described in the NICE guidance. Fixed sites are generally contained within substance misuse services,
which offer a wide range of drug and alcohol treatment interventions. These may include blood-borne
virus testing and treatment, pregnancy testing, one-to-one support, structured day care and group-work
programmes, OST prescription, relapse prevention services, and training volunteering and employment
services. All injecting equipment is offered free of charge, usually in a ‘pick and mix’ style, from which
clients may choose their own equipment to take away. Fixed sites also accept used injecting equipment for
safe disposal and provide health promotion advice regarding the location and care of the injecting site,
overdose avoidance and general welfare.
Pharmacies are contracted by local commissioning bodies to provide needle and syringe exchange, usually
at Levels 1 and 2 as described in the NICE guidance. Injecting equipment is distributed to clients free of
charge, either in a ‘pick and mix’ style or in pre-made pharmacy packs. Pharmacy packs contain various
size needles depending on the colour of the pack and usually come in quantities of 5, 10 or 20 needles
per pack. Some pharmacies are also now beginning to provide ‘one-hit kits’, which contain one needle
and are intended to reduce drug-related litter. Pharmacies also accept used injecting equipment for safe
disposal. Pharmacies may also provide health promotion advice, either verbally or in the form of health
education materials, which are distributed alongside injecting equipment. Pharmacies are usually paid an
‘incentive’ by commissioning bodies to distribute needles and syringes, which can range from £1 to £3 per
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exchange. Pharmacies also receive administrative and overhead support either from local commissioning
bodies or from fixed sites operating in the area; this support includes ordering and delivery of pre-made
needle packs, the collection and disposal of waste, and the administration and collation of service statistics.
Alternative modes of delivery not mentioned by the NICE guidance include peer-led and drop-in centre
distribution, mobile outreach, vending machines and drop-box schemes. Peer-led and drop-in centres
function as places for those with drug and alcohol dependencies to feel safe and comfortable, receive
support in the form of hot meals, washing facilities and/or clean clothes, and find referrals for medical,
legal or housing services. Mobile outreach services have the capability to visit sites in the outer areas of the
city during afternoons and evenings, targeting areas where pharmacy NSP provision is less accessible or
where there is a particularly high need for services. Vending machines are potential mechanisms by
which to allow people to access injecting equipment out of hours and can complement or supplement
existing services.
Sites and settings
Cost data collection took place in three UK cities, namely Bristol, Dundee and Walsall. Sites were
selected through a combination of convenience sampling based on the availability of impact data for the
cost-effectiveness analysis, existing relationships with service managers and the feasibility of conducting
a costing study. The three settings reflected variation in the primary modality through which needles were
distributed, and a range of ‘other’ modalities intended to expand coverage.
The Bristol Drugs Project (BDP) is responsible for all harm reduction and substance misuse treatment in
the Bristol area. They have a fixed site providing a needle exchange as well as other services. Pharmacy
co-ordination is carried out by the BDP, and pharmacy-distributed NSP supplies are provided by the BDP.
Pharmacies in Bristol exclusively distribute equipment in pre-made packs, rather than in a pick and mix
style. Packs are available in two sizes: 10 needles or 20 needles. Most pharmacies in Bristol will also
distribute OST, although commissioning for this is managed separately.
Services in Dundee are commissioned through NHS Tayside and the Sexual Health & Blood-Borne Virus
Managed Care Network Prevention Sub-Group. The Managed Care Network Sub-Group is a multiprofessional
group with representation from secondary care, primary care, the local authority, the voluntary sector and
patient/carer/client representatives throughout Tayside, which has a remit for blood-borne virus prevention
and sexual health improvement. This includes public awareness, education and harm reduction. The Tayside
Substance Misuse Service is made up of two specialist harm reduction nurses, an administrator and a lead
pharmacist. The service helps to co-ordinate pharmacy-based NSP services in addition to having several other
responsibilities. The Cairn Centre is the busiest fixed-site injecting equipment provider in the Dundee area.
Needle exchange services within CAIR Scotland are funded exclusively by the Managed Care Network.
There are 15 pharmacies providing needle exchange services throughout Tayside, six of which are in Dundee.
Pharmacies will offer injecting equipment either in packs or in pick and mix format. Most pharmacies in
Dundee will also distribute OST; however, commissioning for this is managed separately.
Finally, in Walsall, the council commissions all NSP/harm reduction services through Public Health England.
During the period of data collection, Addaction was commissioned to provide all needle/syringe exchange
services in Walsall. Owing to recommissioning occurring after the period of data collection, Addaction
Walsall are no longer in operation. Addaction co-ordinated other agencies providing NSP, including
pharmacies and Hi’s ‘n’ Lows (a drop-in centre; Walsall, UK). There are 12 pharmacies in Walsall offering
needle and syringe exchange services. Most pharmacies in Walsall also distribute OST, although
commissioning for this is managed separately. Hi’s ‘n’ Lows is a peer-run drop-in service, offering a safe
space for people to be and also offering a number of different services including a cheap meal, advice and
counselling, and clothes. They provided needle exchange in co-operation with Addaction (which provided
the needles and handled waste management).
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Data collection
Data collected incorporates the costs for different modalities of NSP provision (pharmacy, specialised and
mobile sites) within each city. In total, we collected cost data for three fixed sites, six pharmacies and three
‘other’ modalities, which could potentially enable scale-up of output and coverage levels. Other modalities
include a mobile outreach service, a drop-in centre and an out-of-hours pharmacy. For pharmacies, only a
subsample was costed in detail owing to the existence of multiple pharmacy NSPs in each setting. The
costs of other pharmacies in each city were estimated using their output data and unit cost data from the
pharmacies where detailed costings were undertaken to give an overall cost estimate per city. The cost
analysis covers a period of 1 financial year (2013–14), the most recent year for which data were fully
available, and takes a provider perspective.
We estimated the total and unit economic costs for distributing clean needles to PWID. Our approach to
costing was incremental to existing services and was particularly focused on needle and syringe exchange.
We followed standard methods for costing in an economic evaluation of a health intervention; we include
all costs regardless of the payer and estimate a ‘shadow cost’ when the price does not accurately represent
the value of resources.82,83
In collecting resource use data, when possible, data were extracted from existing reporting mechanisms,
including budget and expenditure records, human resources records and the management information
system. In addition, we carried out direct observations of staff time and activities in order to confirm
supply use estimations and to allocate resources that are shared between the NSP and other harm
reduction services (such as staff time, building space, equipment or vehicle operation). Shared resources
were allocated to services as a proportion of total services delivered and total time spent on each service.
Current market prices [2014 UK pounds sterling (GBP)] were applied to all resources in order to estimate
a cost. Overhead and support costs were estimated from programme records and a portion allocated
to NSP services. Data were collated in a standardised Microsoft Excel® Version 3 (Microsoft Corporation,
Redmond, WA, USA) spreadsheet. Data collection was primarily conducted by one researcher and
quality-controlled by a second researcher.
Owing to the nature of pharmacy-based needle exchange, there was far less detailed output data available
within pharmacies. We therefore made a number of assumptions in estimating the outputs at pharmacies.
The type of data available for pharmacy-based needle distribution in each city varied: in Bristol, pharmacies
reported on the total number of visits, whereas in Dundee, pharmacies reported on both the number of
visits and the total number of needles distributed. Walsall pharmacies reported on the number of packs
distributed. Based on feedback from both pharmacies and fixed sites, we assumed that 100% of clients
obtaining needles at pharmacies were opioid users. Information on the distribution by sex of clients
accessing pharmacies was available at two sites; this distribution was used to estimate the approximate
breakdown between male and female clients at the other two sites. In order to estimate the total number
of clients at pharmacies, we further assumed that an average of eight visits were made per client at
pharmacies over the course of 1 year; again, this assumption was based on observations at two
pharmacies for which this information was available. We assumed that pharmacies distributed an average
of 1.12 needle packs per transaction. The out-of-hours pharmacy had begun the distribution of ‘one-hit
kits’ shortly before the data collection period; as there was very little information on the quantity of
‘one-hit kits’ distributed per visit, we varied our assumption of ‘one-hit kits’ per transaction between 1
and 10 (the minimum and maximum quantities distributed per visit in the 2 weeks prior to the site visit).
Similarly, data on the proportion of needles distributed to opioid versus image and performance enhancing
drug (IPED) clients at Addaction Walsall were unavailable. We therefore assumed a proportion based on
data in other fixed sites. Detailed information on the sex distribution at the out-of-hours pharmacy and the
peer-led site was also not available; we therefore estimated the same sex distribution as observed in the
two pharmacies for which information on the sex breakdown was available.
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Data analysis
Fixed and variable costs
Costs at all sites were classified as fixed and variable costs to facilitate analysis. Fixed costs are defined as
those costs that are not easily changed in the short term. Fixed costs included the following ingredients:
l Overhead costs for pharmacy/fixed-site management – estimated as the percentage of needle
exchange services delivered compared with other services delivered in the pharmacy/the local area.
l Co-ordination by commissioners – included as an overhead and allocated to the site as the percentage
of needle exchange services delivered, compared with other services delivered in the pharmacy/the
local area.
l Training as a minimum – includes awareness of the need for discretion, but this should also include an
understanding of how to treat people in a non-judgemental way, and may include further education
on common injecting practices and harm reduction messages. Training costs were estimated using an
ingredients-based approach.
l Health and safety training – included as a cost for fixed-site staff but not for pharmacists, who as a part
of their normal job will already have received health and safety training (e.g. needle stick injuries) and
hepatitis B vaccines.
l Vehicle purchase – estimated using an ingredients approach and allocated as the proportion of mileage
used for NSP services compared with for other services.
Variable costs are those costs that vary depending on the volume of services provided and can change in
the short term. Variable costs included in the analysis are:
l Injecting equipment in pre-made packs or ‘pick and mix’ as appropriate to the site/service. Equipment
and paraphernalia distributed varied between pharmacies and fixed sites and from site to site. Equipment
distributed includes pots, water, citric acid, needles/syringes (various types and sized), condoms and
sharps bins. The cost of this equipment will be estimated using a combination of the ingredients-based
approach and step-down accounting. For pharmacies distributing needle packs, the base-case analysis
assumes that packs of 10 are routinely distributed. This is varied to packs of 20 needles in the
sensitivity analysis.
l Staff time costs, including service and administrative staff, allocated to NSP services as a percentage of
their time use for NSP services compared with other services, using a combination of observational and
interview data.
l Waste management and disposal of returned needles.
l Vehicle fuel, insurance and maintenance costs, estimated using an ingredients approach, and allocated
as the proportion of mileage used for NSP services compared with for other services.
Estimating city-level costs
In order to input into the cost-effectiveness model, we estimated the total cost for distribution of needles
to opioid users in each of the three commissioning areas included in the study. We take the assumption
that IPED users are at less risk of HCV infection via shared needles.84 This is based on low reported
prevalence of HCV infection in IPED users.
Our estimate of total costs for distributing needles to non-IPED users is estimated using total fixed costs at
the city level, plus a weighted average variable cost per needle distributed to opioid clients. This estimation
approach is intended to proxy the equivalent costs of providing needles only to opioid users (i.e. it
represents the full fixed cost of the infrastructure necessary to provide needle and syringe exchange, and
the variable cost attributable to non-IPED users). We anticipate this to be a conservative approach, which
does not account for the benefit of distributing needles to IPED users.
Total fixed costs at city level are estimated accounting for the fixed site in each city, as well as all pharmacies
and other modalities operating in each city. For pharmacies not included in our costing sample, we
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estimated an average fixed cost per pharmacy for each commissioning area using the two or three
pharmacies sampled for detailed cost data collection. We then applied an average fixed cost to all
pharmacies across the commissioning area; this information was provided by fixed sites in each city. When
incentive payments were less than or equal to the costs of staff time for transactions, these were treated as
a transfer and not included as an additional cost. When incentive payments were greater than the costs
of staff time, any additional amount was considered an additional cost and was factored into the total
cost estimate.
Average variable costs per opioid needle distributed were estimated for each service modality in each city
and weighted to reflect the total proportion of opioid needles distributed through that service modality
citywide. This weighted average variable cost was then applied to the total number of needles distributed
citywide to come to an estimate of the total citywide variable cost.
Uncertainty analysis
In order to reflect the uncertainty encountered in collecting NSP costs, we conducted a univariate sensitivity
analysis. We included factors in the sensitivity analysis that could not be directly observed or that varied
substantially between sites, including supply wastage, staff time taken for needle distribution, opportunity
costs of volunteer time, equipment wastage, opioid/IPED client mix, number of needles distributed per visit
and discount rate. In addition, we conducted a multivariate analysis of all factors mentioned above,
simultaneously varying all factors with uniform distribution between the minimum and the maximum values
observed over 1000 iterations. (The costing parameters varied in the uncertainty analysis, along with their
minimum and maximum values, are located in Appendix 3, Table 25.)
Results
Needle and syringe programme outputs
The size of fixed-site services varied substantially across the three cities. The largest fixed site handled
> 10,000 visits in the financial year, whereas the smallest fixed site handled only 1756 visits in the same
year (see Appendix 3, Table 26). The client mix at fixed sites also varied between sites. The majority of
clients attending BDP and CAIR Scotland were users of opioids and other drugs, whereas the majority of
clients at Addaction Walsall were IPED users. The total number of clients in 1 year at fixed sites varied from
569 to 1134; however, it is possible that the number of clients was distorted within fixed sites by clients
giving different names on different visits.
The majority of clients at all sites were male: 87% of clients visiting BDP, 62% of clients at CAIR Scotland
and 91% of clients at Addaction Walsall. At BDP, detailed information on the sex breakdown was
available by opioid vs. IPED users. When looking at this breakdown, the sex balance is much more extreme
among IPED users, with 98% of IPED users being male. It is possible that the large number of IPED users at
Addaction Walsall will have resulted in a greater majority of male clients.
There was considerably less variation in outputs within the pharmacies sampled for the collection of cost
data (see Appendix 3, Table 27). The pharmacies for which detailed data were collected reported between
1405 and 2316 visits per year. Pharmacies distributed between 18,518 and 36,100 needles. Two pharmacies
distributed needles in ‘pick and mix’ form; the remaining pharmacies distributed needles in pack form only.
Finally, the three ‘other’ modalities distributed a wide range of needles – between 6816 and 101,326
needles per year (see Appendix 3, Table 28). Although detailed information was not available in the
out-of-hours pharmacy or the drop-in centre on the breakdown of clients using either opioid and IPEDs,
based on feedback from the sites we assumed that 100% of clients at these two sites were opioid users.
The outreach service saw a greater mix of opioid/IPED users, with 72% of clients using opioids and 28% of
clients using IPEDs. The outreach service saw mostly male clients; this imbalance was more exaggerated
among IPED users (at 98% male) than opioid users (84% male).
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Needle and syringe programme costs
Total costs
Total annual costs for the distribution of needles to all users (of both opioids and IPEDs) at fixed sites
ranged from £25,613 to £65,630 per year, depending on the different sizes and reaches of the different
fixed sites (Table 7). Pharmacies saw much less variation in total costs, ranging from £6815 to £10,690 per
annum. Total annual costs for the out-of-hours pharmacy in Walsall were slightly less than the total costs
for day pharmacies, at £5235. The costs for the distribution of needles using the mobile outreach service in
Bristol were £32,887. Total costs for the drop-in centre in Walsall (Hi’s ‘n’ Lows) were lowest, at £2138.
The primary cost driver in most settings was the cost of supplies; this accounted for an average of 60% of
total costs across sites (range 23–80%) (Figure 15). Supplies costs for the out-of-hours pharmacy were less
than those for day pharmacies, owing to the fact that this pharmacy distributed only one-hit kits, whereas
the remaining pharmacies all distributed packs of 5, 10 or 20 needles during the costing period. This was
followed in most cases by administrative and overhead costs, which accounted for 6–45% of total costs.
Mobile outreach service costs were largely driven by transport costs, making up 47% of total costs.
TABLE 7 Total and unit costs by site
Site
Total
annual
cost (£)
Total fixed
costs (£)
Total
variable
costs (£)
Total
opioid
cost (£)
Unit cost
per opioid
needle (£)
Unit cost per
opioid client (£)
Fixed site
BDP 55,854.41 12,229.50 43,624.91 51,860.77 0.21 68.69
CAIR Scotland 65,630.81 5859.49 59,771.32 60,285.41 1.65 86.49
Addaction Walsall 25,613.22 1347.35 24,265.87 23,584.95 0.37 124.13
Other
Out-of-hours
pharmacy (Walsall)
5235.09 519.79 4715.30 5235.09 0.77 24.58
Outreach service
(Bristol)
32,887.50 536.63 32,350.87 22,361.89 0.24 78.19
Drop-in centre
(Walsall)
2138.19 421.68 1716.51 2138.19 0.27 19.01
Pharmacy
Pharmacy 1
(Bristol)
8541.67 860.31 7681.36 9802.99 0.31 48.81
Pharmacy 2
(Bristol)
10,276.01 1262.25 9013.76 11,171.30 0.29 48.36
Pharmacy 3
(Dundee)
6814.59 901.52 5913.07 6814.59 0.31 23.74
Pharmacy 4
(Dundee)
9019.88 2449.12 6570.76 9019.88 0.37 31.15
Pharmacy 5
(Walsall)
10,690.48 650.80 10,039.68 10,690.48 0.58 50.91
Pharmacy 6
(Walsall)
7506.43 443.77 7062.66 7506.43 0.43 36.27
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Table 7 shows the fixed and variable costs per site, and the total cost for needle distribution to non-IPED
users at each site (methods for this estimation are described previously; see Methods). The total opioid cost
varied from £23,584 at Addaction Walsall to £60,285 at CAIR Scotland, and from £6815 at Pharmacy 3 in
Dundee to £10,690 at Pharmacy 5, also in Dundee.
The unit cost per opioid needle distributed varied from £0.21 to £1.65, and the unit cost per non-IPED
client (annually) varied from £19.01 to £124.13. There was no consistent ranking across sites in terms of
unit costs; sites that had high unit costs per client did not necessarily also have high costs per needle, and
vice versa.
City-level costs: non-IPED users
Table 8 shows estimates of the total number of needles distributed to non-IPED users at the city level, total
fixed costs and average variable costs per needle, and estimated total annual costs for needle distribution
to non-IPED users by mode of distribution. Bristol and Walsall spent proportionally more on pharmacies
(68% and 69% of total city-wide costs, respectively) than on fixed-site distribution (22% and 24% of
total city-wide costs, respectively). In contrast, Dundee spent 58% of total city-wide costs on fixed-site
distribution, and only 42% of total city-wide costs on pharmacy distribution. Pharmacies in all three cities
distributed the majority of needles; pharmacies accounted for 59%, 73% and 66% of total citywide needle
distribution in Bristol, Dundee and Walsall, respectively. The fixed site in Dundee had the highest average
variable cost per opioid needle at £1.49. The lowest cost per needle was observed at the fixed site in Bristol,
at £0.16 per needle.
Total city-wide costs for distribution to non-IPED users varied from £104,496 in Dundee to £232,117 in
Bristol. Table 9 presents the total number of needles and total costs distributed compared with the total
opioid injecting population in 2014, as predicted by the impact model. Looking at the total costs incurred
in each city compared with the 2014 population size estimates included in the cost-effectiveness model,
the amount of investment per person injecting non-IPEDs varied across cities (see Table 9). Bristol spent
between £89 and £126 annually per person in the total non-IPED injecting population citywide, whereas
Dundee spent £127–155 per person and Walsall spent £60–86 per person. The variation in investment
at the city level is to some extent a reflection of varying coverage and intensity of interaction. Walsall
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FIGURE 15 Cost drivers as a proportion of total costs.
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distributed an average of 12 needles per visit but had the lowest number of visits per user overall in the
city (12–17 visits per person in the injecting population citywide). In comparison, Dundee distributed an
average of only 10 needles per visit, but saw clients much more frequently (17–20 visits per person).
Finally, Bristol had between 13 and 18 visits per person citywide, but distributed an average of 26 needles
per visit.
Uncertainty analysis
Figure 16 provides an illustration of our univariate and multivariate uncertainty analyses for the NSP
costing, showing the impact of varying each parameter for which there was uncertainty on the estimated
unit cost per opioid needle. The parameter with the greatest effect on costs was that of equipment
wastage; this is to be expected, as injecting equipment is the primary cost driver at most sites. Similarly,
varying assumptions of the total number of ‘one-hit kits’ distributed per client at the out-of-hours
pharmacy impacted the cost per needle substantially. Varying all parameters simultaneously gave a
relatively wide estimate of unit costs per needle. The out-of-hours pharmacy was most sensitive to
assumptions, with the unit cost per needle varying between –229% and +56% of the base-case cost in
the multivariate sensitivity analysis.
TABLE 8 Total costs and needles by city
City and site type Total needles Total fixed costs (£)
Average
variable cost
per needle (£) Total cost (£)
Bristol
Fixed site 252,039 12,229.50 0.16 51,861
Pharmacies (n= 25) 495,500 28,392.32 0.26 157,894
Other 92,171 536.63 0.24 22,362
Total citywide 839,710 41,158.44 0.23 232,117
Dundee
Fixed site 36,455 5859.49 1.49 60,285
Pharmacies (n= 5) 100,604 3880.79 0.41 44,210
Other NA NA NA NA
Total citywide 137,059 9740.28 0.69 104,496
Walsall
Fixed site 63,644 1347.35 0.35 23,585
Pharmacies (n= 12) 151,460 17,357.32 0.46 67,690
Other 14,628 941.47 0.34 7373
Total citywide 229,732 19,646.14 0.35 98,649
NA, not applicable.
TABLE 9 Total investment per opioid user, by city
City
Total
number
of needles
Average variable
cost per opioid
needle (£)
Total
cost (£)
Population
size
Visits
per user
Cost per
user (£)
Needles
per user
Bristol 883,524 0.23 232,116.78 1847–2595 13–18 £89.45–125.67 340–478
Dundee 150,790 0.69 104,495.75 675–825 17–20 £126.66–154.81 183–223
Walsall 245,002 0.35 98,649.03 1144–1646 12–17 £59.93–86.23 149–214
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FIGURE 16 Needle and syringe programme costing uncertainty analysis.
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Conclusions
We observed a degree of variation in costs across the three different commissioning areas evaluated, with
variation in cost and outputs being observed across fixed sites and pharmacies. This was due to substantial
variation in the set-up of NSP services. There is no ‘standard’ for NSP administration in the UK and, as such,
each setting had different types of services, with different degrees of interaction with opioid users. Although
cities varied in their modality of focus (i.e. pharmacy vs. fixed site), there was not a clear correlation between
the primary modality though which needles were distributed in the city and the estimated cost per opioid
user citywide.
Some variation was also due to case mix across the three cities. Addaction Walsall handled a larger
number of IPED users who made very few visits each. This increased the fixed costs, resulting in a greater
cost per opioid client. However, providing needles to IPED users did not necessarily increase the unit cost
per opioid needle distributed; for example, Addaction Walsall distributed a large number of needles to
opioid users, so the unit cost per opioid needle was relatively small.
The difference in costs observed between cities is likely to be driven partly by the type of needle distribution
and ease of access to needles for people injecting drugs. We observed a large variation in the number of
visits per user across cities and in the number of needles distributed at each visit. The variation observed,
however, should be taken in the context of the different characteristics of the injecting population in each
setting and not necessarily reduced efficiency in distribution. A higher number of visits per person in the
injecting population citywide did appear to increase the costs of distribution; however, an increase in the
level of investment per user citywide did not necessarily lead to reduced cost-effectiveness. In fact, the city
with the greatest investment per user (Dundee) also saw the greatest savings as a result of implementing
NSPs in the long term.
Limitations
The primary outcome of interest for this study is needle exchange for the prevention of HCV infection
transmission; we therefore include only those costs and benefits that are relevant to this outcome in this
costing study. We do not include any costs or benefits from other engagement programmes as delivered by
the fixed sites and the peer-led service, such as one-to-one support, sexual health services, legal advocacy,
etc. A larger number of visits per person in the injecting population may be necessary for these benefits;
further research on the impact of these services is required in order to come to any recommendation on the
optimal frequency of visits for injecting populations. These additional services are also likely to bring in
more clients to the needle exchange. This may especially be the case for women, who might access sexual
health-related services at the sites.
We also do not estimate the costs for the clean-up of drug-related litter, which can also be a substantial
investment, and without which some councils would not politically be able to continue the provision of
needle exchange. Drug-related litter is a key reason for implementing the distribution of ‘one-hit kits’ in
some pharmacies, including the out-of-hours pharmacy, as there have been a number of discarded unused
needles found in some study sites. Councils may need to consider the additional costs of litter pick-up
schemes; this can vary widely depending on the number of staff employed and the size of the city. In one
city, we estimated the salary costs for litter pickup to be approximately £4064 per year, not including
transport and equipment costs. In another (larger) city, the overall costs of a dedicated sex- and drug-related
litter pickup scheme are reported to be £80,000 per year.
Our analysis also does not consider any potential impact of the prevention of HCV cases in people injecting
IPEDs, and excludes variable costs encountered by NSPs in providing needles and syringes for IPED use.
Research from Australia indicates that IPED users are at some, albeit reduced, risk of HCV transmission.85
Finally, we encountered a lack of detailed information on the client mix receiving needle exchange services
through pharmacies and we could not obtain any estimates on the relative proportion of IPED to opioid
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injectors accessing pharmacy needle exchanges. Moreover, we could not find information on male-to-
female ratios in pharmacies. Feedback from pharmacies and fixed sites during the costing process indicated
that IPED users rarely access pharmacies and that the proportion of opioid visits to pharmacies is likely to
be close to 100%.
All findings were presented to each site mid-way through the project, when results were presented and
plausibility was discussed. Permission was sought to present the potentially sensitive nature of the findings.
It was agreed not to publish the costings separately but to present these alongside cost-effectiveness
analyses in any public dissemination or peer-reviewed output.
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Chapter 5 Impact modelling
Introduction
Previous modelling for the UK has shown that OST and NSP is likely to have had a large impact on
reducing HCV infection prevalence in the past, whereas further scaling up of these interventions will have
only a modest effect on HCV infection prevalence.86 However, this analysis did not estimate the current
ongoing impact of NSPs and how that may vary in specific UK settings, or assess the impact of scaling up
OST and NSP in terms of HCV infection incidence and HCV infections averted.
The prevalence of HCV infections and the coverage of harm reduction interventions such as NSPs and OST
varies across the UK,16,20,39,44,70,73,87–90 and although the coverage of OST has increased in the past 10 years, the
level of high-coverage NSPs has remained relatively constant.70 In this chapter, a HCV infection transmission
and progression model, incorporating new evidence on intervention effectiveness, is used to assess the impact
of current levels of OST and NSP on HCV infection prevalence, incidence and HCV-related morbidity among
current and ex-injecting drug users in three UK settings, and the probable impact of scaling up NSP coverage.
Methods
Model description
We developed a dynamic ordinary differential equation model of HCV infection transmission and disease
progression among PWID and ex-injecting drug users. The model simulates the movement of PWID
through different injecting durations, intervention, risk and HCV infection disease states, and also follows
them after they have ceased injecting to capture HCV morbidity outcomes.
Stratifications by injecting duration are included in the model to capture higher rates of injecting cessation
during the first few years of injecting,91 and the heightened level of HCV infection acquisition risk among
recently initiated PWID.20,92 There are four injecting duration categories: < 3 years, ≥ 3 years to < 10 years,
≥ 10 years and ex-injecting drug users. All PWID enter the model as recently initiated PWID (< 3 years injecting
category) at a constant rate θ, and then transition to non-recent PWID (at rate 1/3 year–1) and then to
long-term PWID (at a rate of 1/7 year–1 from the non-recent PWID). Each of these categories also has specific
cessation rates of injecting, which results in users entering the ex-injecting drug user class, as well as death
rates that vary by injecting duration, giving a total proportion of PWID leaving the current injector category, µi.
(Figure 17 shows the schematic for this aspect of the model structure. Ex-injecting drug users are also stratified
by the same infection and disease progression states so that morbidity benefits can be tracked.)
People who inject drugs are also tracked through different intervention states: no intervention, on OST
only, > 100% NSP only, and on both OST and > 100% NSP. When PWID start injecting they are assumed
to be in the ‘no intervention’ state. Recruitment on to OST and > 100% NSP occurs at per capita rates β
and η, respectively, with both being assumed to be independent of current risk state for simplicity and lack
of data. The rates of leaving OST and > 100% NSP are γ and κ, respectively. (See Figure 17b for the
schematic for this component of the model structure.)
The model is further stratified by high and low injecting risk, with high-risk behaviours being defined by
characteristics that have been shown to increase the risk of HCV infection acquisition among PWID in the
UK. High risk is defined as being homeless and/or a crack cocaine injector, and low risk is defined as
being neither homeless nor a crack cocaine injector. A proportion of individuals, ϕ, enter the model in the
high-risk category. Movement from the low- to the high-risk category and vice versa occurs at per capita
rates σ and ζ, respectively.
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All PWID enter the model as susceptible individuals and become infected at a per capita rate, (λn,mi,j ) or force of
infection, which depends on the intervention state, injecting duration category and risk category of the
individual, as well as the prevalence of infection. The force of infection for each susceptible state is defined by
the relative risk in that state, such that infectivity and susceptibility are multiplied by the following factors: Γ, Π,
B if the injecting drug user is on OST, ≥ 100% NSP or both, respectively; X1 and X2 if the injecting drug user is a
recent injector or non-recent injector, respectively; and Ξ if the injecting drug user is a high-risk individual.
Because assortative mixing has been shown to have little effect on transmission when there is movement
between high- and low-risk groups, we do not include it here.86 In addition, evidence from Bristol88 suggests
that there is little assortative mixing by injecting duration, so we assumed random mixing between all
categories. For this, the chance of an injecting drug user having a transmission event with an injecting drug user
in a specific risk category is assumed to be proportional to the overall transmission risk of PWID in that state.
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FIGURE 17 Schematic of injecting duration and infection components of model. (a) Injectors cease injecting
(cessation or death) at rate µi, where i = 1, 2 or 3 for recent, non-recent and long-term injectors, respectively.
Injecting duration is modelled in three categories with progression at rate τi, where i= 1 or 2 for recent and
non-recent injectors, respectively; (b) schematic of the intervention component of the model. It is assumed that
the recruitment rates β and η are independent of the current intervention state; and (c) schematic of disease
progression component of the model. Each of the disease states is stratified by injecting duration, n; risk category,
m; OST category, i; and NSP category, j. Progression through the disease states is by a rate determined by the
current disease state, as are disease-related death rates. In addition to current injectors, ex-injecting drug users are
followed through the model when they cease injecting with an identical pathway, except that reinfection is
excluded. All states have a cessation rate from injecting and a background death rate that is not disease related.
Reinfection can occur at any stage but these lines are not shown after compensated cirrhosis. C, chronically
infected; DC, decompensated cirrhosis; F0, F1, F2, F3, chronic infection states; F4, compensated cirrhosis;
HCC, hepatocellular carcinoma; LT, liver transplant; PLT, post liver transplant; S, susceptible. (continued )
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Once infected, a proportion of newly infected PWID, δ, spontaneously clear the infection and remain in the
susceptible category, and the remainder enter the chronically infected category (l n,mi,j ) and remain infected
until they die or are treated. The progression of HCV infection for any PWID who enters the chronically
infected PWID category is modelled as shown in Figure 17c. The disease states modelled are METAVIR stages
F0, F1, F2, F3 (chronically infected), F4 (compensated cirrhosis), decompensated cirrhosis, hepatocellular
carcinoma (HCC), liver transplant and post liver transplant. Individuals progress from F0 through each
METAVIR stage to compensated cirrhosis, from which they progress either to decompensated cirrhosis or to
HCC. Individuals with decompensated cirrhosis can then progress to HCC or can be considered for liver
(c) Infection
Treatment
Progression
S F0 C F0
Reinfection
Treatment
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S F1 C F1
Reinfection
Treatment
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S F2 C F2
Reinfection
Treatment
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FIGURE 17 Schematic of injecting duration and infection components of model. (a) Injectors cease injecting
(cessation or death) at rate µi, where i= 1, 2 or 3 for recent, non-recent and long-term injectors, respectively.
Injecting duration is modelled in three categories with progression at rate τi, where i= 1 or 2 for recent and
non-recent injectors, respectively; (b) schematic of the intervention component of the model. It is assumed that
the recruitment rates β and η are independent of the current intervention state; and (c) schematic of disease
progression component of the model. Each of the disease states is stratified by injecting duration, n; risk category,
m; OST category, i; and NSP category, j. Progression through the disease states is by a rate determined by the
current disease state, as are disease-related death rates. In addition to current injectors, ex-injecting drug users are
followed through the model when they cease injecting with an identical pathway, except that reinfection is
excluded. All states have a cessation rate from injecting and a background death rate that is not disease related.
Reinfection can occur at any stage but these lines are not shown after compensated cirrhosis. C, chronically
infected; DC, decompensated cirrhosis; F0, F1, F2, F3, chronic infection states; F4, compensated cirrhosis;
HCC, hepatocellular carcinoma; LT, liver transplant; PLT, post liver transplant; S, susceptible.
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transplant (as can individuals with HCC), which, if successful, results in the individual moving to the post
liver-transplant stage. HCV disease-related death occurs from the decompensated cirrhosis, HCC, liver
transplant and post liver-transplant stages with disease stage-specific death rates.
Treatment of HCV infection is allowed only in the F0–F3 and compensated cirrhosis (F4) stages, as it is
unclear whether or not treatment in later disease stages is beneficial.93 A number of PWID, Φ, are assumed
to be treated each year and on treatment a proportion, α, achieve a sustained virological response (SVR)
and re-enter the susceptible non-infectious category. Treatment of ex-injecting drug users occurs at per
capita rate r, with the same proportion, α, achieving SVR. Those who do not attain SVR remain in the
infected category and are eligible for retreatment. This simplifying assumption was made based on the
influx of new treatment regimes becoming available. On successful treatment, individuals enter the
respective susceptible category with the same disease stage (see Figure 17c). Disease progression still
occurs among these individuals if they have compensated cirrhosis, but at a slower rate. We assume no
further disease progression if treatment is successful in the F0–F3 chronically infected non-cirrhotic
stages.94,95 The disease progression of ex-injecting drug users is also tracked to assess the long-term impact
that interventions will have on this subpopulation. It is assumed that ex-injecting drug users who are
susceptible or who have been successfully treated cannot be reinfected.
Model parameterisation
The model parameters can be found in Table 10. The model was calibrated to the following parameters
estimated from survey data: HCV infection prevalence, coverage of OST and NSP, proportion of PWID with
high-risk behaviour and injecting duration distribution of PWID over time.
Odds ratio effect estimates for the degree to which the risk of HCV infection transmission is modified
when an injecting drug user is on OST or there is ≥ 100% NSPs in the high-risk category or for different
injecting durations were taken from a pooled analysis of UK and Australian data (see Chapter 2). The OR
combined effect of OST and ≥ 100% NSP was calculated by multiplying together the effects estimates for
OST and ≥ 100% NSP alone, to reflect the assumption that both interventions together would be more
beneficial than alone, giving a range comparable to that from the systematic review (see Chapter 1).
Hepatitis C treatment was assumed to occur in all settings since 2009 at context-specific rates based on
recent data from those settings, except for Walsall where data from Bristol was used because of a lack of
data from that setting. Before 2015, we estimated the SVR rate for pegylated interferon and ribavirin from
a recent study of PWID in the UK.99 After 2015, we assumed that treatment would involve using the new
direct-acting antiviral (DAA) drugs, and so assumed a high SVR rate of 90% for all genotypes.103
Instantaneous HCV infection disease stage progression rates were calculated from a recent meta-analysis
of PWID-specific progression probabilities to compensated cirrhosis101 and a systematic review of general
progression probabilities for other disease stages,101 and, similarly, the spontaneous clearance probability
came from a published meta-analysis.96 Non-HCV-related death and injecting cessation were combined
into one rate for each injecting duration strata, with the death rates being estimated from a cohort study
of PWID in Scotland,91 and the cessation rates being estimated through fitting the model to the observed
distribution of PWID by injecting duration.
The leaving rate from the high-risk category, characterised as homelessness or crack cocaine injection,
came from two studies among PWID in the UK.39,97 The leaving rates from NSP and OST came from a
Welsh cohort study.39 Conversely, the recruitment rates to these states were obtained through calibration.
Model calibration and uncertainty
The model was calibrated to data on PWID population size, historical coverage levels of OST and NSP,
prevalence of high-risk behaviours (crack cocaine injection and homelessness), HCV infection prevalence and
the distribution of injecting duration. These calibration data were collated from various sources (Appendix 4,
Table 29 summarises the data used), including size estimation studies,104–107 three Bristol community surveys
IMPACT MODELLING
NIHR Journals Library www.journalslibrary.nihr.ac.uk
56
TABLE 10 Model parameters
Parameter Symbol Value/range Reference
Epidemiological and demographic parameters
Number of new injectors per year θ Fitted to obtain
population sizes
See Appendix 4, Table 29 and supporting
information
Combined death and cessation
rates per year
µi Fitted to obtain injecting
duration profiles for
each setting
See Appendix 4, Table 29 and supporting
information
Infection rate per year π Fitted to obtain HCV
infection prevalence
required in each setting
See Appendix 4, Table 29 and supporting
information
Proportion of new infections that
spontaneously clear
δ Sampled from uniform
distribution (0.22–0.29)
Micallef et al., 200696
Leaving rate per year from
high- to low-risk behaviour
ζ Sampled range
(0.6761–1.617)
Data from cohort study97 found that 78 out
of 145 injectors were no longer homeless
after 8 months. Transition probability
sampled from beta distribution α = 78 and
β = 67 and converted to instantaneous rate
Recruitment rate per year from
low- to high-risk behaviour
σ Fitted to obtain required
high-risk proportions in
each setting
See Appendix 4, Table 29 and supporting
information
Intervention-related parameters
Leaving rate per year off OST γ 1–3 Duration on OST was 8 months
(4–12 months) in a cohort of PWID in
the UK98
Leaving rate per year off
high-coverage NSP
κ 0.37–0.77 Welsh cohort study: 61% of PWID were still
> 100% NSP after 1 year39
Recruitment rate per year on OST β Fitted to obtain required
OST coverage proportions
in each setting
See Appendix 4, Table 29 and supporting
information
Recruitment rate per year on
high-coverage NSP
η Fitted to obtain required
high NSP coverage
proportions in each
setting
See Appendix 4, Table 29 and supporting
information
Proportion of treatments achieving
SVR prior to 2015
α Sampled from
uniform distribution
(0.3992–0.6653)
Weighted mean of pooled intention to treat
SVR for genotypes 1 and 2/3 taken from
treatment data for PWID in the UK99
Proportion of treatments achieving
SVR post 2015
α Sampled from uniform
distribution (0.859–0.915)
Harris et al., 2014100
Proportion of infected ex-injecting
drug users treated in chronic and
compensated cirrhosis stages
r 0.03 Harris et al., 2014100
Number of PWID treated per year Φ Bristol: 18
Dundee: 34 (2009–15)
and 40 (2015 onwards)
Walsall: 2
Number of HCV infection treatments in
2011. Assumed treatment of PWID
commenced in 2009.99 More recent values
for Dundee from correspondence with John
Dillon (John Dillon, University of Dundee,
2016, personal communication). Walsall
value assumed to be same rate per infected
PWID as Bristol
continued
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TABLE 10 Model parameters (continued )
Parameter Symbol Value/range Reference
Relative transmission risk parameters
Risk associated with being on
OST only
Γ 0.41 (0.22–0.75) sampled
from log-normal
distribution
OR and 95% CI from pooled analysis
(see Chapter 2)
Risk associated with being on
high-coverage NSP only
Π 0.59 (0.36–0.96) sampled
from log-normal
distribution
OR and 95% CI from pooled analysis
(see Chapter 2)
Risk associated with being on
both OST and high-coverage NSP
Γ × Π 0.26 (0.09–0.64) Calculated as product of risk associated with
being solely on OST or NSP. Compares well
with estimate for systematic review
0.29 (0.13–0.65)
Risk associated with being a
recent injector compared with
being a long-term injector
χ1 1.53 (0.93–2.52) sampled
from log-normal
distribution
OR from pooled analysis (Lucy Platt, London
School of Hygiene and Tropical Medicine,
2015, personal communication)
Risk associated with being in the
high-risk category
Ξ For Dundee:
2.13 (1.40–3.24)
OR from pooled analysis. For Dundee, the
OR is just for homelessness because there is
little crack cocaine injection, whereas it is for
crack cocaine injection or homelessness for
Bristol and Walsall
For Bristol and Walsall:
2.75 (1.97–4.22)
Sampled from log-
normal distribution
Disease progression parameters
Yearly progression rate from F0
to F1
ρ1 0.529–0.2095 sampled
from normal distribution
PWID-specific instantaneous rates from
Smith et al., 2015101
Yearly progression rate from F1
to F2
ρ2 0.0216–0.1013 sampled
from normal distribution
Yearly progression rate from F2
to F3
ρ3 0.0450–0.1145 sampled
from normal distribution
Yearly progression rate from F3 to
compensated cirrhosis
ρ4 0.0513–0.1838 sampled
from normal distribution
Yearly progression rate from
compensated cirrhosis to
decompensated cirrhosis
ρ5 0.0166–0.0921 Instantaneous rates calculated from sampled
beta distributions of transition probabilities
in Shepherd et al., 200793
Yearly progression rate from
compensated cirrhosis or
decompensated cirrhosis to HCC
ρ6 0.0003–0.0684
Yearly progression rate from
decompensated cirrhosis or HCC
to liver transplant
ρ7 0.0062–0.0962
Yearly progression rate from liver
transplant to post liver transplant
ρ8 1.0423–2.4412
Decompensated cirrhosis-related
death rate per year
d9 0.1063–0.1842
HCC-related death rate per year d7 0.3904–0.7697
Liver transplant-related death rate
per year
d8 0.0911–0.4348
Post liver transplant-related death
rate per year
d6 0.0280–0.1016
Relative risk for progression
rate from compensated to
decompensated cirrhosis (ρ5)
following SVR
e5 0.07 (95% CI 0.03 to 0.2) Sampled from transformed log-normal
distribution102
Relative risk for progression rate
from compensated cirrhosis to
HCC (ρ5) following SVR
e6 0.23 (95% CI 0.16 to 0.35) Sampled from transformed log-normal
distribution95
IMPACT MODELLING
NIHR Journals Library www.journalslibrary.nihr.ac.uk
58
in 2004, 2006 and 2009,44,73,88,89 yearly UAMP surveys from 1991 (Bristol) or 2006 (Walsall) to 2014,70 and
four surveys from NESI for Dundee from 2008 to 2014.70 Data on incidence for Dundee (NESI) and Bristol
(community survey 2009) were used for model validation as well as for prevalence data post 2006 for Bristol
and Walsall (UAMP).
Model calibration was carried out in three steps with 1000 parameter sets obtained at each step:
1. population size and injecting duration fitting using a PWID demographic submodel without infection
2. NSP and OST coverage fitting using a submodel that includes HCV infection transmission but no disease
progression
3. HCV infection prevalence fitting using the full model with disease progression.
Step 1
In Dundee, survey data70 suggested that the proportion of the PWID population in each injecting duration
category was stable from 2008 to 2014, and so we assumed a constant population size estimated from
unpublished data from Scotland. In Bristol and Walsall, size estimation data suggest that the PWID population
has decreased by between 10% and 30% between 2009 and 2011.104–106,108 Concurrently, survey
data44,70,73,88,89 suggest that the proportion of PWID injecting for > 10 years has increased, whereas the
proportion injecting for between 3 and 10 years has decreased (Figure 18). There has been little change in the
proportion injecting for < 3 years. It was assumed that these changes were partly attributable to a decrease in
the initiation rate of new injectors and a change in the cessation rates of non-recent and long-term injectors.
We allowed for uncertainty around these parameters and estimated them by fitting the model to the
population size and injecting duration profile (proportion of PWID in each injecting duration category) at two
time points for Walsall and Bristol and one time point for Dundee. This fitting was done with a demographic
submodel, which had only three injecting duration categories and no other stratification. We assumed that
the PWID population size was at equilibrium initially (before 2004, 2006 and 2008 for Bristol, Walsall and
Dundee, respectively). We sampled 1000 values for this ‘stable’ initial population size and the cessation rate
from the recent injector category for each setting. For each of these 1000 parameter sets, the wide prior
distributions for the cessation rates from non-recent and long-term injectors (see Appendix 4, Table 29) were
then sampled, and for each sample the model was fit to the initial population size by calculating a suitable
PWID recruitment rate, using the steady state equations for the demographic submodel (for more details, see
Appendix 4). Parameter sets were retained if the resulting injecting duration profile lay within the ranges
suggested from the data, otherwise the cessation rates were resampled. We then sampled 1000 estimates for
the later population size in 2011 for Bristol and Walsall, as well as new cessation rates for non-recent and
long-term injectors, and the PWID recruitment rate was recalibrated to fit to this new sampled population size
for the 2011 data (for Bristol and Walsall only). This refitting of the demographic submodel was done using
the Matlab release 2014b (The MathWorks, Inc., Natick, MA, USA) algorithm fzero applied to the analytic
solution of the model with initial conditions from the first step of fitting. Parameter sets were retained if the
resulting injecting duration profile lay within ranges suggested from data for the years 2004 and 2011 for
Bristol and 2008 and 2011 for Walsall, otherwise the new cessation rates for this second step were resampled
to obtain a fit to each of the first step parameter sets (1000 each for Bristol and Walsall).
Step 2
Coverage levels for PWID currently on OST have increased over the past 12 years. In Bristol, the proportion
of PWID currently on OST increased from 40% in 200473 to 81% in 2009.88 In Walsall, OST coverage
increased from 40% in 2006 to 70% in 2009,70 and in Dundee it increased from 43% in 2008 to 72%
in 2014.87 Conversely, over this same time period, the proportion of PWID with > 100% NSP coverage
remained stable in both Bristol (55%)70,73,88 and Walsall (38%),70 although it increased over time in Dundee
from 41% in 2008 to 60% in 2014.70 Modelled OST coverage levels for each city were calibrated to this
coverage data by varying the recruitment rate onto each intervention. A service provision estimate of NSP
coverage was calculated for each setting using data on needles distributed from the costings analysis
(2014 data), population size (calculated from the model in 2014) and injecting frequency from survey data.
Bootstrap samples of the mean injecting frequency were calculated for each setting using UAMP (Bristol
DOI: 10.3310/phr05050 PUBLIC HEALTH RESEARCH 2017 VOL. 5 NO. 5
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Platt et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
59
20
In
ci
d
en
ce
 p
er
 
10
0 
p
er
so
n
-y
ea
rs
2005
Year
HCV infection incidence
2015
10
0
100
PW
ID
 (
%
)
2005
Year
Long term
2015
50
0
3000
2000
N
u
m
b
er
 o
f 
PW
ID
2005
Year
Total population
(a)
2015
1000
0
100
50
PW
ID
 (
%
)
2005
Year
Recent
2015
0
100
Pr
ev
al
en
ce
 (
%
)
2005
Year
HCV infection prevalence
2015
50
0
100
PW
ID
 (
%
)
2005
Year
Non-recent
2015
50
0
100
PW
ID
 (
%
)
2005
Year
High risk
2015
50
0
100
50
PW
ID
 (
%
)
2005
Year
OST coverage
2015
0
100
PW
ID
 (
%
)
2005 2010
2010
2010
2010
2010
2010
2010
20102010
Year
NSP coverage
2015
50
0
20
In
ci
d
en
ce
 p
er
 
10
0 
p
er
so
n
-y
ea
rs
2008 2010
Year
2012 2014 20162006
HCV infection incidence
10
0
100
Pr
ev
al
en
ce
 (
%
)
2008 2010
Year
2012 2014 20162006
HCV infection prevalence
50
0
2000
N
u
m
b
er
 o
f 
PW
ID
2008 2010
Year
2012 2014 20162006
Total population
1000
0
(b)
100
PW
ID
 (
%
)
2008 2010
Year
2012 2014 20162006
Long term
50
0
100
PW
ID
 (
%
)
2008 2010
Year
2012 2014 20162006
Non-recent
50
0
100
PW
ID
 (
%
)
2008 2010
Year
2012 2014 20162006
Recent
50
0
100
PW
ID
 (
%
)
2008 2010
Year
2012 2014 20162006
High risk
50
0
100
PW
ID
 (
%
)
2008 2010
Year
2012 2014 20162006
NSP coverage
50
0
100
PW
ID
 (
%
)
2008 2010
Year
2012 2014 20162006
OST coverage
50
0
FIGURE 18 Graphs showing model fitting of the baseline scenarios in each setting. Error bars in black are data
points from surveys, error bars in blue are the ranges used for model calibration (for NSP coverage this was the
service provision estimate). (a) Bristol; (b) Walsall; and (c) Dundee. (continued )
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and Walsall) and NESI (Dundee) data. In addition, the mean injecting frequency in Dundee has decreased
from 717 injections per year in 2008 to 388 injections per year in 2014. Therefore, an estimate of NSP
coverage was calculated for each time point. The average service provision estimates of NSP coverage
were 56% and 28% in Bristol and Walsall, respectively, in 2014 and 27% and 49% in 2008 and 2014,
respectively, for Dundee (see Appendix 4, Table 29 for more details). The recruitment rates were estimated
using an intervention submodel that incorporated no onward disease progression, as these mechanisms
have little effect on the coverage levels obtained. Using the Matlab fitting algorithm lsqnonlin, recruitment
rates were found to fit the submodel to the initial and end-point coverage of each intervention (as shown
in Appendix 4, Table 29), while assuming that coverage levels were quasi-stable. In the full model, the
recruitment rates for the initial coverage level were first used to obtain initial conditions for the first time
point for each city, and then the recruitment rate was gradually varied linearly between the two values to
obtain the required increase in coverage for that city.
Survey data suggest that the prevalence of crack cocaine injecting and/or homelessness, our markers of
high HCV infection transmission risk, have remained stable in Dundee (33% homeless) and Walsall
(52% homeless or crack cocaine injection), whereas it has increased in Bristol from 75% in 2004 to 87% in
2014 (homeless or crack cocaine injection). We assumed that a proportion of injectors are high risk when
they initiate injecting, which is consistent with available data.97 The leaving rate from these high-risk
categories was estimated from a cohort study on homelessness, which found that approximately two-thirds
of homeless PWID are no longer homeless after 1 year.97 This agrees with unpublished findings from a
Welsh cohort study for both crack cocaine injecting and homelessness.39,86 The leaving rate was sampled
1000 times and used for all three settings. The proportion of PWID that are high risk was also sampled
1000 times for each setting. The recruitment rates were then calculated for each parameter set using the
steady-state solution of the high- and low-risk submodel (two variables). In Bristol, where the proportion
of high-risk PWID has increased, we calculated a second recruitment rate for the second time point (2014)
using the same method. For Bristol, the recruitment rate was gradually varied linearly to obtain the increase
in the proportion of PWID that are high risk.
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FIGURE 18 Graphs showing model fitting of the baseline scenarios in each setting. Error bars in black are data
points from surveys, error bars in blue are the ranges used for model calibration (for NSP coverage this was the
service provision estimate). (a) Bristol; (b) Walsall; and (c) Dundee.
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Step 3
The last step of the model calibration involved fitting the full model to the HCV infection prevalence data
from each setting (sampled 1000 times from the ranges given in Appendix 4, Table 29). This incorporated the
1000 parameter sets from the previous model calibration steps, and involved calibrating the model’s infection
rate using the lsqnonlin function in Matlab. The model was first fit to the initial prevalence estimate (sampled
from the ranges given in Appendix 4, Table 29) in 2004, 2006 and 2008 for Bristol, Walsall and Dundee,
respectively (see Figure 18 and Appendix 4, Table 29), while assuming that the epidemic was in a stable state
at that time. For Walsall and Bristol, this one infection rate well captured the subsequent baseline epidemic
dynamics (slightly increasing in Bristol and Walsall) and, therefore, no change in the infection rate was
assumed after that point. The baseline transmission rates in Bristol and Walsall were comparable (0.07–0.21
and 0.09–0.22, respectively), whereas Dundee had a slightly higher baseline transmission risk (0.16–0.39).
However, for Dundee, we needed to fit a second increased infection rate (0.36–0.94) to capture the increase
in HCV infection prevalence from 2008 to 2014 (using the parameters from the first prevalence fitting step as
the initial conditions). This suggests either that the epidemic was not stable in 2008 or that there has been a
change in the risk profile of PWID in Dundee that is not fully captured by changes in intervention coverage or
the prevalence of high-risk behaviours. Table 29 in Appendix 4 and Figure 18 show the model parameters
that were fitted in the model.
Impact analysis
First, the model was used to estimate the impact of current intervention activities over the next 15 years,
from 2016 to 2031. This included the impact of current coverage levels of OST, NSP and HCV infection
treatment. To estimate the impact of each intervention, the baseline epidemic projections with these
interventions incorporated were compared with what would happen if the effect of these interventions
were removed from the start of 2016 (i.e. either the efficacy parameter for a specific intervention was set
to one from 2016 or no additional PWID were HCV infection treated). Following this, we also assessed
the detrimental impact of current levels of high-risk behaviours. This was evaluated in the same way over
15 years. The impact of each scenario was assessed in terms of the relative change in prevalence and
incidence, and the relative change in the number of incident infections and the number of disease-related
deaths. Specifically, we investigated how the epidemic in each setting would change from 2016 to 2031 if
the following interventions or behaviours had no effect on HCV infection transmission rates:
l > 100% NSP
l OST intervention
l > 100% NSP and OST intervention
l HCV infection treatment of PWID
l all high-risk behaviours.
Following this, we then considered the potential impact to 2031 of increasing the coverage of > 100%
NSP from 2016 to 80% or 90% over the next 5 years.
Sensitivity analysis
The model calibration algorithm involved probabilistic sampling over a large number of the model
parameters, and we fit the model across the full uncertainty of the calibration data. The different runs
from this model calibration exercise were used to assess those parameters that effected the model
projections most. We undertook a linear regression analysis of covariance109 to determine those parameter
uncertainties that contribute most to uncertainty in the 15-year impact of current NSP coverage levels on
the relative change in the number of infections. The proportion of each model outcome’s sum-of-squares
contributed by each parameter was calculated to estimate the importance of individual parameters to the
overall uncertainty.
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Results
Baseline epidemic projections and model validation
In agreement with available recent HCV infection prevalence data up to 2014, we projected a slightly
increasing HCV infection prevalence in Bristol and Walsall when fitting prevalence to only the first time point
(2004 and 2006, respectively), as shown in Figure 19. The increasing HCV infection prevalence in Dundee
was obtained by fitting the prevalence to two time points. The incidence of HCV infection calculated from
the model in 2014 was used to validate the model and varies between the three settings, with the highest
incidence in Dundee [16.8, 95% credible interval (CrI) 10.7 to 24.7 per 100 person-years], which agrees with
incidence estimates from NESI (14.3, 95% CI 4.9 to 25.9 per 100 person-years). In Bristol, we project a lower
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FIGURE 19 Impact of each intervention scenario on HCV infection prevalence and incidence in each setting.
(a) Bristol incidence; (b) Bristol prevalence; (c) Walsall incidence; (d) Walsall prevalence; (e) Dundee incidence;
and (f) Dundee prevalence. The solid line is the median of the baseline model scenario, with the shaded region
representing the 95% CrIs around those projections. Error bars in black are data points and those in blue are the
ranges used for calibration. py, person-years. (continued )
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FIGURE 19 Impact of each intervention scenario on HCV infection prevalence and incidence in each setting.
(a) Bristol incidence; (b) Bristol prevalence; (c) Walsall incidence; (d) Walsall prevalence; (e) Dundee incidence;
and (f) Dundee prevalence. The solid line is the median of the baseline model scenario, with the shaded region
representing the 95% CrIs around those projections. Error bars in black are data points and those in blue are the
ranges used for calibration. py, person-years. (continued )
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HCV infection incidence of 6.9 (95% CrI 3.9 to 11.5) per 100 person-years, slightly lower than the most
recent HCV infection incidence estimate from 2009 (10.0, 95% CI 9.7 to 14.0 per 100 person-years).88 In
Walsall, we project an even lower HCV infection incidence of 3.4 (95% CrI 1.7 to 6.5) per 100 person-years,
corresponding to the low and decreasing prevalence in that setting. Unfortunately, no empirical estimates of
HCV infection incidence exist for Walsall against which to compare these estimates.
Over the period from 2016 to 2031, the model suggests that HCV infection prevalence will slightly decrease
in Bristol and Walsall, and decrease markedly in Dundee from 36.9% (95% CrI 28.7% to 43.5%) to 10.1%
(95% CrI 0.0% to 42.3%). The decreases in all settings are attributable to the use of more effective DAA
treatment commencing in 2015, with the larger decrease in Dundee being attributable to treatment already
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FIGURE 19 Impact of each intervention scenario on HCV infection prevalence and incidence in each setting.
(a) Bristol incidence; (b) Bristol prevalence; (c) Walsall incidence; (d) Walsall prevalence; (e) Dundee incidence;
and (f) Dundee prevalence. The solid line is the median of the baseline model scenario, with the shaded region
representing the 95% CrIs around those projections. Error bars in black are data points and those in blue are the
ranges used for calibration. py, person-years.
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being scaled up as part of a trial intervention. Over each year, the models project that 32 (95% CrI 21
to 43), 6 (95% CrI 1 to 11) and 14 (95% CrI 9 to 20) HCV-related deaths will occur among PWID and
ex-injecting drug users in Bristol, Dundee and Walsall, respectively, with most (> 85%) of these deaths
occurring among ex-injecting drug users. Baseline prevalence, incidence and disease-related mortality can
be found in Table 11.
Impact of existing interventions
Regardless of setting, removing either or both of NSP and OST would have a large detrimental impact on
both prevalence and incidence in all three settings by 2031, as shown in Figure 19. As expected, removing
both interventions has the biggest effect on the epidemics, with the model suggesting at least a 337%
(range 337–1525% between settings) relative increase in incidence by 2031 compared with baseline 2031
levels, a 125% (range 125–166%) relative increase in the number of new HCV infections over the period
2016 to 2031 and a 35% (range 65–636%) relative increase in prevalence compared with baseline
projections in all settings from 2016 to 2031. Following this, removing OST has the next biggest impact,
resulting in at least a 196% (range 196–1034%) relative increase in incidence, an 86% (range 86–125%)
increase in the number of HCV infections and a 46% (range 46–562%) relative increase in prevalence in
2031. The next biggest impact is removing NSP, which increases incidence by at least 35% (range
35–372%) and prevalence by at least 17% (range 17–275%). NSP has a smaller impact than OST because
it has lower coverage in each setting and lower efficacy (NSP lowers transmission risk by 41% vs. 59% for
OST) as suggested by our pooled analysis. Removing NSP still results in a large relative increase in the
number of new HCV infections by 2031, with a 30% (95% CrI 7.0% to 67.0%) increase in Bristol, a 22%
(95% CrI 6% to 40%) increase in Walsall and 59% (95% CrI 12% to 219%) increase in Dundee, as seen
in Figure 20.
Across the cities, a greater relative impact on prevalence and incidence is seen by removing NSP and/or
OST in Dundee, then Walsall and, finally, Bristol. Removing NSP and/or OST has the greatest impact in
Dundee because HCV infection prevalence and incidence were otherwise decreasing to low levels by 2031,
whereas removing the interventions causes prevalence to increase, as seen in Figure 19.
Removing treatment of PWID in each setting has similar impacts on prevalence and incidence to removing
NSP, as seen in Figure 19. However, less impact is seen on the number of new infections, as seen in
Figure 20. This is explained by treatments lowering incidence indirectly through reducing prevalence, as
opposed to directly reducing the incidence of new infections, which is the case for NSP and OST.
The impact of current high-risk behaviours
When the increased transmission risk associated with homelessness and crack cocaine injecting (or homelessness
only in Dundee) is removed, a decrease in incidence and prevalence of HCV infection occurs. The biggest relative
decrease is seen in Dundee, where incidence decreases by 99% (95% CrI 86% to 100%) and the number of
TABLE 11 Baseline scenario characteristics for each setting
Setting
Prevalence 2016
(%), median
(95% CrI)
Prevalence 2031
(%), median
(95% CrI)
Incidence 2016 per
100 person-years,
median (95% CrI)
Incidence 2031 per
100 person-years,
median (95% CrI)
Disease-related
deaths per year
2016, median
(95% CrI)
Bristol 49.8
(37.4 to 62.2)
44.5
(21.0 to 65.6)
6.9 (3.9 to 11.5) 6.1 (2.2 to 12.3) 32 (21 to 44)
Walsall 21.7
(13.4 to 34.2)
21.2
(7.5 to 42.2)
3.4 (1.7 to 6.5) 4.8 (0 to 23.1) 14 (9 to 20)
Dundee 36.7
(29.2 to 43.6)
10.2
(0.02 to 42.3)
16.9 (10.7 to 24.7) 3.3 (0.9 to 8.2) 6 (1 to 11)
CrI, credible interval.
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new infections decreases by 58% (95% CrI 29% to 77%) between 2016 and 2031 (Figure 21). Similarly, the
number of new infections decreases by 59% (95% CrI 40% to 75%) in Walsall and 64% (95% CrI 45% to
78%) in Bristol. However, despite Bristol having the highest proportion (> 80%) of high-risk PWID, the smallest
relative decrease in prevalence (35%, 95% CrI 22% to 53%) occurs here when we remove the elevated risk
among high-risk PWID; this is compared with a 99% (95% CrI 69% to 99.7%) decrease in Dundee and a 45%
(95% CrI 28% to 64%) decrease in Walsall. This could be due in part to the longer injecting duration predicted
by the model in Bristol, with a median of 15 years injecting in Bristol compared with 8 years in Dundee
and Walsall.
Impact of scaling up needle and syringe programmes
Scaling up > 100% NSP coverage to 80% or 90% has a substantial impact on the number of new infections
by 2031, as shown in Figure 22. For instance, a large impact is seen in Walsall because of the low current
coverage of NSP (21–42%), in which the number of new infections is decreased by 25% (95% CrI 7% to
40%) and incidence decreases by 41% (95% CrI 12% to 61%) when NSP is scaled up to 80% coverage.
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FIGURE 21 Impact of removing transmission risk associated with high-risk behaviour on decreasing the number of new
infections from 2016 to 2031 for each setting. The box plots signify the uncertainty (the middle line is the median,
the limits of the box are the 25% and 75% percentiles, and the whiskers are the 2.5% and 97.5% percentiles).
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Conversely, increasing NSP coverage in Bristol and Dundee has less impact because of the higher current
coverage in both settings (38–82% in Bristol and 34–79% in Dundee), with the number of infections
decreasing by 10% (95% CrI 2.0% to 22%) in Bristol and 26% (95% CrI 6.0% to 48%) in Dundee. Less
impact is always seen on prevalence, with an absolute drop of approximately 4% in all three settings.
Sensitivity analysis
The results of the sensitivity analysis are shown in Figure 23. In Bristol and Walsall, the model parameter
with the largest percentage contribution to the variability in the relative number of infections averted from
current coverage levels of NSP is the efficacy estimate for NSP (which accounts for 41%, 20% and 48%
of variation in Bristol, Dundee and Walsall, respectively). In Bristol and Walsall, the next most important
input was the 2014 coverage of NSP (32% of variation in Bristol and 39% in Walsall). Conversely, for
Dundee, HCV infection prevalence in 2014 had the largest contribution (36%) to the variability, followed
by NSP effectiveness, OST effectiveness then NSP and OST effectiveness (20%, 10% and 6%, respectively).
In Bristol and Dundee, the population size estimate contributed 3% and 5%, respectively, to the variability.
All other parameters and inputs contributed < 5% to the variability in the impact of NSPs on the number
of infections averted. The different patterns seen between Bristol/Walsall and Dundee could be attributable
to the differences in the fitting procedures for each setting. Dundee required an extra fitting step to
calibrate the model to the increasing prevalence from 2008 to 2014 and had a constant population size,
which would account for the impact of those parameters. The presence of the OST and OST + NSP
effectiveness parameters can be explained by the impact of these parameters when NSP is removed,
which results in the OST + NSP effectiveness becoming the same value as the OST effectiveness parameter.
Conclusions
This analysis for three contrasting UK settings suggests that existing coverage levels of > 100% NSP and OST in
combination and separately are currently preventing considerable transmission of HCV infection in these cities,
with their combined removal resulting in at least a 125% increase in the number of new HCV infections over
the next 15 years. Less impact is achieved from NSP on its own, but in combination with OST, synergistic
benefits are generally achieved that increase impact further than would be expected from each intervention
separately. Despite the large impact already achieved, our analyses suggest that the impact could be increased
further, with a relative decrease in new infections by 2031 of 10–26% if NSP coverage is increased to 80% in
all settings. Increasing NSP coverage has a larger effect in low prevalence and coverage settings, such as
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FIGURE 23 Sensitivity analysis results: percentage contribution of the uncertainty in different model parameters to
the overall variation in the relative increase in number of infections when NSP is removed (only those aspects with
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Dundee where local elimination is a feasible possibility, with incidence decreasing by 99% compared with
2016 levels by 2031. In the other settings, these increases in NSP in parallel with DAA treatments being used at
current treatment rates are still likely to reduce incidence considerably (by 29% and 42% in Bristol and Walsall,
respectively), but more will be needed to approach local elimination. Conversely, less impact is achieved on
prevalence by 2031, with a sustained increase in NSP coverage as well as other interventions being needed to
result in large decreases in HCV infection prevalence among PWID if the trend in longer-term injecting
continues. Finally, current factors linked to high transmission risk, homelessness and crack cocaine injection
should also be considered targets for intervention activities because our projections suggest that if the
heightened transmission risk associated with these behaviours is removed it could avert about 60% of HCV
infections over the next 15 years.
Strengths and limitations
Our detailed modelling of contrasting settings gives a better understanding of how the impact of interventions
vary across the UK, with the use of updated empirical efficacy estimates for OST and NSP consistent with the
included systematic review, thereby lending added strength to the results. In addition, our model stratified and
calibrated PWID by injecting duration, allowing it to incorporate possible important changes in injecting
recruitment and cessation over recent years, thus giving more realism to the model projections.
As with all modelling, there are several limitations. The main limitation is the sparsity of data on how
injecting cessation and recruitment has changed; we thus had to extrapolate from imperfect data on size
estimates and changes in the sample distributions by injecting duration in successive surveys. Importantly,
we incorporated the uncertainty in these parameters, and our model projections were informative despite
this. However, better data on these hard-to-quantify parameters would improve the accuracy of our model
projections. Second, we did not consider any impact of OST on injecting cessation or mortality rates.
Long-term OST use has been shown to increase injecting duration and lower mortality rates,91 while being
associated with increased incidences of temporary cessation.110 It is possible that the increasing proportion
of long-term injectors seen in Bristol and Walsall may in part be due to the high current levels of OST in
these settings. Future modelling could consider temporary cessation as well as permanent cessation, with
current OST use impacting on the rates of cessation.
infectionThird, we assumed that the whole population of PWID would be eligible for OST, but there is a
growing proportion (from 3.9% in 2004 to 12% in 2014) of PWID in the UK who inject non-opioid
substances, such as amphetamines, as their main drug.70 This is likely to have diluted the effect estimates
from the pooled analysis, meaning that we may have underestimated the impact of current OST levels on
HCV infection incidence. Fourth, we did not model incarceration, which can be associated with HCV
infection transmission risk in the UK.111 The role of incarceration in driving HCV infection transmission in
the UK is the focus of current research. Finally, we did not consider IPED injectors in this model because
the HCV infection prevalence in this subpopulation of PWID is much lower than psychoactive drug
injectors (3.6% HCV antibody prevalence compared with 50%).70 It is likely that their contribution to the
overall HCV infection epidemic in the UK is small.
Other evidence and implications
Other models have looked at the impact of NSP or OST on HCV infection transmission, but have generally
lacked empirical efficacy estimates for the effect of these interventions on HCV infection acquisition risk,79,112–114
or have not considered impact in specific cities parameterised with detailed data.86 Our modelling extends
existing analyses by including detailed context-specific modelling of the impact of OST, NSP and HCV infection
treatment, as well as the disabling effect of high-risk behaviours and how it varies across UK settings.
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Summary
Our projections are important for showing how the current impact of interventions vary across settings
and where the scale-up of interventions should be targeted. They emphasise the crucial need to avoid
any scale-back in the coverage of current interventions, which could result in huge increases in HCV
infection transmission across these settings. Despite coverage being high in many settings, the projections
also suggest that important benefits could still be achieved from scaling up NSP further, especially in
settings with current low coverage levels. In addition, as suggested by other recent modelling analyses,99,114
scaling up other interventions such as HCV infection treatment could also have a large impact on HCV
transmission, although treatment will need to scale up considerably to see a large impact on incident infections.
Importantly, strategies need to be devised to tackle or reduce the harms associated with homelessness and
crack cocaine injection among PWID, which our modelling suggests is doubling the level of transmission in each
setting. Reducing the risk of HCV transmission among these vulnerable subpopulations should be a priority for
any strategy attempting to reduce HCV transmission or hoping to achieve HCV elimination, as recently set out
by WHO.115 There is now a realistic possibility to reduce HCV to low levels, even in higher-prevalence settings,
and mathematical models could be useful for guiding these efforts.
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Chapter 6 Cost-effectiveness analysis
Methods
The cost data described in Chapter 3 were used to populate a cost-effectiveness model to estimate the
incremental cost-effectiveness of NSPs in each of the three cities described previously.
Model calibration
The model was calibrated for each city using survey data from each city (see Chapter 4 for more detail).
The model was used to estimate the cost-effectiveness of existing levels of NSP compared with if they were
removed from 2016, with the removal of NSP being simulated for 10 years (2016 to end 2025) and then
the subsequent transmission effects simulated for a further 40 years (2026 to end 2065). For the baseline
intervention scenario, we assumed that OST and > 100% NSP coverage levels remained at current levels
and kept other model parameters constant. In the sub-baseline counterfactual scenario, the lower
transmission risk associated with > 100% NSP was set to one, and the transmission risk for current OST
and > 100% NSP use was set to the transmission risk associated with just current OST use. This was
done for 10 years to investigate the detrimental impact of removing current levels of > 100% NSP in
each city. No costs of NSP were assumed over this time. After 10 years, the transmission risks associated
with > 100% NSP, and current OST and > 100% NSP were set to baseline levels again to simulate the
resumption of NSP activities, with the estimated costs of NSP being included for subsequent years. We
calculated the costs and quality-adjusted life-years (QALYs) over two time horizons. First, we calculated
costs and QALYs for a further 40 years after NSP was reintroduced, giving a total time horizon of 50 years.
We also calculated costs and QALYs for a further 90 years after NSP was reintroduced, giving a total time
horizon of 100 years. The numbers of individuals in each category of the model were recorded, and QALYs
and costs were attached to each category as appropriate. Both time horizons are presented in the results.
Uncertainty in the underlying parameters was accounted for, such that demographic and epidemiological
parameters, disease progression rates, costs and health utilities were randomly sampled from appropriate
distributions. For each city, we obtained 1000 matched simulations for the costs and QALYs of the
baseline intervention scenario and the sub-baseline counterfactual scenario.
Using the sampled simulation sets, we calculate the total costs and the total QALYs gained for the baseline
scenario with NSP coverage, and for the scenario removing NSP services for a period of 10 years. These
scenarios are presented as ‘NSP’ and ‘no NSP’ respectively for clarity. All future costs and QALYs were
discounted using a baseline discount rate of 3.5%.
Cost data
The fixed city-level cost and cost per needle of NSP programmes was estimated over 1000 iterations,
simultaneously varying all parameters described in the costing sensitivity analysis, and these 1000 estimates
for costs were input into the model. The number of needles distributed each year was calculated by
multiplying the total number of PWID with > 100% NSP coverage from the model by the mean injecting
frequency per year (see Chapter 4 for details). The total NSP cost per year is then the total number of needles
distributed per year multiplied by the cost per needle, added to the fixed city-level cost. (The sampled values
of the cost per needle and the fixed city-level cost are shown in Appendix 5, Table 30.)
To enable use of the model for the cost-effectiveness analyses, HCV infection care costs were assigned to
different HCV infection stages in the model. These costs were drawn from previously published estimates
of the costs of treatment and care for HCV infection in the UK (see Appendix 5, Tables 31 and 32 for data
used). Detailed estimates of total cost for each disease stage were drawn from the literature and inflated
to 2014 GBP using the hospital and community health services index (see Appendix 5, Table 31 for the
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cost values used in the cost-effectiveness model). We assumed that 50% of chronic infections (F0–F3
disease stages) in PWID and ex-injecting drug users are diagnosed and incur a cost. We also assumed that
treatment costs for active PWID were higher than those for ex-injecting drug users or non-injecting drug
users. Costs associated with the supportive care of compensated cirrhosis were applied to all individuals in
that disease stage.
Effectiveness
Health utility values (QALY weights) are sourced from previous economic evaluations of HCV infection
treatment interventions (see Appendix 5, Table 32). Following previous analyses, we assume that the
baseline quality of life for active injectors is lower than that for ex- or non-injectors. As for the model
fitting for the impact analyses, the HCV infection disease utility and costs were sampled for each run.
Sensitivity analysis
Seven different scenarios were tested in the sensitivity analysis: increasing time horizon to 100 years, no
chronic HCV infection disease (F0–F3) stage cost (baseline was 50% of those infected incurred cost), no
associated disease cost for chronic HCV infection or compensated cirrhosis disease states (F0–F3 and
compensated cirrhosis), a discount rate of 0% for costs and QALYs instead of 3.5%, the same treatment
cost for PWID as for ex-injecting drug users; and, finally, assuming a reduction of 50% in the drug cost
component of the treatment costs from 2016.
Results
Model outputs
Table 12 shows the total deaths and HCV infections averted through NSP compared with no NSP in each city.
Bristol has a median anticipated 21 deaths averted over 50 years and Dundee has a median 23 deaths averted;
Walsall has a median anticipated 5.8 deaths averted over the same time horizon. The number of infections
averted varies by city, from 93 infections in Walsall to 749 infections in Dundee. Walsall has the smallest
prevalence of HCV infection within the injecting population and, therefore, saw the smallest number of deaths
and infections averted, despite the fact that the proportion of deaths and infections averted through NSP was
similar in each city, as shown in Chapter 4. There was wide uncertainty in the outputs in all cities.
Table 13 shows the total health-related costs incurred over the 50-year time horizon for Bristol, Dundee
and Walsall, discounted to reflect their current value. Removing NSPs consistently increases health-related
costs across all cities, including costs of health care for early-stage HCV infection, costs for HCV infection
treatment among PWID and costs for HCV infection treatment among ex-/non-injecting drug users.
These increased costs reflect an increase in HCV infection transmission in the ‘no NSP’ scenario, including
to people who then cease injecting. The costs of NSP are higher in the ‘NSP’ scenario. In Dundee, this
additional cost for NSPs increases the total cost marginally compared with the ‘no NSP’ scenario; however,
in Walsall the total median costs for the ‘NSP’ scenario are lower than those for the ‘no NSP’ scenario,
despite additional NSP costs. In Bristol, total median costs are the same in both scenarios.
TABLE 12 Total deaths and infections averted through NSPs, by city
Site
Deaths averted Infections averted
Median 2.5% CrI 97.5% CrI Median 2.5% CrI 97.5% CrI
Bristol 20.5 4.3 51.1 199.5 42.5 505.2
Dundee 23.1 3.8 57.5 749 119.1 1637.6
Walsall 5.8 1.2 14.9 92.7 22.3 200.5
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Cost-effectiveness
Table 14 presents the average total costs, QALYs and incremental cost-effectiveness ratios (ICERs) for the
50-year time horizon. In Bristol and Dundee, providing NSP services is cost-saving; keeping NSP services is
estimated to save an average of £137,949 in Bristol and nearly £7.5M over the 50-year time horizon in
Dundee. NSPs are also anticipated to contribute 502 and 958 incremental QALYs in comparison to the
‘no NSP’ scenario in Bristol and Dundee, respectively. In Bristol and Dundee, an additional £10M and
£26M, respectively, could be spent on NSP without any additional impact, and NSPs would still fall under
the commonly cited willingness-to-pay (WTP) threshold of £20,000 per QALY gained.
In Walsall, the mean incremental costs of the NSP scenario compared with the ‘no NSP’ scenario are
estimated at £115,250. NSPs are expected to contribute 192 incremental QALYs compared with the
scenario removing NSPs. The mean incremental cost-effectiveness of NSPs in Walsall is estimated at £601
per QALY gained. Our central estimate for the ICER in Walsall is well below the commonly cited NICE WTP
threshold of £20,000–30,000 per QALY gained and, therefore, can be regarded as highly cost-effective.
In fact, an additional £3.7M could be spent with no impact, and NSPs would still fall under the £20,000
per QALY threshold. It has recently been suggested that a more appropriate WTP threshold in a UK setting
would be £13,000, as this is the rate at which the NHS is able to turn costs into QALYs.116 Our central
estimate for Walsall also falls well below this threshold, indicating a high return on investment in the
current NHS setting.
TABLE 13 Total health-related costs over 50 years (GBP millions), by city
Setting and health-care category
Projected total health-related costs (£) over 50-year time horizon
NSPs No NSPs
Mean 2.5% CrI 97.5% CrI Mean 2.5% CrI 97.5% CrI
Bristol
Health-care costs 130.4 60.0 289.8 131.6 60.3 292.6
HCV infection treatment cost 39.9 23.5 58.8 41.1 24.3 60.6
HCV infection treatment PWID cost 9.3 6.6 11.2 9.3 6.7 11.2
NSP cost 6.0 3.7 8.3 3.8 2.3 5.3
OST cost 112.3 86.8 142.5 112.2 86.8 142.4
Total cost 297.8 298.0
Dundee
Health-care costs 27.1 5.8 66.5 28.9 6.5 70.3
HCV infection treatment cost 15.5 8.1 28.2 18.7 9.5 31.1
HCV infection treatment PWID cost 12.9 5.5 24.2 16.2 7.3 24.5
NSP cost 2.9 1.6 4.4 1.9 0.5 2.8
OST cost 37.1 32.1 44.3 37.1 32.1 42.3
Total cost 95.4 102.9
Walsall
Health-care costs 64.1 31.2 131.5 64.5 31.3 132.3
HCV infection treatment cost 23.3 14.4 34.0 23.9 14.8 34.7
HCV infection treatment PWID cost 1.0 0.8 1.2 1.0 0.8 1.2
NSP cost 3.0 1.6 5.3 1.9 1.0 3.5
OST cost 61.7 38.3 96.5 61.7 38.3 96.5
Total cost 153.1 153.0
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Table 15 presents the average total costs, QALYs and ICERs for the 100-year time horizon. Over the
100-year time horizon, NSPs are cost-saving in all cities, saving £687,351, £8,800,186 and £177,778 in
Bristol, Dundee and Walsall, respectively, and contributing 699, 1326, and 278 QALYs, respectively, in that
time. Using the lower WTP threshold of £20,000 per QALY gained, this represents a net monetary benefit
of > £14.6M in Bristol, £35M in Dundee and £5.7M in Walsall over the 100-year time horizon.
The ICERs for Bristol, Dundee and Walsall over 1000 baseline runs for the 50-year time horizon are shown
in Figures 24–26. All cities show some uncertainty in the ICER; however, across all cities there were no
estimates in the bottom-left quadrant (indicating that NSPs are dominated). In Dundee, 99% of iterations
are located in the bottom-right quadrant, indicating that NSPs are cost-saving. In Bristol, 45% of iterations
are cost-saving, and in Walsall, 40% of iterations are cost-saving.
TABLE 14 Cost-effectiveness results: average total costs, QALYs and ICERs for baseline NSPs compared with no NSPs
over a 50-year time horizon
Setting Total cost (£)
Incremental
cost (£) Total QALYs
Incremental
QALYs ICER (£)
Net monetary
benefit (£)
Bristol
No NSP 297,970,375 187,663
NSP 297,832,426 –137,949 188,165 502 –274.76 10,179,353
Dundee
No NSP 102,891,384 124,208
NSP 95,420,292 –7,471,093 125,165 958 –7799.19 26,629,720
Walsall
No NSP 153,007,364 142,702
NSP 153,122,615 115,250 142,894 192 600.68 3,722,082
TABLE 15 Cost-effectiveness results: average total costs, QALYs and ICERs for baseline NSPs compared with no NSPs
over a 100-year time horizon
Setting and
intervention
scenario Total cost (£)
Incremental
cost (£) Total QALYs
Incremental
QALYs ICER (£)
Net monetary
benefit (£)
Bristol
No NSP 334,009,891 225,720
NSP 333,322,534 –687,357 226,419 699 –982.81 14,675,014
Dundee
No NSP 114,678,850 151,461
NSP 105,878,665 –8,800,186 152,787 1326 –6634.97 35,326,845
Walsall
No NSP 173,478,543 176,097
NSP 173,300,765 –177,778 176,375 278 –638.61 5,745,412
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Sensitivity analysis
Figures 27–29 show cost-effectiveness acceptability curves over a range of sensitivity analysis scenarios for
Bristol, Dundee and Walsall, respectively. As indicated in the figures, our model was relatively robust to
assumptions, and the likelihood of cost-effectiveness was not substantially altered in the sensitivity analysis
scenarios. In the base case, 96% of iterations in Bristol, 100% of iterations in Dundee and 95% of
iterations in Walsall are located below the WTP threshold of £13,000 per QALY saved. Using the more
commonly cited lower-bound threshold of £20,000 per QALY saved, 98% of iterations from Bristol, 100%
of iterations from Dundee and 98% of iterations from Walsall are below the threshold.
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The sensitivity analysis scenario with the greatest impact on the ICER assumes a discount rate of 0% for
both costs and QALYs. Under this scenario, 86% of iterations in Bristol, 100% of iterations in Dundee and
85% of iterations in Walsall are below a WTP threshold of £0. The scenario reducing HCV infection
treatment drugs to half of their listed price returns the lowest proportion of iterations below any given
WTP threshold overall. However, even under this scenario, the large majority of iterations are below a WTP
threshold of £20,000 (98% in Bristol, 100% in Dundee and 97% in Walsall).
Conclusions
Overall, we found NSPs to be highly likely to be cost-effective at low WTP thresholds and, in fact, to be
cost-saving in some settings. In both Bristol and Dundee, the large majority of iterations from the model
were cost-saving, and in Walsall the large majority of iterations were considerably below a WTP threshold
of £13,000 per QALY gained.
The difference in ICERs between cities is likely to be driven partly by population size and HCV infection
prevalence in each study setting. Walsall had the lowest population of people injecting drugs citywide, so
NSPs had a lesser impact in the form of a reduction in infections and deaths and, therefore, had less of an
overall impact on cost. There was also a larger amount of uncertainty in the NSP costs for this city owing
to the fact that the out-of-hours pharmacy had only recently begun providing services at the time of data
collection; this generated substantial uncertainty, as we extrapolated observations from the past month to
an annual estimate.
The unit costs presented do not reflect the substantial gains from averting other health problems. Most
importantly, there is substantial evidence that NSPs are highly effective in averting HIV infection.13
Incorporating HIV infections averted through NSPs into our model would further increase the number of
QALYs averted through NSPs, thereby increasing the cost-effectiveness of our estimates. These estimates
also do not reflect the supportive nature of transactions, or any other measures of quality. Quality of
transactions will vary substantially across sites and may be reflected in the costs; for example, a service
might take more time per visit if practitioners engage the client in discussions about their injecting
behaviour and safe practices. Services offering a wider range of injecting equipment may also encounter
higher supply costs; however, this wide range of supplies may draw additional clients in or improve the
quality of services. For example, a number of fixed sites are looking into offering so-called ‘crack packs’ as
a harm-reduction mechanism to encourage clients to smoke rather than inject drugs. Similarly, two fixed
sites offered water for injection in order to enable clients to use clean water when injecting heroin; this will
increase the overall supply costs but will possibly reduce the costs related to injection-site infections.
Furthermore, fixed-site NSPs also commonly provide other services such as wound care, vaccination, links to
social and welfare services, and psychosocial support. Similarly, the drop-in centre offered other services,
including a safe place, psychosocial support, food and bedding for rough sleepers, and a sense of community.
Many of these benefits have not been evaluated for their effectiveness, but are likely to contribute to
well-being among PWID. A co-financing approach whereby funding is split across the multiple sectors
benefiting from an intervention, such as that suggested by Remme et al.,117 would further improve WTP for
NSPs, for example across the health-care and social care sectors in the UK.
Finally, this analysis does not investigate the cost-effectiveness of OST in detail, as it does for NSP. Costs
for OST were not collected in detail as they were for NSP and were instead drawn from published unit
cost estimates from the Personal Social Services Research Unit in the UK. Other benefits of OST, such as
reducing drug-related mortality or incarceration and social costs, have also not been included in the model.
More expansive analyses have shown OST to be cost-saving when these other outcomes are included.
Further research to evaluate the combined impact and cost-effectiveness of both NSP and OST across both
social care and health-care sectors would fill a major gap in current understanding.
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This report presents model projections rather than empirical evidence, and caution is advised in
interpretation of our findings. Key limitations relate to the simplifying assumptions of the model and
uncertainty around several parameters. There was some uncertainty in our estimates of the cost of NSP
programmes and in the anticipated impact for all cities. This was partly due to uncertainty in the primary
data collection in terms of costs and outputs. This was especially true for pharmacies, where detailed
records of needle exchanges are not usually kept. There was also substantial uncertainty in NSP coverage
estimates in the UK. The pooled analysis (see Chapter 2) suggested that estimates of coverage varied
widely, with a median coverage of 2.5 needles distributed per injection (interquartile range 1.4–4.7)
reported in community-recruited surveys of PWID in Leeds but a median of 1 (interquartile range 0.48–2.5)
from the UAMP survey, which primarily recruits from NSPs and low-threshold treatment settings. Coverage
estimates per site were presented at the National Needle Exchange Forum annual meeting in November
2014, and responses from practitioners suggested that coverage estimated through community surveys
was far higher than reported by services.
Nonetheless, this modelling exercise indicates that NSP services are highly likely to be cost-effective at
almost any WTP threshold and, in some settings, are cost-saving. Policies to ensure that NSPs can be
accessed widely alongside the provision of OST are needed, and obstacles preventing the concurrent use
of both NSP and OST could be removed to maximise the reduction in HCV infection transmission. Further
research is also needed to improve our understanding of the mechanisms through which NSPs and OST
achieve their effect and of the optimum contexts to support their implementation.
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Chapter 7 Conclusions and recommendations
A lthough there is good evidence that NSPs and OST in combination reduce injecting risk behaviours andsome evidence to show their impact on HIV incidence, there is little evidence for their impact on HCV
infection incidence among PWID. There have been no economic evaluations of NSPs undertaken in Western
Europe and few have considered the costs saved as a result of care and treatment being averted. All existing
studies have relied on weak measures of NSP effectiveness, with most using changes in self-reported risk
behaviour, which can be biased. This project filled a gap in the evidence by attempting to provide more
robust estimates of the efficacy of NSP and OST on reducing the risk of HCV infection transmission, and an
assessment of the probable impact of existing coverage levels of NSPs and changes in the extent of
provision. It also provided the first assessment of the costs and cost-effectiveness of needle and syringe
provision in UK, and ICERs associated with increasing coverage on HCV infection transmission among PWID.
Opioid substitution therapy and needle and syringe programme
efficacy estimates
Primary meta-analysis of 12 observational studies adjusting for key confounders enrolling 5910 anti-HCV
negative participants showed that the current use of OST compared with no intervention reduced the risk
of HCV infection acquisition by 50% (RR 0.50, 95% CI 0.40 to 0.63). The intervention effect is strong, but
the evidence is considered to be of low quality because it was derived from observational studies with
serious risk of bias. Nonetheless, the findings were robust to sensitivity analyses excluding studies judged
to be at critical risk of bias, studies drawing on unpublished data, case–control and cross-sectional studies
reporting only baseline data, and studies reporting only unadjusted estimates. There also was no evidence
of publication bias. All of these sensitivity analyses showed a statistically significant benefit of OST.
A few studies reported other types of exposure to OST. Three studies reported past exposure to OST and
three reported interrupted OST use [one study measuring OST use for detoxification and two studies
measuring high dosage (≥ 60 mg) or low dosage (1–59 mg) of methadone for daily use]. Among these
exposures, only high dosage of OST was associated with a reduction in risk of HCV infection acquisition.
Primary meta-analysis of seven observational studies pooling unadjusted estimates and enrolling 5669
anti-HCV negative participants showed weak and low-quality evidence that NSP exposure did not reduce
the risk of HCV infection acquisition. This effect remained consistent in sensitivity analyses. After removing
studies from North America, high NSP coverage in Europe was associated with a 61% reduction in HCV
infection acquisition risk (RR 0.39, 95% CI 0.24 to 0.64) with less heterogeneity (I2 = 0%; p = 0.428).
There was moderate-quality evidence for the impact of combined high coverage of NSP and OST from
studies comprising 3356 anti-HCV negative participants, which suggested a 71% reduction in the risk of
HCV infection acquisition (RR 0.29, 95% CI 0.13 to 0.65). There were insufficient data to conduct a
sensitivity analysis with this intervention group. A summary of key findings and quality of evidence is
presented in Table 3.
Findings from a pooled analysis of full harm reduction compared with minimal exposure reduced the risk of
injecting with a used needle/syringes by 50% (AOR 0.5, 95% CI 0.38 to 0.62), as well as reuse of the same
needle/syringe for injecting by 40% (AOR 0.59, 95% CI 0.40 to 0.88) and frequency of injecting. There was
weaker evidence for an association with injecting-site infections or shared used of filters and spoons for
drug preparation. Full harm reduction was associated with twice the odds of testing for both HCV and HIV
(AOR 1.9, 95% CI 1.56 to 2.23 and AOR 1.9 95% CI 1.6 to 2.20, respectively). Combining estimates of
NSP coverage from the systematic review with two data sets69,70 not already represented in the review
strengthened the evidence for the effect of high NSP coverage on reducing the risk of HCV infection
acquisition to 39% (RR 0.61, 95% CI 0.43 to 0.87) with moderate heterogeneity (I2 = 30%; p = 0.189).
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Costs of needle and syringe programme provision through different
modalities
Evidence showed a degree of variation in costs across the three different commissioning areas evaluated;
variation in cost and outputs was observed across fixed sites and pharmacies. The primary cost driver in most
settings was the cost of supplies, which accounted for an average of 60% of total costs across sites (range
28–78%). This was followed in most cases by administrative and overhead costs, which accounted for 9–28%
of total costs. There was some considerable uncertainty in our estimates owing to the fact that cost and
output data on NSP distribution are not routinely collected for some distribution modalities within the UK.
The difference in costs is likely to be driven partly by the type of needle distribution and the ease of access
to needles for PWID. We observed a large variation in the number of visits per user across cities and in
the number of needles distributed at each visit. A higher number of visits per person in the injecting
population citywide did appear to increase the costs of distribution, suggesting that distributing a greater
number of needles in fewer visits may be more efficient than restricting the number of needles distributed
at each visit, assuming that there is demand for greater quantities of needles within a visit.
Cost-effectiveness of needle and syringe programme provision
Overall, we found that needle and syringe exchange services are highly likely to be cost-effective at almost
any WTP threshold and, in fact, are cost-saving in some settings, despite some uncertainty in total outputs.
Under the 50-year time horizon, in Dundee the large majority of iterations from the model were cost-
saving, and in Bristol and Walsall the large majority of iterations were below a WTP threshold of £13,000
per QALY gained. Under the 100-year time horizon, NSP services in all three cities were cost-saving.
The difference in cost-effectiveness between cities is also likely to be driven partly by population size and
HCV infection prevalence in each study setting. Walsall had the lowest population of people injecting
drugs citywide, so a reduction in infections and deaths had less of an overall impact on cost-effectiveness.
There was also greater uncertainty in the NSP costs for this city.
These cost-effectiveness estimates do not reflect the substantial gains from averting other health problems
associated with injecting drug use, including HIV and other infections. Previous research has indicated that
NSPs are highly effective in averting HIV infection; incorporating these health gains would substantially
improve cost-effectiveness.
Impact modelling of needle and syringes programmes and opioid
substitution therapy
Regardless of setting, removing either or both of NSP and OST would have a large detrimental impact
on both prevalence and incidence of HCV infection in all three settings by 2031. As expected, removing both
interventions has the biggest effect on the epidemics, with the model suggesting at least a 109% relative
increase in incidence, a 51% relative increase in the number of new HCV infections and a 23% relative
increase in prevalence being projected in all settings from 2016 to 2031. Following this, removing OST has
the next biggest impact, resulting in at least a 59% relative increase in incidence, a 31% increase in the
number of HCV infections and a 14% relative increase in prevalence by 2031. This is followed by removing
NSPs, which increases relative incidence by at least 8% and prevalence by at least 3%. NSP has a smaller
impact than OST because it has lower coverage in each setting, and lower efficacy (NSP lowers transmission
risk by 41% vs. 59% for OST), as suggested by our pooled analysis. However, removing NSPs still generally
results in a large relative increase in the number of new HCV infections, with a median increase of 32%
(95% CrI 7% to 71%) in Bristol, 23% (95% CrI 6% to 43%) in Walsall and 61% (95% CrI 12% to 219%)
in Dundee.
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Scaling up > 100% NSP coverage to 80% or 90% has a substantial impact on the number of new
infections by 2031. The largest relative impact is seen in Walsall, where the number of new infections is
decreased by 27% (95% CrI 7% to 43%) and incidence decreases by 40% (95% CrI 11% to 59%) when
NSP is scaled up to 80% coverage. This is due to the low current coverage of NSP (21–42%) and the low
prevalence of HCV infections in Walsall. Increasing NSP coverage from the current level of between 38%
and 80% in Bristol up to 80% coverage from 2021 onwards, results in a decrease in actual prevalence of
3% (95% CrI 0.7% to 6.9%) by 2031, corresponding to a relative decrease of 6% (95% CrI 1% to 14%);
however, the number of infections is reduced by 11% (95% CrI 2% to 24%).
Limitations
We have discussed individual limitations of the methods separately in each of the results chapters. Here,
we discuss some overarching limitations that cross all the methods and that stem from the complex nature
of NSPs and OST that do not lend themselves to evaluation through traditional evaluation study designs.
This produced the following limitations.
First, the evidence synthesised in the systematic review was drawn from observational studies. The
ACROBAT-NRSI tool that we applied to assess the risk of bias28 assesses studies according to seven domains
[(1) confounding, (2) selection bias, (3) measurement of interventions, (4) departures from intervention,
(5) missing data, (6) measurement of outcomes and (7) selection of reported results] to give an overall risk
of bias, which can be classified into four categories (ranging from low to critical). A study categorised as
being at low risk of bias would be comparable to a well-performed randomised trial, whereas one that is at
critical risk is defined as being too problematic to provide any useful evidence and should be excluded from
the synthesis. It is worth noting that observational studies are unlikely to be rated as being at ‘low’ risk of
bias because they will always score poorly on the confounding domain, as it is impossible to ensure that
an observational study has adjusted for all possible residual confounding. Assessing quality of study
designs alongside RCTs as a gold standard reduces the strength of the assertions that we can make about
observational evidence. The use of the GRADE system to assess the overall quality draws heavily on the
risk-of-bias assessment, further reducing confidence in the strength of the evidence. Many of the studies
included in the systematic review were assessed as being at severe risk of bias and only two were judged
as being at moderate overall risk of bias. It is questionable how appropriate it is to apply this quality
assessment system to complex interventions such as NSP and OST, which rely on observational study
designs to measure effect. Individual random allocation to the intervention would be unethical, as there is
sufficient evidence of their effectiveness in relation to other adverse health outcomes. Other reviews
conducted outside Cochrane that do not assess quality against a RCT as a gold standard conclude that
there is much stronger evidence of effect, although they present comparable results and are drawn from
comparable study designs.17
Second, it is clear from both the systematic review and the pooled analysis that there are difficulties in
accurately measuring the use of NSPs. We used a simple definition of NSP use, encompassing coverage that
requires correct recall of frequency of injecting and the numbers of needles/syringe obtained in the same
time period. It is clear that the use of NSPs purely for obtaining clean needles/syringes oversimplifies its
benefits for PWID. This definition does not consider any of the other engagement programmes delivered by
the fixed-site NSP services, such as one-to-one support, sexual health services, help with housing, welfare
benefits, legal advocacy or other social welfare issues. These linked support services are key to bringing
people into the NSP and providing the necessary enabling environment for both participants and providers
to reduce behaviours that lead to HCV infection. The oversimplification of the use of NSPs may further
explain the weaker efficacy estimates that we found in the pooled analysis and systematic review. This
has subsequent implications for the mathematical modelling that estimated the impact of NSPs on HCV
infection transmission, because the modelling estimates are only as strong as the parameters on which the
model draws. These additional services were not evaluated in the cost-effectiveness analysis but are likely to
contribute to well-being among PWID and to further improve WTP.
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Finally, another limitation of the project was that we set out to consider strategies for achieving improved
coverage of the interventions, including different methods of delivery, and to consider this as part of the
cost-effectiveness analysis. However, we were unable to source any estimate on the potential effect of
strategies to improve coverage in order to parameterise the model and, thus, we were unable to do this.
Patient and public involvement
People who inject drugs and NSP/OST service providers were consulted on the research at several stages of
the project. We convened an advisory group consisting of members of the National Needle Exchange
Forum, Addaction and the Hepatitis C Trust, who we met to consult on the study design and emerging
findings. Through close consultation with them, we selected the NSP sites across the UK in which to
conduct the costing analysis. These sites were selected to represent a range of NSP delivery modalities,
different types of injecting drug use and epidemiology of HCV infection, as well as being driven by
pragmatic reasons and the availability of data. Preliminary findings of the pooled analysis and the costing
analysis were also presented at the annual meeting of the National Needle Exchange Forum, attended by
NSP employees and service users. They provided some feedback on the initial findings and commented on
the plausibility of our NSP coverage estimates derived from the pooled analysis and for use in the impact
modelling. Further consultation on the findings of the costing analysis and results of the systematic review
were elicited from each of the collaborating sites (Bristol, Dundee and Walsall) through sites visits. As well
as receiving feedback on the findings, we sought opinion on appropriate strategies for scale-up from staff
and service users. However, further input from PWID would have been beneficial and its absence should
be recognised as a limitation of the project.
Implications for service and local decision-makers
Findings emphasise the crucial need to avoid any scale-back in the coverage of current interventions, which,
if it occurred, could result in huge increases in HCV infection transmission across these settings. Despite NSP
and OST coverage being high in many settings, model projections also suggest that important benefits
could still be achieved from scaling up NSP further, especially in settings with current low coverage levels.
NSPs are neglected in most countries by government officials and funders, and are often underprioritised by
drug treatment organisations.23 This can be seen clearly in the UK, where priorities have shifted to treatment
and recovery interventions, and these policies need to be addressed to prioritise harm reduction and the
provision of NSPs and OST.118,119 Policies to ensure that NSPs can be accessed widely alongside provision of
OST are needed. Policies that insist on the cessation of injection to qualify for OST prescriptions could be
stopped to encourage ongoing use of NSPs alongside OST. Evidence shows that the co-location of NSPs
with OST provision services can act as a disincentive to the use of NSPs. Preventing the concurrent use of
both NSP and OST needs to be removed to maximise reduction in HCV infection transmission.
Strategies are needed to reduce the harms associated with homelessness and crack cocaine injection among
PWID, which our modelling suggests is doubling the level of transmission in each setting. Reducing the
risk of HCV infection transmission among these vulnerable subpopulations should be a priority for any
strategy attempting to reduce HCV infection transmission or hoping to achieve HCV infection elimination as
recently set out by WHO.115
Research priorities
Given the body of evidence demonstrating the effectiveness of OST and NSPs in reducing the transmission
of HCV and HIV shown here and elsewhere,16,17 research needs to turn to understanding how NSPs and
OST can be most effective and efficient in responding to HIV/HCV and the other health needs that PWID
have. Improving our understanding of the mechanisms through which NSPs and OST achieve their effect
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and the optimum contexts in which to support their implementation is integral to reducing the health
inequalities experienced by PWID in the UK and internationally.
We know that the effectiveness of NSP varies by geographical location, and without the provision of
counselling, education and drug treatment services including OST, NSPs are not sufficient to reduce
epidemics of HIV and HCV infection among PWID, even when sufficient clean needles are distributed to
cover each injection.120 There is a need to understand the pathways between contextual factors and
mechanisms of service delivery, and the extent to which these influence effectiveness across different
outcomes. This is particularly relevant in the UK in the current austerity climate and ongoing financial
pressure on health and social care services. Further research on what happens to distributed needles/
syringes, how much wastage there is and whether it is better to distribute single needle/syringes or packs
is needed. Better information on this would facilitate decision-making around service provision and
improve efficiency. There is also a need to improve the understanding of the ways in which the coverage
of NSPs might be expanded and the potential impact of these various methods of expanding coverage.
Finally, routine data collection on costs associated with NSP provision is needed to reduce uncertainty in
NSP costings and to facilitate cost-effective analyses incorporating costs associated with other health gains
that NSPs bring. Particularly in pharmacies, there is currently little tracking of the numbers and types of
patients accessing needle exchange.
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Appendix 1 Supplementary material for
Chapter 2
TABLE 16 Univariable metaregression analysis for adjusted studies measuring impact of current OST use on HCV
infection incidence
Variable Number of studies Univariable RR (95% CI) Ratio of RRs (95% CI) p-value τ2
Geographic region
Europe 8 0.51 (0.37 to 0.70) 1.0 (reference)
Australia 5 0.55 (0.28 to 1.11) 1.12 (0.52 to 2.41)
North America 6 0.69 (0.44 to 1.08) 1.42 (0.73 to 2.78) 0.53 0.103
Site of recruitment
Service attenders 12 0.67 (0.49 to 0.92) 1.0 (reference)
Community 7 0.49 (0.33 to 0.73) 0.73 (0.42 to 1.27) 0.256 0.06
Females 9 1.59 (1.13 to 2.29) 0.01 0.04
Prison 7 1.06 (0.61 to 1.79) 0.821 0.4303
Homelessness 6 1.08 (0.83 to 1.40) 0.521 0.2327
Injection of stimulants 7 0.89 (0.65 to 1.22) 0.405 0.15
Daily injection 4 0.88 (0.64 to 1.22) 0.373 0.17
Reproduced from Platt et al.,26,27 which are published open access under the terms of the Creative Commons Attribution-
Non-Commercial Licence, which permits use, distribution and reproduction in any medium, provided the original work is
properly cited and is not used for commercial purposes.
TABLE 17 Univariable metaregression analysis for studies measuring impact of high NSP coverage on HCV infection
incidence
Variable Number of studies Univariable RR (95% CI) Ratio of RRs (95% CI) p-value τ2
Geographic region
Europe 5 0.44 (0.24 to 0.80) 1.0 (reference)
North America 3 1.58 (0.57 to 4.42) 3.73 (0.95 to 14.7) 0.057 0.41
Site of recruitment
Service attenders 3 0.67 (0.28 to 1.59) 1.0 (reference)
Community 5 0.82 (0.29 to 2.32) 0.76 (0.12 to 4.88) 0.74 0.89
Females 7 2.97 (0.38 to 23.1) 0.24 0.87
Prison 3 NA
Homelessness 6 1.01 (0.38 to 2.67) 0.976 1.53
Injection of stimulants 7 1.08 (0.47 to 2.51) 0.827 1.15
Daily injection 5 3.66 (0.22 to 61.3) 0.239 1.15
NA, not applicable.
Reproduced from Platt et al.,26,27 which are published open access under the terms of the Creative Commons Attribution-
Non-Commercial Licence, which permits use, distribution and reproduction in any medium, provided the original work is
properly cited and is not used for commercial purposes.
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Appendix 2 Supplementary material for
Chapter 3
TABLE 18 Association between intervention coverage defined as a combination of harm-reduction interventions
and NSP coverage, and OST alone and injecting with a used needle/syringe
Explanatory factors n Total % OR 95% CI p-value AOR 95% CI p-value
< 100 NSP, no OST 181 911 20 1.0 1.0
> 100 NSP, no OST 196 1462 13 0.6 0.50 to 0.78 < 0.001 0.5 0.38 to 0.62 < 0.001
< 100 NSP, OST 219 1301 17 0.8 0.66 to 1.02 0.0682 0.7 0.57 to 0.94 0.0155
> 100 NSP, OST 313 2126 15 0.7 0.57 to 0.85 0.0004 0.5 0.41 to 0.65 < 0.001
Female 1.2 1.00 to 1.37 0.0431 1.1 0.95 to 1.37 0.1644
History of prison 1.2 1.00 to 1.35 0.0516 1.4 1.19 to 1.73 0.0002
Injection of crack cocaine 0.8 0.67 to 0.89 0.0004 1.2 1.00 to 1.42 0.0501
Duration of injection (years)
0–3 1.0 1.0
3.1–5 1.1 0.82 to 1.58 0.4498 1.0 0.67 to 1.47 0.953
6–10 1.1 0.85 to 1.44 0.4456 1.1 0.78 to 1.45 0.6853
11+ 1.2 0.96 to 1.49 0.1014 1.1 0.86 to 1.49 0.3613
Study
Bristol 1 1.0 1.0
Leeds 0.2 0.11 to 0.31 < 0.001 0.2 0.11 to 0.32 < 0.001
Birmingham 0.1 0.04 to 0.17 < 0.001 0.1 0.05 to 0.18 < 0.001
Wales 0.2 0.16 to 0.38 < 0.001 0.3 0.17 to 0.48 < 0.001
Bristol 2 0.2 0.15 to 0.38 < 0.001 0.2 0.12 to 0.34 < 0.001
NESI 5.7 4.03 to 8.13 < 0.001 7.7 5.24 to 11.37 < 0.001
UAMP 0.3 0.23 to 0.41 < 0.001 0.3 0.22 to 0.40 < 0.001
ANSPS 0.5 0.39 to 0.68 < 0.001 0.7 0.50 to 0.92 0.0121
On OST 1.0 0.87 to 1.16 0.929 0.9 0.76 to 1.07 0.2319
High NSP coverage 0.8 0.65 to 0.86 < 0.001 0.6 0.50 to 0.69 < 0.001
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TABLE 19 Association between intervention coverage defined as a combination of harm-reduction interventions
and NSP coverage, and OST alone and reuse of the same needle/syringe for injecting
Explanatory factors n Total % OR 95% CI p-value AOR 95% CI p-value
< 100 NSP, no OST 62 181 34 1.0 1.0
> 100 NSP, no OST 62 224 28 0.73 0.48 to 1.12 0.154 0.71 0.45 to 1.09 0.1187
< 100 NSP, OST 125 318 39 1.24 0.85 to 1.82 0.2625 1.11 0.74 to 1.66 0.6196
> 100 NSP, OST 116 472 25 0.63 0.43 to 0.91 0.0133 0.59 0.40 to 0.88 0.0088
Female 0.79 0.58 to 1.07 0.1287 0.8 0.56 to 1.13 0.1997
History of prison 1.21 0.88 to 1.65 0.2484 1.06 0.74 to 1.52 0.7349
Injection of crack cocaine 1.48 1.14 to 1.91 0.0032 1.5 1.13 to 2.00 0.0055
Duration of injection (years)
0–3 1.0 1.0
3.1–5 1.41 0.81 to 2.46 0.2201 1.24 0.68 to 2.26 0.4791
6–10 1.8 1.19 to 2.73 0.0054 1.72 1.10 to 2.70 0.0178
11+ 1.54 1.05 to 2.27 0.0275 1.37 0.89 to 2.10 0.1511
Study
Bristol 1 1.0 1.0
Leeds 0.38 0.27 to 0.54 < 0.001 0.39 0.27 to 0.56 < 0.001
Birmingham 0.33 0.23 to 0.47 < 0.001 0.35 0.24 to 0.51 < 0.001
Bristol 2 0.59 0.42 to 0.81 0.0012 0.57 0.40 to 0.81 0.0018
On OST 0.98 0.76 to 1.27 0.8821 0.93 0.70 to 1.22 0.5873
> 100 NSP 0.58 0.45 to 0.73 < 0.001 0.59 0.46 to 0.76 < 0.001
High NSP coverage 0.58 0.45 to 0.73 < 0.001 0.59 0.46 to 0.76 < 0.001
TABLE 20 Association between intervention coverage defined as a combination of harm-reduction interventions
and NSP coverage, and OST alone and frequency of injecting
Explanatory
factors Mean (n) OR 95% CI p-value OR 95% CI p-value
< 100 NSP, no OST 72.4 (1156) Reference Reference Reference
> 100 NSP, no OST 48.6 (2184) –23.8 –28.3 to –19.3 < 0.001 –21.6 –26.2 to –17.0 < 0.001
< 100 NSP, OST 56.1 (2083) –16.2 –20.8 to –11.7 < 0.001 –18.4 –23.1 to –13.8 < 0.001
> 100 NSP, OST 30.3 (5091) –42 –46.1 to –37.9 < 0.001 –41.2 –45.5 to –37.0 < 0.001
Female 0.2 –2.4 to 2.85 0.882 –0.14 –10.0 to 9.71 0.2
History of prison 7.9 5.5 to 10.3 < 0.001 6.3 3.58 to 9.07 < 0.001
Injection of
crack cocaine
15.7 13.1 to 18.2 < 0.001 11.7 8.59 to 14.8 < 0.001
Duration of injection (years)
0–3 Reference Reference
3.1–5 1.6 –3.06 to 6.18 0.508 2.3 –2.8 to 7.38 0.384
6–10 3.2 –0.63 to 7.03 0.101 3.82 –0.44 to 8.09 0.079
11+ 2.6 –0.78 to 5.92 0.132 4.35 0.44 to 8.27 0.029
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TABLE 20 Association between intervention coverage defined as a combination of harm-reduction interventions
and NSP coverage, and OST alone and frequency of injecting (continued )
Explanatory
factors Mean (n) OR 95% CI p-value OR 95% CI p-value
Study
Bristol 1 Reference Reference
Leeds –3.08 –13.3 to 7.12 0.554 –0.14 –9.98 to 9.71 0.978
Birmingham –10.63 –20.7 to –0.51 0.04 –5.32 –15.1 to 4.45 0.286
Bristol 2 –1.85 –10.5 to 6.80 0.674 4.21 –6.15 to 14.6 0.426
On OST 7.29 –2.64 to 17.22 0.150 7.98 –1.94 to 17.90 0.115
High NSP coverage –13.3 –20.7 to –5.87 < 0.001 1.82 –5.62 to 9.26 0.632
TABLE 21 Association between intervention coverage defined as a combination of harm-reduction interventions
and NSP coverage, and OST alone and use of shared spoons and filters
Explanatory factors n Total % OR 95% CI p-value AOR 95% CI p-value
< 100 NSP, no OST 442 1027 43 1.0 1.0
> 100 NSP, no OST 572 1684 34 0.68 0.58 to 0.80 < 0.001 0.77 0.63 to 0.93 0.0063
< 100 NSP, OST 644 1606 40 0.89 0.76 to 1.04 0.1353 0.8 0.66 to 0.97 0.0252
> 100 NSP, OST 1021 2906 35 0.72 0.62 to 0.83 < 0.001 0.78 0.66 to 0.93 0.0066
Female 0.93 0.84 to 1.03 0.1855 1.08 0.95 to 1.24 0.2457
History of prison 1.46 1.32 to 1.61 < 0.001 1.15 1.01 to 1.31 0.0417
Injection of crack cocaine 1.72 1.56 to 1.88 < 0.001 1.11 0.98 to 1.27 0.1099
Duration of injection (years)
0–3 1.0 1.0
3.1–5 1.09 0.90 to 1.32 0.3731 1.01 0.79 to 1.29 0.9344
6–10 1.27 1.09 to 1.49 0.0021 0.95 0.78 to 1.16 0.6396
11+ 0.93 0.81 to 1.06 0.2796 0.87 0.73 to 1.04 0.127
Study
Bristol 1 1.0 1.0
Leeds 0.78 0.29 to 2.12 0.6227 0.78 0.29 to 2.12 0.624
Birmingham 0.04 0.02 to 0.08 < 0.001 0.04 0.02 to 0.08 < 0.001
Wales 0.03 0.01 to 0.06 < 0.001 0.03 0.01 to 0.06 < 0.001
Bristol 2 0.18 0.08 to 0.41 < 0.001 0.19 0.08 to 0.45 0.0001
NESI 0.01 0.00 to 0.01 < 0.001 0.01 0.00 to 0.02 < 0.001
UAMP 0.01 0.00 to 0.02 < 0.001 0.01 0.00 to 0.02 < 0.001
ANSPS 0.01 0.00 to 0.02 < 0.001 0.01 0.00 to 0.02 < 0.001
On OST 1.01 0.91 to 1.11 0.8797 0.94 0.83 to 1.06 0.3343
High NSP coverage 0.69 0.63 to 0.76 < 0.001 0.88 0.78 to 0.98 0.0244
DOI: 10.3310/phr05050 PUBLIC HEALTH RESEARCH 2017 VOL. 5 NO. 5
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Platt et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
105
TABLE 22 Association between intervention coverage defined as a combination of harm-reduction interventions
and NSP coverage, and OST alone and injecting-site infection
Explanatory factors n Total % OR 95% CI p-value AOR 95% CI p-value
< 100 NSP, no OST 213 621 34 1.0 1.0
> 100 NSP, no OST 254 596 43 1.42 1.13 to 1.79 0.0029 1.2 0.90 to 1.51 0.2524
< 100 NSP, OST 450 1082 42 1.36 1.11 to 1.67 0.003 1.4 1.14 to 1.81 0.002
> 100 NSP, OST 698 1960 36 1.06 0.88 to 1.28 0.5509 1.2 0.99 to 1.52 0.0603
Female 1.29 1.13 to 1.48 0.0002 1.3 1.12 to 1.58 0.0011
History of prison 1.02 0.90 to 1.16 0.7517 0.9 0.77 to 1.08 0.2929
Injection of crack cocaine 0.94 0.84 to 1.05 0.2946 1.4 1.18 to 1.58 < 0.001
Duration of injection (years)
0–3 1.0 1.0
3.1–5 1.15 0.91 to 1.46 0.2518 0.99 0.74 to 1.33 0.9442
6–10 1.01 0.84 to 1.22 0.9081 0.94 0.74 to 1.18 0.5745
11+ 0.93 0.79 to 1.09 0.3797 1.22 0.99 to 1.50 0.0637
Study
Bristol 1 1.0 1.0
Leeds 0.56 0.41 to 0.78 0.0005 0.58 0.42 to 0.80 0.001
Birmingham 0.68 0.49 to 0.94 0.0188 0.72 0.52 to 1.00 0.0509
Wales 1.81 1.36 to 2.40 < 0.001 2.76 1.89 to 4.03 < 0.001
Bristol 2 0.6 0.44 to 0.82 0.0014 0.55 0.39 to 0.76 0.0004
ANSPS 0.27 0.21 to 0.35 < 0.001 0.26 0.20 to 0.33 < 0.001
On OST 1.12 0.98 to 1.28 0.0843 1.29 1.11 to 1.50 0.0007
High NSP coverage 0.87 0.77 to 0.98 0.0262 1.03 0.89 to 1.18 0.7318
TABLE 23 Association between intervention coverage defined as a combination of harm-reduction interventions
and NSP coverage, and OST alone and HCV infection testing
Explanatory factors n Total % OR 95% CI p-value AOR 95% CI p-value
< 100 NSP, no OST 858 1126 76 Reference 1.0
> 100 NSP, no OST 1748 2101 83 1.6 1.29 to 1.85 < 0.001 1.4 1.13 to 1.69 0.0015
< 100 NSP, OST 1727 2028 85 1.8 1.49 to 2.15 < 0.001 1.7 1.41 to 2.12 < 0.001
> 100 NSP, OST 5833 6781 86 1.9 1.65 to 2.24 < 0.001 1.9 1.56 to 2.23 < 0.001
Female 1.2 1.08 to 1.32 0.0004 1.4 1.22 to 1.57 < 0.001
History of prison 1.9 1.77 to 2.11 < 0.001 1.6 1.45 to 1.83 < 0.001
Injection of crack cocaine 1.6 1.42 to 1.76 < 0.001 1.4 1.20 to 1.62 < 0.001
Duration of injection (years)
0–3 1.0 1.0
3.1–5 1.9 1.63 to 2.21 < 0.001 1.7 1.41 to 2.06 < 0.001
6–10 2.8 2.43 to 3.15 < 0.001 2.2 1.83 to 2.52 < 0.001
11+ 5.5 4.86 to 6.15 < 0.001 3.3 2.82 to 3.80 < 0.001
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TABLE 23 Association between intervention coverage defined as a combination of harm-reduction interventions
and NSP coverage, and OST alone and HCV infection testing (continued )
Explanatory factors n Total % OR 95% CI p-value AOR 95% CI p-value
Study
Bristol 1 1.0 1.0
Leeds 1.2 0.77 to 1.78 0.4674 1.1 0.72 to 1.73 0.6138
Birmingham 0.8 0.52 to 1.13 0.1813 0.8 0.55 to 1.26 0.3816
Wales 0.2 0.15 to 0.30 < 0.001 0.3 0.21 to 0.46 < 0.001
Bristol 2 2.5 1.54 to 4.02 0.0002 2.6 1.47 to 4.45 0.0009
NESI 1.0 0.71 to 1.29 0.7937 1.3 0.93 to 1.78 0.1267
UAMP 1.2 0.90 to 1.67 0.1888 1.3 0.94 to 1.80 0.1136
ANSPS 2.8 1.98 to 3.81 < 0.001 3.6 2.52 to 5.20 < 0.001
On OST 1.5 1.36 to 1.65 < 0.001 1.5 1.36 to 1.71 < 0.001
High NSP coverage 1.4 1.27 to 1.54 < 0.001 1.2 1.04 to 1.31 0.0098
TABLE 24 Association between intervention coverage defined as a combination of harm-reduction interventions
and NSP coverage, and OST alone and HIV testing
Explanatory factors n Total % OR 95% CI p-value AOR 95% CI p-value
< 100 NSP, no OST 765 1092 70 1.0 1.0
> 100 NSP, no OST 1586 2037 78 1.5 1.27 to 1.78 < 0.001 1.3 1.10 to 1.58 0.0028
< 100 NSP, OST 1582 1975 80 1.7 1.45 to 2.04 < 0.001 1.7 1.40 to 2.02 < 0.001
> 100 NSP, OST 5452 6732 81 1.8 1.58 to 2.10 < 0.001 1.9 1.60 to 2.20 < 0.001
Female 1.2 1.12 to 1.36 < 0.001 1.4 1.22 to 1.53 < 0.001
History of prison 1.6 1.51 to 1.78 < 0.001 1.4 1.25 to 1.54 < 0.001
Injection of crack cocaine 1.3 1.20 to 1.46 < 0.001 1.2 1.04 to 1.34 0.0121
Duration of injection (years)
0–3
3.1–5 1.7 1.48 to 2.01 < 0.001 1.6 1.31 to 1.88 < 0.001
6–10 2.2 1.92 to 2.48 < 0.001 1.8 1.52 to 2.05 < 0.001
11+ 3.8 3.41 to 4.29 < 0.001 2.7 2.33 to 3.07 < 0.001
Study
Bristol 1 1.0 1.0
Leeds 0.8 0.56 to 1.18 0.2786 0.8 0.52 to 1.12 0.1644
Birmingham 0.7 0.51 to 1.05 0.0903 0.8 0.53 to 1.13 0.1824
Bristol 2 1.5 1.01 to 2.22 0.0463 1.3 0.83 to 1.94 0.2724
NESI 0.9 0.64 to 1.11 0.2365 1.0 0.70 to 1.27 0.7086
UAMP 1.1 0.84 to 1.48 0.4395 1.1 0.83 to 1.50 0.4803
ANSPS 2.0 1.49 to 2.69 < 0.001 2.2 1.61 to 3.04 < 0.001
On OST 1.4 1.27 to 1.53 < 0.001 1.5 1.36 to 1.68 < 0.001
High NSP coverage 1.2 1.04 to 1.27 0.0044 1.2 1.05 to 1.30 0.0037
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Appendix 3 Supplementary material for Chapter 4
TABLE 25 Parameters for costing uncertainty analysis
Parameter Base case Minimum Maximum
Discount rate (%) 4 1 6
Salaries multiplier (%) 100 50 200
Equipment wastage (%) 100 50 200
Opportunity cost of volunteer time (annual) 18,992.87 – 18,992.87
Opportunity cost of volunteer time (hourly) 0 0 12.5
Per cent of visits for non-IPED users
Fixed sites 92 75 90
Pharmacies 100 100 100
Walk-in centres 100 100 100
Per cent of needles to non-IPED users
Fixed sites 81 75 90
Pharmacies 100 100 100
Walk-in centres 100 100 100
Visits per client
Pharmacies 8 6 10
Walk-in centres 8 6 10
Needle distribution
Needle pack size 10 10 10
Needle packs per transaction 1.06 1.00 1.12
‘One hit kit’ packs per transaction 4 1 10
TABLE 26 Outputs: fixed sites
Site and
output type
Total outputs Opioids and other IPEDs
Total, N Male, n (%)
Female,
n (%) Total Male, n (%) Total Male, n (%)
BDP
Total clients 1134 991 (87) 143 (13) 755 (67) 618 (82) 379 (33) 373 (98)
Total visits 10,796 9353 (87) 1443 (13) 9937 (92) 8502 (86) 859 (8) 851 (99)
Total needles 286,698 252,039 (88) 34,659 (12)
CAIR Scotland
Total clients 817 504 (62) 201 (25) 697 (85) 121 (15)
Total visits 6251 5692 (91) 559 (9)
Total needles 50,186 36,455 (73) 13,731 (27)
continued
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TABLE 27 Outputs: pharmacies in cost study
Site Distribution style
Total clients (all opiate users)
Total visits
Total needles
distributedTotal, N Male, n (%) Female, n (%)
Pharmacy 1 (Bristol) Packs 176a 132 (75)a 44 (25)a 1405 28,100a
Pharmacy 2 (Bristol) Packs 213a 160 (75)a 53 (25)a 1705 36,100a
Pharmacy 3 (Dundee) Pick and mix 287 224 (78) 62 (22) 1940 21,982
Pharmacy 5 (Dundee) Pick and mix 210 149 (71) 61 (29) 1914 18,518
Pharmacy 4 (Walsall) Packs 290a 217 (75)a 72 (25)a 2316a 24,520
Pharmacy 6 (Walsall) Packs 207a 155 (75)a 52 (25)a 1656a 17,530
a Value was estimated using assumptions described in Chapter 3, Methods.
TABLE 26 Outputs: fixed sites (continued )
Site and
output type
Total outputs Opioids and other IPEDs
Total, N Male, n (%)
Female,
n (%) Total Male, n (%) Total Male, n (%)
Addaction Walsall
Total clients 569 520 (91) 44 (8) 190 (33) 379 (67)
Total visits 1756 1609 (92) 147 (8)
Total needles 78,914 63,644 (81)a 15,270 (19)a
a Value was estimated using assumptions described in Chapter 3, Methods.
TABLE 28 Outputs: other needle distribution modes
Site and
output type
Total Opioids and other IPEDs
Total, N Male, n (%)
Female,
n (%) Total, n (%) Male, n (%) Total, n (%) Male, n (%)
Out-of-hours pharmacy (Walsall)
Total clients 213 160 (75)a 53 (25)a 213 (100) 0
Total visits 1704 1704 (100) 0
Total needles 6816 6816 (100) 0
Drop-in centre (Walsall)
Total clients 113 84 (75)a 28 (25)a 113 (100) 0
Total visits 900 900 (100) 0
Total needles 7812 7812 (100) 0
Outreach service (Bristol)
Total clients 396 348 (88) 48 (12) 286 (72) 240 (84) 110 (28) 108 (98)
Total visits 1778 1438 (81) 340 (19) 1207 (68) 1248 (79) 192 (11) 190 (99)
Total needles 101,326 92,171 (91) 9155 (9)
a Value was estimated using assumptions described in Chapter 3, Methods.
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Appendix 4 Supplementary material for Chapter 5
Model equations
Sn,mi,j,k and C
n,m
i,j,k are the number of susceptible and chronically infected individuals in the model, in which i = 0,1
for off OST and on OST respectively, j = 0,1 for < 100% NSP and > 100% NSP, respectively, n = 1,2,3,4 for
recent and non-recent or long-term injectors and ex-injecting drug users, m = l,h for low and high risk,
respectively, and k = 1,2 . . . 6 for the disease progression states chronic infected, compensated cirrhosis,
decompensated cirrhosis, HCC, liver transplant and post liver transplant, respectively.
The ordinary differential equation model is made up of 300 equations, which are described below for
different aspects of the model.
Inflow of injectors
There are only two variables in the model that allow an inflow of new injectors. These are low- and
high-risk susceptible individuals in the first disease progression category with no intervention: the number
of new low-risk individual per year is θ(1 – ϕ) and the number of new high-risk individuals per year is θϕ.
Injecting duration progression
These terms in the equations are concerned with movement from one injecting duration category to
another as well as PWID-related and background mortality. IDn,mi,j,k denotes the terms in an ordinary
differential equation of injecting duration category n. It occurs for all values of m,i,j,k. Yn,mi,j,k is used to
describe one of the variables in the model, in which Y = S or C and the subscripts and superscripts are as
described previously.
ID1,mi, j,k
ID2,mi, j,k
ID3,mi, j,k
0
BB@
1
CCA =
−τ1−µ1 0 0
τ1 −τ2−µ2 0
0 τ2 −τ3
0
BB@
1
CCA
Y 1,mi, j,k
Y 2,mi, j,k
Y 3,mi, j,k
0
BB@
1
CCA (1)
When n = 4 (ex-injecting), the terms have a different form:
ID4k = ∑
i, j,m
ω1Y
1,m
ijk + ∑
i, j,k,m
ω2Y
2,m
ijk + ∑
i, j,k,m
ω3Y
3,m
ijk −v4Y
4
k . (2)
Interventions: opioid substitution therapy and needle and syringe programmes
These terms in the equations are concerned with the movement of injectors from one intervention
category to another. ITn,mi, j,k denotes the terms in the ordinary differential equation of OST intervention
category i and NSP intervention category j. These terms can be found for all values of m,k and current
injector categories but not for the ex-injecting drug user category (n = 4):
ITn,m0,0,k
ITn,m1,0,k
ITn,m0,1,k
ITn,m1,1,k
0
BBBBB@
1
CCCCCA =
−η− β γ κ 0
β − γ− η 0 κ
η 0 −κ − β γ
0 η β −γ − κ
0
BBBBB@
1
CCCCCA
Yn,m0,0,k
Yn,m1,0,k
Yn,m0,1,k
Yn,m1,1,k
0
BBBBB@
1
CCCCCA. (3)
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High and low risk
These terms in the equations are concerned with movement of current injectors between low and high
risk. HRn,mi,j,k denotes the terms in the ordinary differential equation of risk category m. These terms can be
found in the equations for all values of i, j, k and n = 1,2,3.
HRn,li, j,k
HRn,hi, j,k
 !
=
−σ ζ
σ −ζ
 !
Yn,li, j,k
Yn,hi, j,k
 !
(4)
Disease progression
These terms in the equations are concerned with movement through the disease states. Infection and
treatment are described separately. DSn,mi,j,k denotes the terms in the ordinary differential equation of disease
category k for susceptible individuals and DCn,mi,j,k for infected individuals. These terms can be found in the
equations for all values of I,j,n,m.
DSn,mi, j,1
DSn,mi, j,2
DSn,mi, j,3
DSn,mi, j,4
DSn,mi, j,5
DSn,mi, j,6
0
BBBBBBBBBB@
1
CCCCCCCCCCA
=
0 0 0 0 0 0
0 −e3ρ3−e4ρ4 0 0 0 0
0 e3ρ3 −ρ5−ρ4−d3 0 0 0
0 e4ρ4 ρ4 −d4 0 0
0 0 ρ5 0 −ρ6− d5 0
0 0 0 0 ρ6 −d6
0
BBBBBBBBB@
1
CCCCCCCCCA
sn,mi, j,1
sn,mi, j,2
sn,mi, j,3
sn,mi, j,4
sn,mi, j,5
sn,mi, j,6
0
BBBBBBBBBB@
1
CCCCCCCCCCA
(5)
DCn,mi, j,1
DCn,mi, j,2
DCn,mi, j,3
DCn,mi, j,4
DCn,mi, j,5
DCn,mi, j,6
0
BBBBBBBBBB@
1
CCCCCCCCCCA
=
−ρ2 0 0 0 0 0
ρ2 −ρ4−ρ3 0 0 0 0
0 ρ3 −ρ5−ρ4−d3 0 0 0
0 ρ4 ρ4 −d4 0 0
0 0 ρ5 0 −ρ6−d5 0
0 0 0 0 ρ6 −d6
0
BBBBBBBBB@
1
CCCCCCCCCA
Cn,mi, j,1
Cn,mi, j,2
Cn,mi, j,3
Cn,mi, j,4
Cn,mi, j,5
Cn,mi, j,6
0
BBBBBBBBBB@
1
CCCCCCCCCCA
(6)
Infection terms
The forces of infection below are concerned with acquiring infection. The terms are of the form:
FOIn,mi, j,k = λ
n,m
i, j,kS
n,m
i, j,k. (7)
When the ordinary differential equation is for susceptible, the force of infection term is subtracted and the
same term is added to the matching infectious category.
λ1,l0,0,k = πX1(1−δ)ϒ
λ2,l0,0,k = πX2(1−δ)ϒ
λ3,l0,0,k = π(1−δ)ϒ
λ1,h0,0,k = πX1Ξ(1−δ)ϒ
λ2,h0,0,k = πX2Ξ(1−δ)ϒ
λ3,h0,0,k = πΞ(1−δ)ϒ
λn,m0,1,k = Γλ
n,m
0,0,k
λn,m1,0,k = Πλ
n,m
0,0,k
λn,m1,1,k = Bλ
n,m
0,0,k
(8)
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Define:
Cn,m = ∑
6
k=1

Cn,m0,0,k C
n,m
0,1,k C
n,m
1,0,k C
n,m
1,1,k

,
Sn,m = ∑
6
k=1

Sn,m0,0,k S
n,m
0,1,k S
n,m
1,0,k S
n,m
1,1,k

,
I =
1
Γ
Π
B
0
BB@
1
CCA,
(9)
to give
ϒ =

X1

C1,l + ΞC1,h

+ X2

C2,l + ΞC2,h

+

C3,l + ΞC3,h

I
X1

C1,l + S1,l + Ξ

C1,h + S1,h

+ X2

C2,l + S2,l + Ξ

C2,h + S2,h

+

C3,l + S3,l + Ξ

C3,h + S3,h
n o
I
.
(10)
Treatments
There are a fixed number of treatments per year, given by Φ. When the total number of infected
individuals in the model is greater than this number, the treatments are allocated proportionately. When
the total number of infected individuals is less than the number of possible treatments per year, all are
treated. Only the first two disease progression categories are eligible for treatment and will have treatment
terms. If the ordinary differential equation is for an infected category, the treatment term will be
subtracted and for a susceptible category, the term will be added. If:
Φ < ∑
2
k=1
∑
3
n
∑
m,i, j
Cn,mi, j,k = C
treat ,
Tn,mi, j,k

Cn,mi, j,k

=
αΦCn,mi, j,k
Ctreat
,
(11)
for k = 1,2, then n = 1,2,3.
Otherwise:
Tn,mi, j,k

Cn,mi, j,k

= αCn,mi, j,k, (12)
for k = 1,2, n = 1,2,3.
For ex-injecting drug users, treatment is more straightforward, with a proportion, r, of the chronically
infected and compensated cirrhosis individuals being treated each year.
T 4k

C4k

= αrC4k, (13)
for k = 1,2.
As an example, below is the ordinary differential equation for the susceptible category for the first disease
progression category, with no interventions, a recent injector (< 3 years) and at low risk. On the right-hand
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side in order from left to right there is an inflow term, injecting duration terms, intervention terms,
high- and low-risk terms, disease progression terms, infection term and treatment term.
ds1,l0,0,1
dt
= θ(1−ϕ) + ID1,l0,0,1 + IT
1,l
0,0,1 + HR
1,l
0,0,1 + DS
1,l
0,0,1−λ
1,l
0,0,1S
1,l
0,0,1 + T
1,l
0,0,1 (14)
Submodels used in the fitting procedure
Injecting duration model
A model with three injecting duration categories was used to fit the population data and the injecting
duration profiles from survey data. Here, Si is the number of susceptible injectors in the i category. The
categories are: r, recent injector; n, non-recent injector; and l, long-term injector. The µi and τi, are as
described above.
dSr
dt
= θ− (µ1 + τ1)S
r
dSn
dt
= µ1S
r− (µ2 + τ2)S
n
dSl
dt
= µ2S
n−µ3S
l
(15)
The steady state solution of this model is given below:
Sr =
θ
µ1 + τ1
, Sn =
θτ1
(µ1 + τ1)(µ2 + τ2)
, Sl =
θτ1τ2
µ3(µ1 + τ1)(µ2 + τ2)
  . (16)
With total population N = Sr + Sn + Sl, the analytical solution of this system is:
Sr (t) = Sr (0)e−(µ1+τ1)t +
θ
µ1 + τ1
(1−e−(µ1+τ1)t ),
Sn(t) =
τ1θ
(µ1 + τ1)(µ2 + τ2)
+ Sn(0)e−(µ2+τ2)t +
τ1
µ1 + τ1−µ2−τ2
Sr (0)(e−(µ2+τ2)t−e−(µ1+τ1)t )
+
τ1θ
µ1 + τ1−µ2−τ2
*(e−(µ1+τ1)t /(µ1 + τ1)−e
−(µ2+τ2)t /(µ2 + τ2)),
Sl(t) = e−µ3t Sl(0) +
τ2
µ2 + τ2−µ3
.
τ1S
r (0)
µ1 + τ1−µ3
−
τ1θ
µ3(µ1 + τ1−µ3)
+ Sn(0)
  
+
e−(µ2+τ2)tτ2
µ2 + τ2−µ3
τ1S
r (0)
µ2−τ2 + µ1 + τ1
+
τ1θ
(µ2 + τ2)(−µ2−τ2 + µ1 + τ1)
−Sn(0)
 
.
+
e−(µ1+τ1)tτ1τ2θ
(µ1 + τ1)(µ1 + τ1−mu3)(µ1 + τ1−µ2−τ2)
+
τ1τ2θ
µ3(µ1 + τ1)(µ2 + τ2)
.
High-risk model
A model with a high and low risk only was used to calculate parameter values in the calibration process.
The variable Sh denotes high risk and Sl denotes low risk:
dSh
dt
= −ζSh + σSl
dSl
dt
= ζSh−σSl
. (17)
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As this is a closed system, we can use N − Sh = Sl, which gives:
dSh
dt
= −ζSh + σ(N − Sh). (18)
Setting the left-hand side to zero and rearranging gives the proportion of the total population that are
high risk (Φ):
Φ =
σ
σ + ζ
. (19)
This expression was used to calculate the required value of the recruitment rate σ from the sampled values
of the proportion of high-risk individuals and the leaving rate σ.
TABLE 29 Summary of data collated for each setting for model calibration
Parameter Bristol Walsall Dundee Relevant parameter
Current PWID
population size
2004: sampled
111–125%106 of
2011 value104
2006: 125%106 of
2011 value
Constant level:
675–825 local
estimate adjusted
from King et al.
(2013)107
Sampled uniformly
θ, number of new
injectors per year.
Value of θ found using
steady-state equations
of population submodel
for the first time point
in all three settings. In
Bristol and Walsall, a
second value of θ is
found using Matlab
fzero and analytical
solution to population
submodel that gives
population size required
with sampled
cessation rates
2011: 2025–2564
adjusted from Jones
et al. (2016)104 to
include only 60% of
people on OST not in
contact with other
services.104 Sampled
uniformly
2011: 1296–1623
estimated from local
number on OST and
unpublished PWID
prevalence estimates
for West Midlands.
Sampled uniformly
Injecting duration
profile: proportion
of PWID that are R,
NR or LT
2004: R, 0.04–0.2;
NR, 0.25–0.45;
LT, 0.4–0.6573
2006: R, 0.1–0.3; NR,
0.45–0.65; LT, 0.2–0.3
Constant level: R,
0.15–0.35; NR,
0.36–0.65; LT,
0.12–0.35 (NESI)
Death and cessation
rates (µi) (per year). Prior
distribution for µ1
(0.0351–0.1702)
calculated from
assumption that
between 10% and 40%
of recent initiates cease
injecting within
3 years.91 A large upper
bound of 0.4 was
assumed for the prior
distributions of µ2 and
µ3 owing to a lack of
information. Lower
bounds of 0.004 and
0.008 were chosen to
ensure that the leaving
rate was greater than
the likely death rate.98
Parameter sets were
accepted if PWID
demographic submodel
fits were within the
ranges for each
injecting duration
2014: R, 0.075–0.2;
NR, 0.05–0.22; LT,
0.55–0.85 (UAMP)
2014: R, 0.1–0.3; NR,
0.15–0.4; LT,
0.4–0.6 (UAMP)
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TABLE 29 Summary of data collated for each setting for model calibration (continued )
Parameter Bristol Walsall Dundee Relevant parameter
Chronic HCV
infection prevalence
(75% of HCV
antibody prevalence)
Constant level
40–50% (community
surveys, UAMP);
sampled from
truncated beta
(305.25,364.75)
2006: 11–26%
(UAMP); sampled from
truncated beta
(30.75,132.25)
2008: 15–30%
(NESI); sampled
from truncated
beta (18.75,64.25)
π, infection rate used to
fit the HCV infection
prevalence estimates
2014: 15–39% (no
fitting required)
2014: 31–44%
adjusted from
(NESI); sampled
from truncated
beta (54.6.90.4)
Proportion high risk 2004: 70–80%
(2004, 2006
community surveys
and UAMP).
Sampled uniformly
Constant level of
40–65% (UAMP);
sampled uniformly
Constant level of
26–42% (NESI);
sampled from
beta (156,315)
ϕ, proportion of
injectors initially high
risk assumed to be the
same as sampled
proportion high risk
σ, recruitment rate per
year from low- to
high-risk behaviour,
calculated from sampled
leaving rate, ζ, and
proportion high risk, ϕ
2014: 80–95%
(UAMP); sampled
uniformly
Proportion on OST 2004: 33.3–46.7%121
sampled from
truncated
beta (81,121)
2006: 30–50%
(UAMP); sampled from
truncated beta (32,48)
2008: 433–53%
(NESI) sampled from
beta (36,47)
β, recruitment rate per
year on to OST
2009: 76.5–86.3%
(community survey,
2009) sampled from
truncated beta
(241,55)
2009: 61–82%
(UAMP); sampled from
truncated beta (47,18)
2014: 65–79%
(NESI) sampled from
beta (106,40)
Proportion > 100%
NSP [needles
distributed/
(population
size × injecting
frequency)]
Needles distributed
in 2014
(786,542–844,646),
population size in
2014 and injecting
frequency (470–859
per year from UAMP)
sampled. Mean
calculated coverage
56%
Needles distributed
in 2014
(225,275–237,111),
population size in
2014 and injecting
frequency (435–716
per year from UAMP)
sampled. Mean
calculated coverage
28%
Needles distributed
in 2014 (assumed to
be the same as in
2008), population
size in 2008 and
injecting frequency
(517–999 per year
from NESI) sampled.
Mean calculated
coverage 27%.
Needles distributed
in 2014
(138,246–145,768),
population size in
2014 and injecting
frequency (251–533
per year from NESI)
sampled. Mean
calculated
coverage 49%
η, recruitment rate
per year onto high-
coverage NSP
LT, long-term injectors; NR, non-recent injectors; R, recent injectors.
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Appendix 5 Supplementary material for
Chapter 6
TABLE 31 Cost associated with different stages of disease progression for cost-effectiveness model
Disease stage Annual costs (2014 GBP) Distribution Source
OST (specialist prescribing) 2839.28 Gamma PSSRU122
Uninfected 0.00 Gamma Wright et al., 2005123
F0 and F1 mild HCV infection 187.59 Gamma Wright et al., 2005123
F2 and F3 moderate
HCV infection
974.68 Gamma Wright et al., 2005123
Compensated cirrhosis 1546.98 Gamma Wright et al., 2005123
Decompensated cirrhosis 12,397.57 Gamma Wright et al., 2005123
HCC 11,170.04 Gamma Wright et al., 2005123
Liver transplant 40,273.00 Gamma Martin et al., 2016124
Post transplant 2041.00 Gamma Martin et al., 2016124
Hospital costs year of transplant 13,937.00 Gamma Martin et al., 2016124
Treatment Gamma
Sofosbuvir + Ledipasvir
(Harvoni®, Gilead) – PWID
48,816.00 Gamma Martin et al., 2016124
Sofosbuvir + Ledipasvir – ex- or
non-injecting drug user
40,680.00 Gamma Martin et al., 2016124
Liver-related death 0.00 Gamma Assumption
TABLE 30 Cost associated with NSP for cost-effectiveness model
Setting
Fixed citywide cost (£) Cost per needle distributed (£)
Median Minimum Maximum Median Minimum Maximum
Bristol 44,142 36,758 49,890 0.26 0.14 0.42
Dundee 10,159 8672 11,807 0.78 0.37 1.19
Walsall 21,068 16,320 26,318 0.45 0.20 1.03
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TABLE 32 Quality-of-life values used in cost-effectiveness analysis
Disease stage QALYs Distribution Source
Uninfected
Ex- or non-injecting drug user 0.94 Constant Martin et al., 2016124
Injecting drug user 0.85 Uniform(0.8, 0.9) Martin et al., 2016124
Mild HCV infection
Without treatment (F0 and F1) 0.77 Beta(521.2375, 155.6943)
SVR (F1 only) 0.82 Beta(65.8678, 14.4588)
Moderate HCV (F2 and F3) Martin et al., 2016124
Without treatment 0.66 Beta(168.2461, 86.6723) Martin et al., 2016124
SVR 0.72 Beta(58.0608, 22.592)
Compensated cirrhosis
Without treatment 0.55 Beta(47.1021, 38.5381) Martin et al., 2016124
SVR 0.61 Beta(58.0608, 37.1124) Martin et al., 2016124
Decompensated cirrhosis 0.45 Beta(123.75, 151.25) Martin et al., 2016124
HCC 0.45 Beta(123.75, 151.25) Martin et al., 2016124
Liver transplant 0.45 Beta(123.75, 151.25) Martin et al., 2016124
Post transplant 0.67 Beta(59.2548, 29.1852) Martin et al., 2016124
Liver-related death 0 Martin et al., 2016124
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